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Lysosomal storage diseases (LSDs) are a group of more than 40 genetically inherited 
diseases that result from dysfunction of specific proteins, often an enzyme, located in 
lysosomes within cells which leads to abnormal lysosomal accumulation of specific 
macromolecules. As a result, cell malfunction occurs and escalates into multi-tissue 
and multi-organ failures, often resulting in premature death. For several early onset 
LSDs, the central nervous system (CNS) is also affected and manifests fatal 
neuropathic and/or neurodegenerative symptoms. Within the last two decades, 
treatment for selective LSDs has become clinically available. Specifically, enzyme 
replacement therapy (ERT) by intravenous injection of recombinant enzymes holds 
relevant promise. Yet current ERT results in suboptimal enzyme biodistribution to 
  
many target organs, including the peripheral organs and also the CNS. Delivery to the 
CNS is particularly impeded due to the tight blood-brain barrier (BBB) that strictly 
regulates passage between the circulation system and the brain tissue. We explored 
the use of targeted drug delivery systems to address this issue. Specifically, we 
focused on targeting intercellular adhesion molecule-1 (ICAM-1), a cell surface 
glycoprotein that is upregulated under pathological conditions, including LSDs. In 
this dissertation, using in vitro, cell culture, and in vivo techniques, we examined 
whether ICAM-1-targeted polymer nanocarriers: (1) enhance binding, uptake, and 
lysosomal delivery of different enzymes in cells, (2) provide targeting and transport 
across endothelial and subendthelial cells of the BBB, and (3) improve accumulation 
of lysosomal enzymes to peripheral organs and the brain. Results suggest that after 
intravenous injection of enzyme coupled to ICAM-1-targeted nanocarriers, ICAM-1 
targeting shift these enzymes from the circulation to tissues, enhancing enzyme 
accumulation over non-targeted counterparts both in peripheral organs and the brain. 
This could be modulated by varying parameters such as the density of targeting 
antibodies on the carrier coat or the carrier bulk concentration. Also, ICAM-1-
targeted nanocarriers were transported across BBB models followed by uptake and 
lysosomal transport to neuron-like cells. ICAM-1-targeted nanocarriers preferentially 
bound to diseased cells and were internalized and trafficked to lysosomes, resulting in 
degradation of the accumulated substrate. Therefore, overall, ICAM-1-targeting 
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Section 1: Introduction and Overview 
1.1. Problem Description and Motivation 
Lysosomal storage disorders (LSDs) are a group of more than 40 inherited genetic diseases 
that affect as frequent as 1 in 2000 live births [1-9]. Each LSD is caused by a defect or 
deficiency of a particular functional lysosomal-associated protein, often a lysosomal enzyme, 
which leads to accrual of excess substrate in the lysosomes within cells, eventually results in 
cell death, tissue malfunction, and multi-organ failures, including both peripheral organs and 
the nervous system [1-8]. 
Currently there are only a few treatment options clinically available for LSDs [4, 10]. 
The most popular and among the most effective treatments is enzyme replacement therapy 
(ERT), in which a recombinant enzyme is intravenously (i.v.) injected into the patient in 
order to replace the missing activity, which requires the enzyme to bind, internalize and be 
trafficked to lysosomes within cells [4, 10]. This is possible because recombinant lysosomal 
enzymes have mannose-6-phosphare (M6P) residues that target the corresponding cell 
receptors, M6P receptor (M6PR), and lead to cell uptake with lysosomal trafficking [11, 12]. 
This costs an average of $300,000 annually per patient [13-15]. However, ERT is still 
suboptimal since the majority of the injected enzyme accumulates in clearance organs (which 
are also disease targets) but not to other target tissues, such as the lungs, heart, muscle, etc. 
[4, 10].  
Unfortunately, in addition to peripheral organ failures, often the central nervous 
system (CNS) is also affected in LSDs [16]. Drug delivery to the brain to treat the CNS is 
notoriously difficult due to the highly regulating blood-brain barrier (BBB). The BBB is 




with the blood circulation [17, 18]. Unlike vascular endothelial cells that line capillaies in 
some peripheral organs, the brain endothelium lacks fenestrations and has extremely tight 
cell-cell junctions [17, 18]. Additionally, the endothelial lining of the BBB is juxtaposed with 
subendothelial cells (the subendothelial layer) made up of mainly pericytes and astrocytes 
[19].  
To treat brain symptoms in LSDs, several physicians have resorted to direct brain 
injections of the therapeutic or bone marrow transplant (BMT) [4, 8, 20]. Direct injection of 
bone marrow mesenchymal stem cells to the brain can stimulate growth of healthy neural 
networks [20, 21]. Unfortunately, aside from other side effects that may potentially occur 
with this method, such as graft versus host disease, direct brain injections (e.g. 
intracerebellar, intracerebroventricular, intraparenchymal, intrathecal, etc.) are rather invasive 
and carry risks of severe complications [4, 8, 21, 22]. Moreover, although this method can 
deliver treatment to the brain, the treatment does not reach peripheral organs that are also 
affected by LSDs. Therefore, LSD treatment options that include systemic delivery of 
lysosomal enzymes to both peripherally affected organs and the brain are still needed. A 
method to enhance targeting of ERT to all peripheral and CNS tissue, allowing uptake by 
cells and lysosomal transport throughout the body, may improve treatment efficacy and 
perhaps decrease the cost. 
 
1.2. Our Approach 
Targeted drug delivery systems have paved a path in the field to enhance the efficacy of 
several treatments [23-25]. Scientists have targeted cell markers, receptors, enzymes, etc. to 
guide delivery of drugs to affected cells [23-26]. Researchers have also looked to nature for 




to sites of disease, or how lysosomal proteins are trafficked to lysosomes. Previous targeted 
drug delivery approaches to enhance distribution of therapeutic enzymes for LSDs have 
involved conjugation of recombinant enzymes to peptides, proteins, or antibody derivatives 
that target the insulin receptor (InsR), mannose-6-phosphate receptors (M6PR), receptor-
associated protein (RAP), etc. receptors which are known to be associated to clathrin-coated 
pits, the pathway that is inherently used by endogenous lysosomal enzymes [11, 12, 24]. 
However, research has shown signs of impaired endocytosis by clathrin pathways in some 
LSDs [27-29]. To circumvent this, other strategies have focused on development of enzymes 
targeted by protein transduction domain peptides, which often render delivery inside the cell 
[30-33]. Nonetheless, although these strategies may enhance uptake into cells they still fail to 
improve passage from blood to tissue, particularly to the CNS [4, 8, 10, 34, 35]. 
In this dissertation, we focus on a strategy to target enzyme-loaded nanoparticles to 
intercellular adhesion molecule-1 (ICAM-1), a cell surface glycoprotein involved in adhesion 
and extravasation of leukocytes during inflammation [36-38]. ICAM-1 is expressed on most 
cell types and is upregulated under many pathologies, including LSDs [38, 39]. Hence, 
utilizing a drug delivery system with an affinity moiety specifically targeted to ICAM-1 can 
potentially enhance enzyme delivery to cells affected by LSDs. Due to the nature of LSDs, 
where the disease affects most cells and tissues, requiring systemic treatment, ICAM-1-
targeted drug delivery systems could broadly enhance delivery of enzymes in the body. 
Additionally, previous work in our lab has shown that coating a nanoparticle with antibodies 
targeting ICAM-1 instigates a multivalent engagement of ICAM-1, which induces 
endocytosis of the nanoparticle through a non-classical route [40]. Therefore, this strategy 
holds potential to bypass disrupted clathrin-mediated endocytosis found in some LSDs [27-
29]. Indeed, our lab has shown that ICAM-1-targeted nanocarriers enhance delivery of acid 




Niemann-Pick Disease (NPD) [41], along with enhanced degradation of the lysosomal 
substrate [42]. Whether this is applicable to other LSDs and whether the brain can also be 
targeted by this strategy remained to be tested. 
In view of this, the global hypothesis for this dissertation is that ICAM-1-targeted 
nanocarriers can: a) generally enhance accumulation of lysosomal enzymes throughout the 
body, b) facilitate transport across the endothelial and subendothelial layer of the blood-brain 
barrier, and c) enable preferential binding to diseased cells with internalization, trafficking to 
lysosomes, and degradation of the accumulated substrate. 
Investigation of the potential of ICAM-1-targeted nanocarriers for LSD treatment is 
assessed in cell culture and in vivo in mice. Cell culture systems enable studies to elicit 
distinct binding and resultant internalization, intracellular trafficking, and potential transport 
characteristics to selective cells and cell layers in a controlled environment. In vivo studies in 
mice, on the other hand, can then determine circulation time and accumulation at organ level, 
illustrating distribution patterns in a physiological system subjected to complex biological 
constraints (e.g. blood flow shear stress, presence of cell barriers, clearance from circulation, 
etc.) that are not present in an isolated cell culture models. Hence, both types of systems must 
be used to accurately learn the characteristics and potential efficacy of ICAM-1-targeted drug 
delivery system to deliver enzymes for LSD treatment. 
The next section (Section 2) will provide background information on the several 
issues that ICAM-1-targeted nanocarriers aim to address. This includes LSD treatment 
options as well as current nanotechnology-based strategies and targeting approaches 
exploited to improve various disease treatments. The methods used to perform the work 




and discussion in Section 4, and, finally, the overall conclusions of this work and potential 
future directions (Section 5). 
 
1.3. Significance and Novelty 
Previous work with ICAM-1-targeted delivery of ASM to NPD cellular and animal models 
showed promise [41, 42]. Additionally, ICAM-1-targeted platform has shown to be capable 
of transcellular transport across cell barriers, such as gastro-intestinal epithelial cells in 
culture [43]. Moreover, ICAM-1-targeting nanoparticle formulation and dose can be modified 
to modulate biodistribution pattern [44]. All in all, these studies suggest the potential for 
ICAM-1-targeted nanoparticles to improve enzyme delivery for LSD treatment. However, 
prior to the work described in this dissertation, whether enhanced lysosomal enzyme delivery 
by targeting ICAM-1 was unique to ASM or can be translated to improve delivery of other 
lysosomal enzymes had not been investigated; whether ICAM-1-targeting nanocarriers can 
traverse across other cell barriers such as that of the BBB remained unanswered; lastly, 
whether ICAM-1-targeted nanocarrier formulation with an enzyme load can be optimized 
without decreasing targeting specificity had also not been evaluated. Hence, this thesis aims 
to answer these questions. 
The significance of the work presented in this thesis is the expanded knowledge on 
utilizing and modulating ICAM-1-targeting nanocarriers to enhance enzyme delivery for two 
other LSD treatments. Specifically, we studied delivery of α-galactosidase (αGal) for 
treatment of Fabry disease (FD) [45] and α-glucosidase (GAA) for treatment of Pompe 
disease (PD) [46], expanding the application of ICAM-1-targeted delivery from previously 




cells (e.g. healthy versus diseased cells), internalization into cells, mechanism of 
internalization, lysosomal trafficking, and lysosomal substrate alleviation in disease cell 
models achieved by enzyme delivered by ICAM-1-targeted nanocarriers in cell culture 
(Section 4.1.).  This is the first time the expansion of ICAM-1-targeting application has been 
thoroughly studied and compared amongst three different LSDs. Additionally, NPD and 
several other LSDs bear neuropathy manifestations and current ERT does not reach the brain 
due to tightly regulated brain cell barriers [4, 8, 10, 35]. Hence, the efficacy of ICAM-1-
targeted nanoparticles to enhance enzyme delivery across the BBB with delivery to cells of 
the brain was demonstrated (Section 4.2.). This was done by thoroughly studying binding 
specificity to cells of the BBB and the brain (e.g. healthy versus diseased cells), 
internalization and/or transport efficiency into and across these cells, mechanism of 
internalization and/or transport, and intracellular trafficking to lysosomes in cells in culture. 
To our knowledge, this is the first time that transport of ICAM-1-targeted nanocarriers across 
brain cell barriers has been studied. Furthermore, in vivo work provided insight into 
circulation patterns, biodistribution to peripheral organs and, notably, the brain, and tissue 
specificity of enzyme delivered by ICAM-1-targeted nanocarriers compared to non-targeted 
enzymes, unique to the enzyme delivered (Section 4.3.). Lastly, we also describe for the first 
time that ICAM-1-targeted nanocarriers bearing enzyme cargo can be modulated to enhance 
enzyme delivery without negatively affecting targeting specificity by altering the formulation 
to shift the density ratio of enzyme cargo to targeting moiety and by increasing the 
concentration of the administered dose (Section 4.4.).  
In summary, the results from this dissertation portray that the potential of enhancing 
delivery of therapeutic enzymes by ICAM-1-targeting strategies for LSD treatment is not 
unique to ASM. ICAM-1-targeting platform can be used to enhance delivery of at least two 




[47, 48]. Additionally, we note that ICAM-1-targeting can assist in delivery across cell 
barriers to intractable tissue, a poignant challenge in current ERT treatment. In fact, ICAM-1-
targeted nanocarriers were transported across the BBB [49] and targeted cells of the brain in 
cell culture, paralleling with accumulation of lysosomal enzyme in the brain of mice [47, 48, 
50], important for treatment of neuropathic symptoms evident in several LSDs [16]. 
Furthermore, ICAM-1-targeting nanocarriers can be modulated to modify the amount of 
enzyme delivered to tissue. Interestingly, different formulations of ICAM-1-targeted 
nanocarriers carrying different enzyme cargo show differences in binding, internalization, 
lysosomal trafficking behavior and distinct in vivo biodistribution patterns, depicting a 
unique relationship between the particular enzyme cargo and ICAM-1-targeting system [47]. 
Hence, this emphasizes that cell culture and in vivo studies to investigate and optimize further 
applications of ICAM-1-targeting strategy for treatment of other LSDs must be carried 
through individually. Nonetheless, ICAM-1-targeting strategy is promising to improve 
current ERT for LSD treatment, especially as a systemic treatment that can target diseased 
tissue and deliver enzyme to the lysosome of cells via a non-classical route, bypassing 




SECTION 2: BACKGROUND 
2.1. Lysosomal storage disorders 
Lysosomal storage disorders (LSDs) are a group of rare inherited metabolic diseases 
comprised of more than 40 different diseases and have been reported to plague as many as 1 
in 2000 newborns every year [1-9]. LSDs are individually classified based on the lysosomal-
associated protein dysfunction that leads to complications [16]. Dysfunctional lysosomal-
associated proteins leading to particular LSDs can include lysosomal enzymes, lysosomal 
enzyme activator proteins, proteins in ion pumps in the lysosomal membrane, proteins 
involved in intracellular vesicular trafficking, or other transport machinery [52].  
Lysosomes are membrane-enclosed intracellular vesicular organelles that are 
dynamic and constitute ~5% of intracellular space in mammalian cells [53]. Lysosomes are 
crucial for the cell homeostasis and, therefore, tissue and organ structure and function [53, 
54]. They function to maintain a cell’s homeostasis by degrading different extracellular 
substrates that the cell accumulates through endocytosis or intracellular substrates through 
autophagy (e.g. lipids, nucleic acids, proteins, sugars). Lysosomes also play a role in assisting 
disposal of invasive pathogens and in repair of damaged plasmalemma lipids and proteins by 
removal of these lipids and/or proteins and/or supplying monomeric subunits to rebuild it [53-
59]. To digest these substances and objects, lysosomes contain more than 50 acidic 
hydrolases that are active in an acidic environment, pH of 4.5 to 5.0, which is maintained in 
lysosomes by proton pumps and H+-ATPases [54, 55, 60, 61]. These hydrolases are not active 
in neutral environments (e.g. the cytoplasm with a pH of ~7.2), thereby restricting the 




result if any function related to the lysosome fails or is faulty, putting the cell homeostasis in 
jeopardy. 
LSDs can result from genetic defects affecting any of the lysosomal components, 
most commonly enzymes, where mutations on the genes encoding these enzymes can affect 
their synthesis, folding, catalytic activity, functionality, etc [61]. Low levels of lysosomal 
enzyme activity affect all cells at varying degrees, leading to a build up of these 
macromolecular substrates in the lysosome that results in cellular injury, tissue dysfunction, 
and multi-organ failure leading to death. Approximately half, if not more, of LSDs affect the 
central nervous system (CNS), particular in LSDs that manifests soon after birth [16, 62]. 
Other complications include, but are not limited to, cardiac, hepatic, renal, and splenic failure, 
depending on the deficient enzyme and substrate accumulation. Organomegaly, defects on the 
connective-tissue, ocular pathology, and vasculopathy are also common symptoms of LSDs. 
Such is the case for diseases used as LSD examples in this study, including Fabry disease 
(FD) due to deficiency of acid α-galactosidase A (αGal), Type A and B Niemann-Pick 
disease (NPD) due to deficiency of acid sphingomyelinase (ASM), and Pompe disease (PD) 
due to deficiency of acid α-glucosidase (GAA) [45, 46, 63]. 
FD is an X-linked LSD caused by mutations of the GLA gene that encodes for αGal. 
This results in a deficiency in functional αGal, which leads to inefficient hydrolysis of 
glycolipids as galabiosylcermide and, mainly, globotriaosylceramide (Gb3), a side product of 
catabolized glycospingolipid globoside that is a structural part of the plasma membrane [64]. 
As a result, excess Gb3 accumulates in lysosomes, preferentially in glycolipid rich cells, such 
as endothelial, epithelial, smooth muscle cells, etc, leading to a progression of cardiac 





 Type A and B NPD are LSDs caused by mutation in the sphingomyelin 
phosphodiesterase 1 (SMPD1) gene, which encodes for ASM, resulting in a deficiency of 
active ASM. This leads to an excess accumulation of lipids, mainly sphingomyelin, a 
sphingophospholipid structurally prominent in cell membranes and a key player in signaling 
pathways such as apoptosis. Both type A and B NPD manifest complications in the lungs, 
liver, and spleen. In addition, type A NPD also severely affects the brain, leading to 
neurodegeneration and often death by age 2 or 3 years. On the other hand, type B NPD 
minimally affects cells of the brain, but more severely affects the lungs [63]. 
PD is an autosomal recessive LSD caused by mutations in the gene encoding GAA.  
These mutations lead to a deficiency of active GAA, resulting in excess accumulation of 
glycogen in all cells, an important form of energy storage. This disease markedly affects 
glycogen rich tissue, such as the liver and striated muscle cells (cardiac, respiratory, and 
skeletal muscles), resulting in muscle weaknesses and cardiopulmonary failure. In addition to 
the heart, liver, and muscles, this disease affects the vasculature and, sometimes, the brain 
[46]. 
Since deficient enzymes affect all lysosomes and, hence, all cells in both peripheral 
organs and the nervous system (although at varying degrees), a systemic drug delivery 
approach to treat LSD is crucial.  
 
2.2. Treatments for LSDs and their challenges 
Before the past two decades, the only treatment available for LSD patients was focused on 
supportive and palliative care [65]. With more studies leading to a better understanding of 




approaches. Research has focused on: 1) reduction of accumulated substrate, 2) augmentation 
of enzyme activity in cases where patients have residual enzyme activity, or 3) replacement 
of the deficient lysosomal enzyme. Combination of these therapies has also been proposed. 
 As mentioned, the cause of most LSDs is a defective lysosomal enzyme, leading to 
excess lysosomal accumulation of a particular substrate. Some patients synthesize normal 
amounts of enzyme, but is poorly active due to protein misfolding or instability [8, 52]. 
Hence, these patients can benefit from the use of substrate reduction therapy (SRT). This is a 
method where small molecules are used to restrict the synthesis of the enzyme substrate, 
thereby slowing the rate to allow endogenous residual enzyme to degrade the substrate at a 
manageable pace with optimal outcome [66]. Miglustat (Zavesca®, Actelion Pharmaceuticals 
Ltd, Allschwil, SWT), the molecule used as SRT for type I Gaucher disease and NPD type C, 
has gained clinical approval [66, 67]. Although promising results have been seen, serious side 
effects and metabolic imbalances have also been reported, and this treatment is often 
combined with other modalities [8]. 
Another strategy researchers have developed to treat LSD patients with innate low 
enzyme activity levels is to enhance the activity of the endogenous enzyme (enzyme 
enhancement therapy, EET). This has been pursued using small molecules for 
pharmacological chaperone therapy (PCT). Some LSDs can manifest due to enzyme 
misfolding or unfolding, e.g. 80% of patients diagnosed with non-neuronopathic Gaucher 
disease which is caused by a deficiency of active β-glucosidase [67]. Misfolded or unfolded 
enzymes are often halted upstream in the protein synthesis route, i.e. in the endoplasmic 
reticulum, with the mutated protein never reaching the lysosome and degrading in the 
endoplasmic reticulum. Pharmaceutical drugs act as “chaperones” to restore endogenous 
misfolded proteins by at least partially assisting them to fold into a functional conformation 




apparatus and downstream to the lysosome [66, 67]. Hence, with the assistance of PCT the 
now active enzyme can possibly reach the lysosome to degrade the accumulated substrate. 
Although positive outcomes have been obtained, this approach is only helpful for LSDs 
caused by misfolded or unfolded enzyme, limiting PCT as a therapeutic option to only a few 
cases and necessitating identification of the precise mutations involved [66, 68]. 
Gene therapy is another strategy pursued in order to treat LSDs. Most gene therapy 
efforts focus on complete replacement of the gene that encodes the defective enzyme, opting 
for the potential of absolute correctness and a long-term effect. This treatment method may be 
a viable treatment option for patients with rare LSDs [65]. For decades, researchers have 
conjectured the potential of gene therapy to directly transfer the normal gene for enzyme 
synthesis into deficient cells, through in vivo (injection of recombinant cDNA) or ex vivo 
transfection of cells from the patient followed by implantation, using viral vectors (e.g. 
adenovirus, adeno-associated virus, lentivirus, retrovirus) or non-viral vectors (e.g. 
liposomes, particles, Lipofectin®-peptide complex, CMV promoter driven or TAT-tagged 
pDNA) [69, 70]. Optimistically, initial successes were seen in mouse models; however, 
safety concerns of this approach have not been thoroughly addressed yet, mainly because the 
risks are still unknown [65]. Some clinical trials have showed leukemia-like disease 
developing in human patients treated with gene therapy, seemingly a result of insertional 
mutagenesis presented by the implanted transfected cells [70]. Regardless, more research is 
currently being conducted to optimize this approach. 
Stem cell transplantation has also been tested, such as bone marrow transplantation 
(BMT). Bone marrow mesenchymal stem cells provide a clean slate of cells that can be 
differentiated into several healthy cell types based on their environment. Similar to other 
methods previously discussed, BMT has provided relief in peripheral organs affected by the 




a few LSDs, although results remain fairly unpredictable depending on timing of treatment 
[72, 73]. Yet, for more severe neuropathic LSDs delivery of treatment to the CNS is still 
difficult due to the BBB. To mediate this, mesenchymal stem cells extracted from the bone 
marrow can be directly injected into the brain to form functioning neuronal networks [20, 
74]. However, this is highly invasive and risky. Serious complications and side effects have 
been seen in human trials, including issues with graft versus host disease [21, 22]. Another 
stem cell transplantation approach is extracting hematopoietic stem cells from umbilical cord 
blood. Previous work in immune deficient mouse models showed these cells to cross the BBB 
and differentiate into healthy cells that produce the wild-type protein in the brain [75, 76]. 
However, similar to BMT, graft versus host disease is a concern [76].  
Lastly, the most common and clinically available treatment method for LSDs is 
enzyme replacement therapy (ERT). ERT consists of systemic injections of recombinant 
lysosomal enzymes in hopes that this reaches the diseased tissue and enters cells to traffic to 
the subcellular target organelle, the lysosome (Figure 1). This method was first proposed by 




Figure 1. Enzyme replacement therapy (ERT) for 
lysosomal storage diseases (LSDs). Lysosomal 
enzymes (isolated from tissue or organism, or 
recombinant) are intravenously (i.v.) administered 
and anticipated to be endocytosed, and 





2.3. Enzyme replacement therapy for LSDs 
In the 1960s, the first LSD was classified as such and within that same decade ERT was first 
tested.  Unaltered GAA extracted from Aspergillus niger fungus or human placenta were 
intramuscularly and i.v. injected into infants with Pompe disease. This resulted in little effect, 
however moderate reduction of glycogen in the liver showed the potential of using this 
method [52, 77, 78]. This strategy was improved upon by observing the natural mechanism 
by which endogenous lysosomal enzymes are synthesized and targeted. Endogenous 
lysosomal enzymes are post-translationally modified in the Golgi apparatus to incorporate 
mannose-6-phosphate (M6P) residues which bind to M6P receptors (M6PR) and are then 
trafficked from the Golgi apparatus directly to lysosomes via clathrin coated vesicles [79-81]. 
Also, a fraction of these enzymes are secreted to the extracellular mileu. There, M6P 
containing enzymes bind to M6PRs present on the plasma membrane, resulting in clathrin-
mediated endocytosis and traffic to lysosomes [79-81]. Understanding how endogenous 
lysosomal enzymes could be trafficked to lysosomes from the extracellular milieu facilitated 
scientists to design ERT strategies. The recombinant enzymes used in ERT must contain M6P 
to target M6PR on the cell surface [82, 83]. Current technology to scale up production of 
recombinant enzymes and our ability to study proof-of-concept ERT in existing animal 
models have lead to the development, testing, and clinical implementation of ERT.  
Currently, ERT is approved for only six out of more than 40 LSDs. Type A and B 
NPD does not have a clinically available ERT option yet. On the other hand, ERT for FD and 
PD are available, albeit suboptimal, as discussed below. Fabrazyme® (Genzyme Corporation, 
Cambridge, MA) or Replagal® (Shire Human Genetic Therapies, Wayne, PA) are available 
for FD treatment, while Myozyme® and Lumizyme® (Genzyme Corporation, Cambridge, 




of ERT products largely successful in ameliorating LSD symptoms, especially in peripheral 
organs such as the liver and kidneys [35, 84, 85].  
Despite ERT’s effectiveness at alleviating symptoms in some peripheral organs, 
several tissues remain minimally treated, such as the brain, heart, and vasculature [34, 86-88]. 
Hence, even with ERT, LSD may still cause multiple organ complications and failures [34, 
86-89]. This could be due to the fact that although M6PR exists on most mammalian cells, 
expression is not uniform in all cells [80, 90]. In fact M6PR expression in organs shifts with 
age [91, 92], with expression of cation-independent M6PR becoming more prevalent in 
reticuloendothelial system (RES) organs with age, such as the liver [92]. Also, M6PR 
expression does not correlate to the homeostasis state of the cell, hence, targeting enzymes to 
M6PR does not predominately target enzymes to cells that are pathologically affected. 
Naturally occurring filtration by kidneys and clearance by RES may explain the preferential 
distribution of ERT to these organs. Even though some RES organs are targets for 
intervention, all tissues are affected and require treatment [93, 94]. Such is the case for ERT 
for FD and PD, and ERT for NPD that was under trial [10]. Additionally, the circulating 
recombinant enzymes (t1/2 ~10 to 20 minutes [10]) tend to be attacked by the immune system, 
including uptake by macrophages and anti-enzyme antibodies [95-100]. Some benefit does 
arise from delivering recombinant enzymes to diseased macrophages, such as in the case of 
treatment for Gaucher disease [100], but this also rapidly prevents enzymes from reaching 
other affected cells. Also, antibody against the injected enzyme develops, leading to 
resistance, as seen in ERT for FD and PD [95-101]. In addition, targeting M6PR may be 
viable for only some LSDs. Cellular uptake dependent on M6PR is reliant on clathrin-
mediated endocytosis, which has been observed to be disrupted in several LSDs [27-29, 51]. 
A method to deliver lysosomal enzymes via bypassing clathrin-mediated endocytosis may be 




Therefore, although ERT is promising and shows improvements in certain organs, it 
still proves to be suboptimal, lacking predominant targeting of diseased cells and capitalizing 
on defunct endocytosis routes for therapeutic uptake. 
 
2.4. Drug delivery systems for treatment of LSDs  
ERT improvement could perhaps be achieved by using drug delivery systems. For instance, 
the development of nanotechnology has enabled drug delivery through the development of 
nanoscale drug carriers (nanocarriers, Figure 2).  
 
Figure 2. Examples of 
compositions and 
architecture of carriers and 
other assemblies used for 
drug delivery. The group 
shaded in blue corresponds 
to inorganic nanocarrier 
formulations, the groups 
shaded in yellow or pink 
are examples of 
biomolecule or polymer 
based nanocarrier 
formulations, respectively. 
(Figure reproduced from 
[102]).  
 
Nanocarriers are macromolecular assemblies that improve the delivery of therapeutic and/or 
imaging agents by enhancing and/or controlling solubility, bioavailability, circulation time, 
biodistribution, and cargo release rate [102]. Nanocarrier material can be derived from 
biomolecules (lipids, DNA, protein) or can be synthetics (inorganic, organic), or hybrid. 




biodegradability, biocompatibility, tissue targeting, etc. In addition to the material of 
nanocarriers that make them unique, the structure of nanocarriers also plays a role in its 
function. Nanocarriers can take shape in linear form (linear polymers), spherical solid 
particles (quantum dots, metal particles), porous particles (carbon nanotubes), hollow or 
porous capsules (micelles, liposomes), or highly branched, tree-like structures (dendrimers), 
among many others.  
Biomolecule-based nanocarriers are attractive compared to all inorganic structures 
since risks are still relatively unknown and necessitate research to better understand toxicity. 
As an example, recent studies found that multiwall carbon nanotubes can induce cell 
permeability and risk increasing inflammation markers [103]. Biomolecule-based 
nanocarriers can be constructed of lipids, proteins, organelles, etc, which are deemed 
relatively biocompatible. The oldest examples studied are lipid-based formulations. 
Liposomes are lipid-based nanocarriers (50 nm to several µm in diameter) that form a shell 
with a bi-layer of phospholipids such that the lumen is an aqueous space that can hold 
hydrophilic macromolecules. The lipids forming the bi-layer are similar to a cell membrane, 
which is the distinct factor that makes liposomes highly biocompatible [104]. Lipid-micelles 
have also been attractive. They are constructed with a single layer of lipids, forming a 
hydrophilic shell with a hydrophobic core that can be loaded with hydrophobic molecules 
[105]. Nanocarriers can also be constructed with biocompatible proteins, which are low in 
cytotoxicity and can be formulated and structurally fabricated to bind well with the drug 
cargo [106]. Interestingly, to avoid immune rejection and ensure biocompatibility, natural 
cellular organelles have been extracted and loaded as nanocarriers for drug or gene delivery, 
such as exosomes [107]. Also, as an example of micrometer size carriers, whole cells have 




Nonetheless, for decades, polymer nanocarriers fabricated with synthetic, natural, or 
a hybrid of synthetic and natural materials have been the most popular and widely used drug 
delivery systems due to good control of charge, size, shape, and structure (hydrophobic 
versus hydrophilic, hollow versus solid versus porous, linear versus particle versus 
dendrimeric) [102]. Some examples include polymersomes, similar to lipososomes but 
constructed with block copolymers as opposed to lipids, polymeric micelles, and polymer 
dendrimers [102]. Some examples of synthetic polymers are polyanhydrides, 
polycaprolactone, poly(ethylene glycol) (PEG), poly(ethylenimine) (PEI), polylactides, 
polyglycolides, poly(lactide-co-glycolide) (PLGA), polyorthoesters, and poly(vinyl alcohol), 
most of which are minimally toxic and therefore regarded as biocompatible [102]. PLGA is 
commonly proposed in drug delivery since it is a material that has been previously used in 
FDA-approved devices (e.g. sutures, grafts, and prosthetics) and has been repeatedly proven 
to be biocompatible [108]. Moreover, PLGA’s degradability can be controlled, which is 
advantageous for monitoring drug release, and its size and structure modified by shifting the 
lactic to glycolic acid ratio [109]. In fact, several PLGA-based drug delivery systems are 
already approved for clinical use and several more are currently investigated [110, 111]. 
Degradation of some polymers can be controlled by calculating the biodegradation rate of the 
formulation, deeming it effective for controlling the release of a loaded cargo. Some 
polymers can mask the cargo from immune recognition, thereby prolonging circulation time 
and potentially improving tissue delivery, e.g. PEG [109, 112, 113]. Additionally, some 
polymer nanocarriers can protect active enzymes from proteolysis [114].  
Drug delivery systems have been widely applied to several therapies, including those 
aimed at LSDs. In fact, one of the first applications of liposomes studied in the 1970s was the 
encapsulation of enzymes for LSD treatment [115]. One major setback to currently available 




101]. Encapsulation could mitigate this by shielding the enzyme until delivered to lysosomes 
within cells. Efficiency of enzyme delivery to cells was improved by liposomes, but release 
of the enzyme cargo into the cytosol or other non-lysosomal compartments was observed 
[115]. Yet, altering liposome formulations (e.g. by coating liposomes with PEG) showed to 
prolong circulation and therapy activity by days [116]. PEG can also add ‘stealth’ properties 
[54, 117-119] and can be used to directly modify enzymes, e.g. PEG-modified dextranase 
encapsulated in liposomes prolonged circulation time without immune-recognition [117]. 
Calcium alginate microspheres have also been studied as a potential drug delivery vehicle 
that encapsulates therapeutic enzymes for a prolonged release [120]. However, this method 
can only be used for localized release, requiring implantation [120]. In addition, the use of 
drug delivery systems also applies to delivery of gene therapies, such as exploiting solid lipid 
nanoparticles to deliver plasmid that codes for αGal, which has shown great potential of 
inducing production of functional αGal in cells [121]). This could be also used, 
hypothetically, in SRT. Yet, the use of drug delivery systems for LSD treatment remains 
largely unexplored [62]. 
 
2.5. Targeting strategies for treatment of LSDs 
Lysosomal ERTs available today are i.v. administered by injecting the therapeutic enzyme 
into the vasculature to target cells that express M6PR for intracellular lysosomal delivery via 
clathrin-mediated endocytosis [82, 83]. However, M6PR expression is not uniform through 
tissues, does not differentiate healthy from diseased affected tissue, and the associated 
clathrin pathway is affected in some LSDs [27-29]. Hence, targeting M6PR may contribute to 
suboptimal effect observed [27-29]. Additionally, M6PR-based ERT does not cross cellular 




accumulation in affected organs, lack of delivery across cell barriers to intractable tissues, 
and limited intracellular delivery of ERT should be improved. This could be achieved by 
utilizing a targeted drug delivery system, which has the potential to shield the therapeutic 
enzyme from immune recognition and exploit a different targeting strategy to improve 
enzyme transport across cell barriers, distribution to main target organs, selectivity toward 
diseased cells, and internalization and lysosomal delivery in cells through an M6PR-/clathrin-
independent pathway. 
 Targeting a therapeutic in a physiological system means to mediate an interaction 
between the therapeutic with the system. This interaction can be mediated for delivery of 
therapeutics with the assistance of the material of the drug delivery system (e.g. shape, size, 
material properties, etc.), but the most common way of active targeting is ligand-mediated. In 
fact, ligand-mediated binding occurs frequently in normal physiology functions (e.g. 
neurotrasmitters bind to receptors on neurons for uptake into the cell [123]), even in 
pathophysiological circumstances (e.g. virus infection [124]). To achieve this targeting 
strategy targeting moieties are often exploited, especially in an effort to address select sites by 
promptly binding to specific molecules. Targeting moieties can include a vast variety of 
molecules, such as proteins, peptides, nucleotides, sugars, small molecules, etc [24]. Mainly 
antibodies are used due to their high affinity and specificity towards their targets. Antibodies 
can be conjugated directly to therapeutics or to drug delivery vehicles carrying said 
therapeutics. Additionally, due to immune response concerns with using antibodies, 
fragments of antibodies, specifically the variable binding domains, have been developed to 
conserve antibodies’ high affinity and specificity to distinct targets without the recognizable 
Fc region that results in clearance and/or immunorecognition [125-127]. Natural ligands to 
cell receptors are also widely used as they inherently bind to respective cell receptors without 




[24]. Similarly, small molecules such as vitamins (e.g. folate, vitamin B12) and sugars (e.g. 
monosaccharide mannose) are exploited to bind to their respective cell surface receptors with 
minimal modification necessary [24].  
Combining targeting strategies to drug delivery vehicles can enhance delivery of 
therapeutics by increasing biocompatibility of the loaded therapeutic, promoting stealth-like 
properties, selective binding and transport, and control release of the carried cargo, thereby 
improving bioavailability of the carried therapeutic. Currently, fast clearance and lack of 
protection of ERT yields enzyme degradation (e.g. by proteases) in circulation. By loading 
the enzyme on a drug delivery vehicle, the enzyme circulation half-life may improve and 
these molecules can be shielded from immune recognition. In combination with a rapid 
targeting, clearance could be minimized with more enzyme being available to distribute to 
other organs.  
Methods to use targeted drug delivery vehicles to improve ERT have been studied. 
Exploiting liposomes to deliver enzymes for LSDs was introduced in the early 1960s. 
However, much of the work noted that liposomes may protect enzyme during circulation and 
even extend enzyme activity to days (versus hours of non-encapsulated enzyme) but does not 
avoid clearance, ~70% of the dose still accumulated into the liver [116]. This may be 
beneficial for LSD that exhibit storage in the liver, but the lack of enzyme distribution to 
other organs suggests that other affected tissue would not be efficiently treated. Hence, by the 
1970s, Finkelstein and Weissmann suggested to improve and refine delivery of liposome-
encapsulated enzyme to certain cell types by incorporating ligands recognizable by cell 
surface receptors into liposomes or coated onto liposomes [115]. Yet this idea was only tested 
to improve liver delivery [24]. Today, researchers focus on other targeting strategies. For 
instance, fusion proteins provide a glycosylation-independent mechanism of enzyme 




different domain on M6PR by fusion with a 67-amino acid peptide fragment from insulin-like 
growth factor II (IGF-II) that interacts with the binding site IGF-II/M6PR, which improved 
delivery of enzyme to the heart, kidney, lungs, versus that of non-targeted counterpart [11, 
62, 128]. Also, when GAA was fused with IGF-II peptide fragment to treat Pompe disease 
mice, delivery to target tissues (heart and skeletal muscle) was improved compared to 
currently available GAA ERT, yet, the liver (which is not a Pompe disease target) still 
accumulated more enzyme [129]. Alternative to targeting M6PR, targeting of other receptors 
have also been studied. Specifically, GAA (Pompe disease), and α-L-iduronidase (Hurler 
syndrome) were fused with receptor-associated protein (RAP) to target LDL receptor, 
transferrin to target transferrin receptor (TfR), or a peptide from an antibody specifically 
targeted to the insulin receptor (InsR) [12, 24, 62]. Interestingly, preparing fusion proteins 
may not be necessary: e.g. simply mixing recombinant enzyme with a targeting peptide 
consisting of tripeptidyl peptidase I with a 36-amino acid peptide composed of an apoE 
peptide and polylysine to treat Neuronal ceroid lipofuscinosis, prior to injection, was 
sufficient to improve targeting to the brain [130]. These methods demonstrate that targeting 
alternative to M6PR is valuable in improving enzyme biodistribution. Yet, the combination of 
targeting strategy and drug delivery system is still poorly explored. 
  
2.6. Endocytosis and subcellular transport of drug delivery systems for LSD 
treatment  
Transport across cellular barriers is necessary when therapeutic agents (such as lysosmal 
ERT) are aimed to treat tissue beyond the vasculature. In this case, targeting strategies can be 
directed to either enhance the paracellular transport between cells or the transcellular 




transport by opening all junctions may be relatively unsafe unless very transient [26, 105, 
131-133]. To achieve transcellular transport, the therapeutic must first be endocytosed into 
the cell from its apical membrane, then trafficked through the cell body via vesicular 
transport, and then exocytosed from the basolateral membrane of the cell. One method to 
achieve uptake is targeting cell markers that induce trafficking to distinct subcellular 
organelles, such as those exploited by the shiga and cholera toxins that target molecules of 
the cell surface and induce uptake and trafficking to the Golgi and endoplasmic reticulum 
[24, 134, 135]. Another method is to initiate transcellular routes by targeting pathways that 
inherently exist, such as folate, insulin, LDL, or transferrin receptors with corresponding 
ligands. Often, these targets uptake bound material and transport them via classical 
endocytosis/transcytosis routes, clathrin- or caveolae-mediated pathway [24]. 
 
 
Figure 3. Paracellular versus transcellular transport across a cell barrier. Delivery of 
therapeutics to tissue often requires transport across cell barriers. Transport across cell 
barriers occurs via one of two key pathways of transport: paracellular (between cells) and 
transcellular (across cells). The latter route is medicated by either membrane transporters or 





Vesicular transport similar to that emphasized for transcytosis can be used to achieve 
lysosomal transport. This can be achieved by inducing engulfment as a result of immune 
recognition or by using specific targeting agents. If macrophages and or phagocytic cells are 
the target, as is the case for Gaucher disease and some other LSDs, then inherent enzyme 
engulfment by these cells would situate the enzyme in lysosomes of the target cells [100]. 
However, if these cells are not the intended targets, other strategies must be used. As 
discussed above, fusion proteins are a promising targeting strategy for delivering lysosomal 
enzymes for treatment of LSDs (Section 2.5.). In fact, a major setback for currently available 
ERT to treat LSDs is its ineffectiveness to deliver therapeutics to treat difficult to reach 
tissue, specifically target tissue that require therapeutics to cross cell barriers (e.g. brain). 
Fusion proteins can potentially mitigate this impediment. Studies showed that fusion of α-L-
iduronidase with peptide binding fragment from aplipoprotein E (apoE) to target LDL 
receptor, from antibody targeted to InsR, or from antibody targeted to TfR helped deliver 
enzymes across the BBB to the brain [136-138]. Interestingly, one study showed that treating 
mothers with fusion proteins of β-glucuronidase with Fc domain of IgG targeting neonatal Fc 
receptors delivered the enzyme to the Mucopolysaccharidosis VII model mouse fetuses, 
crossing the placenta.  However, all the above targeting strategies discussed (targeting InsR, 
LDL receptor, M6PR, TfR) capitalize on clathrin-mediated endocytosis for uptake of enzyme 
into the cell and trafficking to lysosomes, which does not address the issue of clathrin-
impairment present in some LSDs [27-29]. Therefore, an alternative pathway must be 





2.7. ICAM-1-Targeting strategies for LSD applications 
Targeting and transport strategies often observe and take advantage of ligand-receptor 
binding examples that occur naturally. One target molecule of interest is intercellular 
adhesion molecule-1 (ICAM-1), a transmembrane glycoprotein that’s expression is naturally 
upregulated on cells under stress, such as in pathology. Its role is to allow leukocyte adhesion 
to inflamed tissue [139]. ICAM-1 is expressed on most cell types, including epithelial cells, 
fibroblasts, macrophages, neurons, tumor cells, but most prominently expressed on 
endothelial cells that line the vasculature [39]. Hence, its placement on endothelial cells of 
the vasculature is convenient to assist transportation of leukocytes from circulation and to 
inflamed tissue. 
ICAM-1 has an extraceullar region with 5 domains, one single transmembrane-
spanning domain, and an intracellular cytosolic tail [39]. Binding of extracellular domains 
triggers intracellular signaling mediated by the cytosolic domain. The signaling cascades 
triggered by binding of ICAM-1 vary amongst cell types and triggering ligands [39]. Some 
activated signaling cascades can involve cell survival and apotosis [140] and some involve 
stress response and apoptosis [141].  
Due to its role in inflammation, ICAM-1 expression can mark sites affected by 
disease. In fact, diagnostic methods have been developed to visually monitor disease 
progression by tracing ICAM-1 [142, 143]. Beyond diagnostic purposes, targeting ICAM-1 
can enhance drug delivery. If ICAM-1 is bound by anti-ICAM or anti-ICAM decorated 
nanocarriers (anti-ICAM NCs), it potentially creates steric hindrance by physically blocking 
leukocytes from binding to ICAM-1, theoretically acting as an anti-inflammatory agent [144, 
145]. Additionally, the expression profile of ICAM-1 and its enhancement in diseased-tissue 




delivery of drugs to specific locations [144, 146-156]. Indeed, our previous work confirmed 
that anti-ICAM NCs bound significantly more to diseased cell models (endothelial cells 
treated with TNFα to mimic pathological conditions) than to non-treated healthy cells [157].  
To control targeting and endocytic rate without affecting endocytic route, the size and 
shape of anti-ICAM drug delivery systems can be adjusted, e.g. 100 nm to 5 µm carrier 
diameter, spherical- versus disk-shaped [158, 159]. Small spherical carriers bind and are 
endocytosed faster than larger and/or non-spherical shaped anti-ICAM NCs. Hence, to study 
enzyme delivery treatment for LSDs, 100-nm diameter spherical NCs coated with anti-ICAM 
and cargo to optimize coating density and bulk delivery for quick binding and uptake into 
cells seemed appropriate. Another method to control endocytic rate of anti-ICAM 
nanocarriers is to engineer the system to distinctly target specific or combinations of various 
eptitotes of ICAM-1 [160]. Or, delivery of ICAM-1-target vehicles can be additionally loaded 
with biologics that can trigger more rapid signaling pathways to enhance delivery [161]. 
Another method to minimize size of anti-ICAM NCs is to replace whole antibody molecules 
with anti-ICAM targeting fragment, peptides, or ligands, which has shown to still efficiently 
achieve ICAM-1-targeting [125]. Additionally, this method may help anti-ICAM NCs evade 
immune recognition. Indeed, using monomolecular anti-ICAM approach would minimize 
size and eliminate the large size of nanoparticles. However, binding as a result of 
monomolecular anti-ICAM potentially induces different response and distribution profile 
than multivalent anti-ICAM drug delivery system [152, 162]. Although little is known of 
monomolecular anti-ICAM conjugated drug delivery, the distribution pattern of delivered 
cargo (e.g. enzyme therapeutic) can be expected to be different compared to the drug delivery 
pattern of its multivalent anti-ICAM drug delivery system counterpart. 
Bound multivalent anti-ICAM drug delivery systems trigger vesicular endocytosis 




cellular adhesion molecule (CAM)- mediated endocytosis, independent of the classical 
caveolae- or clathrin-mediated endocytosis pathways and different from phagocytosis and 
macropinocytosis [40]. This pathway involves signaling cascades commonly observed when 
ICAM-1 is bound by its natural ligand, leukocytes [39]. This novel endocytic pathway route 
is advantageous for diseases requiring an alternative treatment delivery pathway to the 
classical endocytosis routes, such as LSDs [27-29, 51]. In fact, anti-ICAM NCs transport 
across gastrointestinal epithelial cell monolayer is also mainly through CAM-mediated 
transport [43]. This parallels well with known occurrences of micron size leukocyte 
extravasation from circulation to tissues, without opening endothelial cell junctions [38, 39], 
and is promising for therapies requiring endocytosis and transport via an alternative to 
classical pathway. 
In this thesis we focus on improving delivery of lysosomal enzymes for LSD 
treatment using ICAM-1-targeted NCs (anti-ICAM/enzyme NCs). We note that the previous 
discussed issues with ERT can be addressed and/or avoided using anti-ICAM NCs. 
Specifically, in Section 4.1. we discuss our findings of enzyme loaded anti-ICAM NCs (anti-
ICAM/enzyme NCs) internalized into LSD-model cells via CAM-mediated endocytosis in 
culture, and delivered enzyme efficiently to lysosomes to degrade accumulated substrate [42, 
47, 48]. This bypasses the impaired clathrin-mediated route current ERT utilizes [27-29, 51]. 
Granted, our previous work with anti-ICAM/ASM NCs showed promise for improving ERT 
for Type A and B NPD [42]. However, for the first time, we show in this thesis that anti-
ICAM NCs can be used as a generic platform with the potential to improve ERT delivery for 
Fabry disease and Pompe disease [47, 48]. Moreover, current ERT is unable to deliver 
therapeutic enzyme to the brain [4, 8, 10, 35]. In Section 4.2., we discuss for the first time 
how anti-ICAM/enzyme NCs can cross BBB cell models to target cells of the brain. 




organs analyzed in vivo by several folds as compared to non-targeted enzymes, which 
includes intractable tissues, such as the brain and previously noted tissues that ERT was 
incapable to sufficiently treat, such as the heart, skeletal muscles, and vascular-rich lungs [4, 
8, 10, 34, 35, 41, 42, 47, 48, 86-88]. Since LSD is a systemic pathology, affecting all cell 
types at varying degrees of severity, it is beneficial to deliver treatment to all tissue.  Lastly, 
in Section 4.4., we discuss the potential of optimizing enzyme delivery, without negatively 
affecting enzyme biodistribution, by modulating anti-ICAM/enzyme NC formulation. 
 




Section 3: Methods 
3.1. Antibodies and reagents 
Monoclonal antibodies to ICAM-1, R6.5 (mouse anti-human) [139] and YN1 (rat anti-mouse) 
[163], were purified from hybridomas and obtained from ATCC (Mananssas, VA). Non-
specific mouse or rat IgG, as well as fluorescently labeled secondary antibodies, were 
purchased from Jackon Immunoresearch (West Grove, PA). Neutral α-galactosidase (αGal; 
~32.25 kDa) from Escherichia coli or green coffee beans were purchased from Calbiochem 
(SanDiego, CA) and Sigma-Aldrich (St. Louis, MO). Recombinant neutral α-glucosidase 
(GAA; ~68.5 kDa) from Saccharomyces cerevisiae was also from Sigma-Aldrich (St. Louis, 
MO). Recombinant human acid sphingomyelinase (ASM; ~75 kDa) was kindly provided by 
Dr. Edward Schuchmann (Mount Sinai School of Medicine; New York, NY). Fluoresbrite® 
polystyrene latex particles of 100-nm diameter size were from Polysciences (Warrington, 
PA). Radioisotope labeling with 125Iodine was done using Na125I from PerkinElmer 
(Waltham, MA) and Iodogen pre-coated tubes from Thermo Fisher Scientific (Waltham, 
MA). Unless stated otherwise, all cell culture media and related supplements were from 
Cellgro (Manassas, VA) and all other reagents were from Sigma-Aldrich (St. Louis, MO). 
 
3.2. Iodination of proteins 
Radioisotope labeling of antibodies or enzymes with 125Iodine was done by incubating 
~20 µCi of Na125I from PerkinElmer (Waltham, MA) and Iodogen beads or Iodogen pre-
coated tubes from Thermo Fisher Scientific (Waltham, MA) with 100 µL of 1 µg/µL protein 




protein mixture through centrifugation (1000g for 4 minutes) in a 6 kDa cutoff gel size 
exclusion column (Biorad, Hercules, CA), which eluted only the iodinated protein. Prior to 
filtering the iodinated protein, the column was inverted several times to thoroughly 
homogenize the gel, then washed with 2 mL of phosphate-buffered saline (PBS), and packed 
by centrifugation (1000g for 1 minute). The concentration of the eluted iodinated protein was 
determined with a Bradford assay compared to known bovine serum albumin (BSA) 
concentrations. The amount of free 125I still remaining in the eluted iodinated sample was 
estimated by performing trichloroacetic acid (TCA) precipitation assay by mixing 2 µL of 
iodinated protein to 1 mL of 3% BSA-PBS (PBS supplemented with 3% BSA) and 0.2 mL of 
100% TCA to precipitate the iodinated protein. After a 15 minute incubation period at room 
temperature, TCA samples were centrifuged (2755g for 5 min) and the supernatant was 
measured for 125I content using a gamma counter (2470 Wizard2; PerkinElmer; Waltham, 
MA). From this, the percent of free 125I was determined and subtracted to estimate the 
specific activity of the iodinated protein (CPM/µg). 
 
3.3. Nanocarrier preparation and characterization 
Model polymer nanocarriers (NCs) were prepared as described [47, 48], by adsorbing 
(hydrophobic interactions) either enzyme (ASM, αGal, or GAA), control non-specific IgG, a 
mix of anti-ICAM and IgG (95:5 or 40:60 mass ratio), or a mix of anti-ICAM and enzyme 
(95:5 or 50:50 antibody-to-enzyme mass ratio) on the surface of 100-nm diameter, FITC-
analog labeled polystyrene particles (enzyme NCs, IgG NCs, anti-ICAM NCs, anti-
ICAM/enzyme NCs). Non-coated counterparts were separated by removing the supernatant 
after centrifugation (13.8g for 3 minutes), and coated nanocarriers were resuspended at the 




for in vitro cell culture experiments, followed by gentle sonication to prevent aggregation 
(~25 pulses for 5 seconds at ~22.5 µm amplitude, using a sonicator with a set output 
frequency of 22.5 kHz; Microson™ XL2000; Qsonica, LLC; Newtown, CT). A resultant 
final concentration of ~6.8x1011 NCs/mL and ~50 µg of protein/mL of prepared nanocarriers 
was obtained, and was then further diluted by 10-folds in complete medium supplemented 
with 1% BSA for cell culture experiments. Concentration of nanocarriers used in mice 
experiments varied (as indicated below) between ~1.8x1013 to ~8.2x1013 NCs/kg mice, which 
equated to ~1.3x103 to ~6.0x103 µg of protein/kg mice. Where specified, the targeting 
antibody or enzyme cargo was labeled with 125I for radioactive tracing or NIR fluorophore 
(Alexa Fluor 750; Invitrogen; Carlsbad, CA) for fluorescence tracing. 
The number of antibody and/or enzyme molecules per nanocarrier was determined by 
using 125I-labeled antibodies or enzymes to coat nanocarriers, as stated above. The total 125I-
count remaining in the nanocarrier preparation was divided by the total number of 
nanocarriers coated to calculate total CPM/NC. This value was then multiplied by the known 
specific activity of the iodinated protein (CPM/µg) to determine the total mass of protein 
coated per NC, which could then be converted to molecules or protein per nanocarrier by 
Avogadro’s constant and the protein’s molecular weight. The nanocarrier surface was 
estimated to become fully covered with antibody and/or enzyme, with no BSA found on the 
coat (≤0.5% of total coat molecules). The diameter and zeta potential of coated nanocarriers 
were measured via dynamic and phase analysis light scattering (Zetasizer nano-ZS90; 
Malvern Instruments; Westborough, MA). 
The release of 125I-enzyme from anti-ICAM/125I-enzyme NCs was determined as 
described [47, 48] at 30 min, 1, 5, 8, 24, 48, and 72 hours after particle preparation by 
centrifugation to separate free enzyme from particle bound fraction and measured with a 




by pipetting, and sonication. Enzyme release was also tested during incubation in storage 
buffer (1% BSA-PBS), complete cell medium (described below), or fetal bovine serum 
(FBS), at 4 °C or 37 °C, pH 7.4 or pH 4.5, and in the absence or presence of αGal substrate 
analog 2-μg/ml N-Dodecanoyl-NBD-ceramide trihexoside (NBD-Gb3; Matreya, LLC, 
Pleasant Gap, PA) to mimic Fabry disease or GAA substrate 50 mg/mL glycogen to mimic 
Pompe disease. 
 
3.4. Cell culture  
Human primary cell lines were used for all cell culture experiments: human umbilical vein 
endothelial cells (HUVECs; Clonetics, San Diego, CA), human brain microvascular 
endothelial cells (HBMECs; Applied Cell Biology Research Institute, Kirkland, WA), human 
NHA astrocyte cells (ACs; Lonza Walkersville Inc., Walkersville, MD), and human brain 
vascular pericyte cells (PCs; Sciencell Research Laboratory, Carlsbad, CA). Human 
neuroblastoma subclone SH-SY5Y cells (NBCs; American Type Culture Collection, 
Manassas, VA) were cultured and differentiated into neuron-like cells for cell culture 
experiments. All cells were cultured in 37°C, 5% CO2, and 95% humidity environment in 
respective supplemented medium. For microscopy experiments, mono-cultures of cells 
between passage 4 to 10 were seeded onto glass coverslips and cultured with 100 U/mL 
penicillin and 100 µg/mL streptomycin in the following media: HUVECs were seeded onto 
1% gelatin coated glass coverslips at a density of 7.5x104 cells/cm2 and grown in M-199 basal 
medium supplemented with 15% FBS, 2 mM L-glutamine, 15 µg/mL endothelial cell growth 
supplement, and 100 µg/mL heparin; HBMECs were seeded onto 1% gelatin coated glass 
coverslips at a density of 7.5x104 cells/cm2 and cultured in RPMI-1640 basal medium 




supplement, and 100 µg/mL heparin; ACs were seeded onto 1% gelatin coated glass 
coverslips at a density of 5.0x104 cells/cm2 and cultured in DMEM basal medium 
supplemented with 15% fetal bovine serum (FBS), 50 µg/mL gentamicin, and 2 mM L-
glutamine; PCs were seeded onto poly-L-lysine coated glass coverslips at a density of 
2.5x104 cells/cm2 and cultured in Pericyte media (ScienCell Research Laboratories, Carlsbad, 
CA) supplemented with 20% FBS and 15 μg/mL pericyte growth factor; NBCs were first 
propagated then differentiated into neuron-like cells (NLCs). NBCs were seeded on 1% 
Matrigel (BD Biosciences, Franklin Lakes, NJ) coated flasks at a density of 5.0x103 cells/cm2 
and propagated in RPMI-1640 basal medium supplemented with 10% FBS, 2 mM L-
glutamine, and 1 mM sodium pyruvate. NBCs were passaged when cultures grew to be 60% 
confluent, no more than 10 times prior to differentiation. To differentiate NBCs into NLCs, 
NBCs were seeded onto 1% matrigel coated coverslips at a density of 7.5x103 cells/cm2 and 
cultured in DMEM supplemented with 5% FBS and 10 µM retinoic acid (without penicillin 
and streptomycin) for 5 days, then cultured in Neurobasal medium supplemented with B-27, 
50 µg/mL gentamicin, 2 mM GlutaMaxI, 2 mM dibutyryl-cyclic AMP, 20 mM potassium 
chloride, 50 ng/mL recombinant human brain-derived neurotrophic factor, 100 U/mL 
penicillin, and 100 μg/mL streptomycin, as instructed [164, 165].  
Skeletal muscle cells were isolated from C57BL/6 mouse gastrocnemius and 
quadriceps by digestion with 0.2 mg/mL collagenase in culture medium (described below) for 
24 hours at 37°C. Muscle cells were then washed with DMEM, seeded on Matrigel coated 
glass coverslip, and cultured in DMEM supplemented with 2 mM L-glutamine, 100 U/mL 





3.5. ICAM-1 expression 
ICAM-1 expression on all cell types listed above was assessed by fluorescence microscopy. 
Cells seeded onto glass coverslips as aforementioned were treated with or without 10 ng/mL 
TNFα overnight, and then fixed with cold 2% paraformaldehyde for 15 minutes at room 
temperature. Fixed cells were then washed three times with 1 mL of PBS and then incubated 
with 55.5 pM anti-ICAM, or non-specific IgG as a control, in 1% BSA-PBS for 1 hour at 
room temperature, followed by incubation with 26.7 pM FITC- or Texas Red-labeled 
secondary goat-anti-mouse antibody for 30 minutes at room temperature. The nucleus was 
stained with 14.3 µM blue 4′,6-diamidino-2-phenylindole (DAPI). Fluorescence images were 
captured with SlideBook 4.2 software (Intelligent Imaging Innovations, Denver, CO) using 
Olympus IX81 microscope (Olympus, Inc., Center Valley, PA), ORCA-ER camera 
(Hamamatsu, Bridgewater, NJ), and a 40x objective (Olympus Uplan F LN; Olympus, Inc., 
Center Valley, PA) with a DAPI, FITC, and/or Texas Red filter (1160A-OMF, 3540B-OMF, 
4040B-OMF; Semrock, Inc., Rochester, NY). Sum fluorescence intensity (A.U.) per cell and 
fluorescence intensity per area of each cell was analyzed in with the Image Pro 6.3 software 
(Media Cybernetics, Inc., Bethesda, MD) and normalized to the background fluorescence. 
Phase-contrast was used to delimit the cell borders.  
 
3.6. Binding of ICAM-1-targeted nanocarriers to cells  
Healthy or diseased (TNFα, TNFα and DGJ, or TNFα and turanose treated, as indicated 
below) cells were incubated with green Fluoresbrite IgG NCs, anti-ICAM NCs, or anti-
ICAM/enzyme NCs (50:50 antibody to enzyme mass ratio; 6.8x1010 NCs/mL) at 37°C for 1, 




stained with 14.3 µM DAPI. Fluorescence microscopy was used to capture micrographs as 
described above with a 40x or 60x objective to estimate the total number of green fluorescent 
NCs associated per cell. This was achieved using a macro that normalizes the area of specific 
fluorescence (over a threshold background) to the number of pixels that theoretically 
correspond to the size of a single particle, viewed under the magnification used to image. 
 
3.7. Endocytosis of ICAM-1-targeted nanocarriers into cells 
Healthy or diseased cells were incubated with green Fluoresbrite labeled anti-ICAM NCs or 
anti-ICAM/enzyme NCs (50:50 antibody to enzyme mass ratio; 6.8x1010 NCs/mL) for 1, 3, or 
5 hours continuously at 37°C, or for 30 minutes pulse then washed to remove unbound NCs 
followed by replacement of fresh medium for a total incubation time of 1 hour at 37°C. Cells 
were then washed to remove any unbound NCs, then fixed with paraformaldehyde. Surface 
bound NCs were counter stained with 26.7 pM Texas Red goat-anti-mouse secondary 
antibody. Since fixed cells were not permeabilized, the secondary antibody can only bind to 
anti-ICAM coat on nanocarriers located on cell surface and can not reach NCs that are 
endocytosed into the cell [40]. Nuclei were stained with 14.3 µM DAPI. Fluorescence 
microscopy was used to visualize cell samples and collect micrographs. In merged 
micrographs, green fluorescence alone revealed endocytosed NCs, yellow fluorescence 
(green + red) revealed surface bound NCs, and blue fluorescence (DAPI) located nuclei. 
From this, the total number of NCs endocytosed per cell could be estimated and compared to 





The mechanism by which cells endocytose anti-ICAM NCs or anti-ICAM/enzyme 
NCs was studied by performing similar experiments in the presence of one of the following 
pharmacological inhibitors of endocytic transport: 3 mM amiloride (which inhibits CAM-
pathway), 1 μg/mL filipin (which inhibits caveolae-mediated pathways), or 50 μM 
monodansylcadaverine (MDC; which inhibits clathrin-mediated pathways) [40]. The effects 
of these inhibitors on the uptake of NCs was evaluated similarly as stated above, using 
fluorescence microscopy to calculate the internalization efficiency in each condition and 
compared to that of the control, incubation in absence of an inhibitor. 
 
3.8. Lysosomal trafficking of ICAM-1-targeted nanocarriers in cells 
Lysosomes were labeled by incubating cells with 100 µM Texas Red dextran (10 kDa) for 45 
minutes at 37°C to allow for cellular uptake followed by removal of the medium containing 
this marker. Incubation was then continued with medium without this marker for a total of 1.5 
hours at 37°C to ensure trafficking of internalized dextran to lysosome [166]. Since dextran is 
a polysaccharide that cannot be enzymatically degraded in mammalian cells, it therefore 
stably accumulates in lysosomes to permit their visualization [157]. Cells were then incubated 
with green Fluoresbrite anti-ICAM NCs or anti-ICAM/enzyme NCs (50:50 antibody to 
enzyme mass ratio; 6.8x1010 NCs/mL) for 1 hour at 37°C to allow for binding. Medium was 
then washed to remove unbound NCs, followed by replacement with fresh medium and 
additional incubation for 0, 2, or 4 hours at 37°C (total incubation time of 1, 3, or 5 hours) to 
synchronize transport of pre-bound NCs. Cells were then fixed and the nucleus stained with 
DAPI. The number of NCs that colocalized with Texas Red dextran-labeled lysosomes was 
semi-quantitatively measured using fluorescence microscopy. Green fluorescence alone 




revealed lysosomes without NCs, and yellow fluorescence (green + red) revealed NCs 
localized to labeled lysosomes. From this the total number of NCs co-localized with 
lysosomes could be estimated for each cell and compared to the total number of NCs 
associated per cell in order to extrapolate lysosomal trafficking efficiency as percent NC co-
localization in lysosomes. 
 
3.9. Cell culture models of the blood-brain barrier 
For experiments studying transport across the BBB, a monolayer of HBMECs was seeded at 
a density of 1.25x105 cells/cm2 on 1 µm porous membrane Transwell inserts (BD Falcon, 
Franklin Lakes, NJ) and grown for 7 days, exchanging medium every 2 days, to achieve 
confluence as recommended [167, 168]. To confirm integrity of the confluent monolayer, 
trans-endothelial electrical resistance (TEER) values were measured across the monolayer in 
initial experiments showing values consistent with published work, ~45 Ohms·cm2 on day 7, 
confirming our model [167, 168]. For co-culture BBB models, first ACs or PCs were seeded 
at a density of 5.0x103 cells/cm2 on the basolateral side of the transwell membrane insert 
(inverted) for 3 hour at 37°C in respective culture media to develop the subendothelial BBB 
layer. Excess, unbound cells were then removed by aspirating remaining media and the 
transwell membrane inserts were flipped upright into 24-well plates. Then, HBMECs were 
seeded on top of the transwell membrane insert (apical side) to develop the endothelial BBB 
layer, while keeping the subendothelial BBB layer attached by addition of culture media in 
both apical and basolateral chambers [167]. These bi-layer BBB models were grown in 
HBMEC complete medium for 7 days, replacing the medium every 2 days. For experiments 
requiring diseased BBB models, cells were incubated with 10 ng/mL TNFα-supplemented 





3.10. Transcytosis of ICAM-1-targeted carriers across BBB cell models 
Endothelial (HBMECs) monolayers were cultured on transwell inserts with or without 10 
ng/mL TNFα. 125I-anti-ICAM NCs or non-specific 125I-IgG NCs (6.8x1010 NCs/mL) were 
added to the apical chamber over HBMEC monolayers for 30 minutes at 37°C. Both apical 
and basolateral chambers were then washed to remove unbound NCs as well as NCs that may 
have leaked to the basolateral chamber. NCs that remained bound continued to be incubated 
for a total of 1 or 5 hours at 37°C to allow for potential transport. Incubations were conducted 
in control medium or in medium containing either 222 pM anti-ICAM to competitively bind 
ICAM-1 or 20 μM 5-(N-ethyl-N-isopropyl)amiloride (EIPA; an amiloride derivative) to 
inhibit CAM-mediated transport. The endothelial layer on the transwell insert was collected 
to measure 125I-anti-ICAM NC or 125I-IgG NC content in the cell fraction, and the medium in 
the basolateral chamber was collected to estimate transported 125I-anti-ICAM NC or 125I-IgG 
NC fraction were quantified with a gamma counter. Free 125I in each fraction was measured 
by TCA precipitation assay and subtracted from results to eliminate potential errors 
contributed by presence of free 125I, which may result from degradation during binding, 
endocytosis, and/or transcellular transport. The total number of anti-ICAM NCs or IgG NCs 
associated to cells and transported across cells per area of the transwell membrane was 
estimated. 
To study transport across bi-layered endothelial (HBMEC) and subendothelial (ACs 
or PCs) BBB cell models, cells were cultured with 10 ng/mL TNFα and incubated with 125I-
anti-ICAM NCs (6.8x1010 NCs/mL) for 1, 5, or 24 hours at 37°C. The endothelial and 
subendothelial layers were separately scraped and collected to measure 125I-anti-ICAM NC 




chamber was also collected to estimate the transported 125I-anti-ICAM NC fraction. As 
aforementioned, free 125I was accounted for by TCA precipitation and subtracted from results. 
Similarly, the total number anti-ICAM NCs associated to cells and transported across cells 
per area of the transwell membrane was estimated. Additionally, visual confirmation of anti-
ICAM NCs associated to the endothelial and subendothelial layers was performed using 
confocal fluorescence microscopy. Cells were fixed, nuclei stained with DAPI, and transwell 
membranes excised and mounted on microscopy slides. Green fluorescence showed presence 
of anti-ICAM NCs and blue fluorescence (DAPI) located nuclei. 
 
3.11. Cell culture models for disease 
To develop diseased cells mimicking pathological environments, cells were cultured with 
respective complete media supplemented with a cytokine that stimulates enhanced ICAM-1 
expression, similar to pathological conditions. Specifically, cells were incubated with 10 
ng/mL tumor necrosis factor α (TNFα) for 16 to 20 hours (overnight) at 37°C prior to 
experimentation. 
To mimic deficiency in αGal encountered in Fabry disease (FD), HUVECs were 
incubated with 10 ng/mL TNFα, to mimic pathological stimulation, and also 500 µM 
deoxygalactonojirimycin hydrochloride (DGJ), to inhibit endogenous αGal, for 16 hours at 
37°C. To visually verify intracellular globotriaosylceramide (Gb3), a substrate of αGal, cells 
were also incubated with a fluorescent analog for 16 hours: 2–10 μg/mL NBD-Gb3. Gb3 
accumulation was semi-quantitatively measured by microscopy by tracking the fluorescence 
intensity. Fluorescence images were captured with SlideBook 4.2 software (Intelligent 




Valley, PA), ORCA-ER camera (Hamamatsu, Bridgewater, NJ) and a 40x objective 
(Olympus Uplan F LN; Olympus, Inc., Center Valley, PA) with a FITC filter (3540B-OMF; 
Semrock, Inc., Rochester, NY). Fluorescence intensity (A.U.) corresponding to stained Gb3 
substrate in cells was analyzed in captured images with the Image Pro 6.3 software (Media 
Cybernetics, Inc., Bethesda, MD). 
To model Pompe disease (PD) due to GAA deficiency, HUVECs were concurrently 
incubated with 10 ng/mL TNFα and a competitive inhibitor of GAA, 300 or 600 μM D-(+)-
turanose, overnight. Accumulation of the substrate of this enzyme, glycogen, was confirmed 
by staining fixed cells with periodic acid-Schiff (PAS) [169]. Glycogen accumulation was 
semi-quantitatively measured using microscopy by capturing bright-field micrographs with 
SlideBook 4.2 software using the Olympus microscope with a 40x objective and ORCA-ER 
camera stated above, with blue, green, and red filters (1160A-OMF, 3540B-OMF, 4040B-
OMF; Semrock, Inc., Rochester, NY), composing colored pictures. The red stained glycogen 
was analyzed from these images with the Image-Pro 6.3 software. 
 
3.12. Substrate degradation by ICAM-1-targeted carriers in cells  
FD-model HUVECs loaded with green fluorescent NBD-Gb3 or PD-model HUVECs were 
incubated at 37°C for 5 hours with 6.8x1010 NCs/mL of respective anti-ICAM/enzyme NCs 
(50:50 antibody to enzyme mass ratio) or respective equivalent non-targeted enzyme (2.5 
μg/mL enzyme), in the presence of 300 μM chloroquine. Chloroquine was used since 
removal of DGJ in FD-model cells or turanose in PD-model cells (required to avoid 
inhibition of the delivered αGal or GAA) may render the endogenous enzyme active. 




which have acidic pKa values, without affecting the exogenous neutral αGal or GAA. After 
incubation with enzyme or NCs, cells were fixed. Fluorescence microscopy was used to 
assess degradation of NBD-Gb3 in FD-model cells. For PD-model cells, fixed samples were 
stained with PAS, and analyzed by microscopy to quantify glycogen degradation. 
Micrographs were imaged to semi-quantitatively estimate substrate degradation as follows: 
 
3.13. Visualization of ICAM-1-targeted carriers in mice 
Visualization of anti-ICAM/IgG or IgG NCs in vivo was assessed by evaluating the 
biodistribution of NC versus NC coat in mice through optical imaging. To trace NCs, green 
Fluoresbrite labeled NCs were used. To trace cargo coated onto NCs, IgG molecules were 
labeled with Near Infra-Red (NIR-IgG). Female NIH Swiss mice (Harlan; Indianapolis, IN) 
were anesthetized with isoflurane inhalant (2 to 2.5% in O2) and intravenously (i.v.) injected 
with either non-specific IgG/NIR-IgG green Fluoresbrite-NCs or targeted anti-ICAM/NIR-
IgG green Fluoresbrite-NCs. After 30 minutes, mice were euthanized and the abdominal and 
chest cavities opened for full body imaging using a Xenogen IVIS-200 system (Caliper Life 
Sciences; Hopkinton, MA). Additionally, organs (brain, heart, kidneys, liver, lungs, and 
spleen) were collected and separately imaged for semi-quantitative fluorescence intensity 
measurements to estimate the relative NC versus NC coat accumulation in each organ. 
Protocols used for these experiments followed IACUC humane care guidelines approved by 
University of Maryland Baltimore. Experiments were conducted in collaboration with Dr. 
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Scott Burks and Dr. Joseph Kao of the Department of Physiology and Center for Biomedical 
Engineering and Technology at University of Maryland Baltimore. 
 
3.14. In vivo circulation and biodistribution of ICAM-1-targeted carriers in mice 
NC circulation and biodistribution patterns in vivo were studied. C57BL/6 mice (Jackson 
Laboratory; Bar Harbor, ME) were anesthetized with an intraperitoneal injection (using a 
28G hypodermic needle) of a 100 mg ketamine/10 mg xylazine/kg body weight buffered in 
250 µL PBS. Anesthetized mice were then injected with 1.6x1013 or 2.4x1013 NCs/ kg mice 
bodyweight of anti-ICAM/125I-enzyme NCs (95:5 or 50:50 antibody to enzyme mass ratio) or 
equivalent 125I-enzyme dose (1.7, 16.7, or 25 µg/mice buffered with 0.3% BSA-PBS). Blood 
samples (100 µL) were collected by retro-orbital bleeds at 1, 15, and 30 minutes post-
injection. After 30 minutes or 24 hours, mice were euthanized by cervical dislocation under 
anesthesia and tissues (brain, heart, kidneys liver, lungs, spleen, left gastrocnemius muscle 
and quadriceps muscle) were collected either with or without previous perfusion with 50 mL 
of PBS to eliminate blood and circulating NC fraction. Tissues were weighed and measured 
for 125I content using a gamma counter. The weight and 125I content of each organ and blood 
sample were used to calculate the following parameters: the percentage of injected dose 
(%ID), the percentage of injected dose per gram of tissue to compare among organs of 
different size (%ID/g), the localization ratio to compare tissue-to-blood distribution (LR; 
%ID/g organ : %ID/g in blood), and the specificity index to compare targeted-to-non-targeted 
counterparts (SI; LR of anti-ICAM/enzyme NCs : LR of enzyme).  
In addition, organs were crudely sectioned and imaged by confocal microscope Leica 
TCS SP5 X, using Leica Lite 2.0.2 Software (Leica Microsystems, Wetzlar, Germany) to 




University of Maryland College Park, IACUC protocols defining humane care guidelines 
were approved and strictly followed. 
 
3.15. In vivo distribution of ICAM-1-targeted carriers in mouse brain 
C57Bl/6 mice were i.v. injected with anti-ICAM/125I-enzyme green Fluoresbrite NCs (50:50 
antibody to enzyme mass ratio; 2.4x1013 NCs/kg mice bodyweight) and euthanized after 30 
minutes. The brain was collected and crudely sectioned into 8 coronoal slices. The weight 
and 125I content of each section were measured in a gamma counter to estimate the 
comparative content of 125I-enzyme present. Additionally, these sections were also imaged 
using Xenogen, and the fluorescence intensity measured to reveal the localization of 
accumulated NCs, as described in Section 3.13. 
 
3.16. Statistics 
In vitro enzyme release experiments were performed in triplicates per condition and with at 
least 2 repeats. In vitro cell culture experiments were performed in duplicates, with a sample 
size of ≥20 cells, and with at least 2 repeats (total n≥54 cells). In vivo experiments were 
performed with ≥ 3 mice per experiments. Data were calculated as mean ± standard error of 
the mean (SEM). Statistical significance between two samples of equal variance was 
determined by Student's unpaired t-tests in which p<0.05. Analysis of variance (ANOVA) 
with α=0.05 was used to determine statistical difference among three or more samples. If 
results showed statistical difference (F>Fcrit), then student’s unpaired t-tests were then 




SECTION 4: RESULTS AND DISCUSSION 
4.1. Lysosomal enzyme delivery to cells by ICAM-1-targeted nanocarriers 
4.1.1. Introduction 
Fabry disease (FD) caused by deficient α-galactosidase A (αGal) and Pompe disease (PD) 
caused by deficient α-glucosidase (GAA) are examples of LSDs for which ERT treatment is 
available. ERT for FD and PD involves i.v. administration of recombinant αGal and GAA, 
respectively. These recombinant enzymes have M6P residues and can target M6PR on cells, 
rendering clathrin-mediated endocytosis and lysosomal trafficking [79-83]. However, M6PR 
is not overexpressed in disease sites and does not provide preferential enzyme delivery to 
these areas, leading to ineffective targeting to most affected cells, tissues, and organs [27-29, 
34, 35, 84, 85]. Moreover, clathrin-mediated endocytosis associated to M6PR has been shown 
to be impaired in some LSDs, and therefore, cellular uptake of these recombinant enzymes 
results in suboptimal intracellular (lysosomal) delivery [27-29]. The lack of cellular targeting 
and effective endocytosis reduce the effectiveness of the therapy and render ERT suboptimal. 
Therefore, research for more optimal methods to deliver LSD treatment is still on-going. 
In this thesis we investigate the potential to improve delivery of enzymes for LSDs 
by targeting them to ICAM-1 since this molecule is expressed on most cells and tissues that 
targets for intervention in these diseases, particularly those most severely altered by 
pathological conditions [39]. Targeting ICAM-1 triggers endocytosis via the non-clathrin 
non-caveolae CAM-mediated pathway [40], bypassing limited function of clathrin-mediated 
pathways in some LSDs [27-29]. The Muro lab had previously shown that ICAM-1-targeting 
nanocarriers carrying ASM (anti-ICAM/ASM NCs), for treatment of NPD, effectively bound 




was attenuated as a result of the delivered enzyme [41, 42]. In vivo work showed that anti-
ICAM/ASM NCs rapidly targeted and accumulated to organs with high ICAM-1 expression, 
specifically the lungs and liver [41, 42]. These results demonstrated that this strategy can be 
useful to treat NPD. However, whether these outcomes are unique to anti-ICAM/ASM NCs 
or whether this anti-ICAM NC platform can be translated to other LSDs was unknown. Since 
different LSDs pose different challenges and the corresponding lysosomal enzymes have 
different properties, the combination of anti-ICAM/enzyme NCs may yield varying results 
and each application must be separately tested. Hence, in this thesis, we evaluated the 
efficacy of using anti-ICAM NCs to deliver αGal and GAA necessary for treatment of FD 
and PD, respectively, as an example of other ERTs. 
 
4.1.2. Coating of enzyme onto ICAM-1-targeted nanocarriers 
As a proof-of-concept, model ICAM-1-targeted nanocarriers were prepared by coating 100-
nm diameter polystyrene nanocarriers via surface adsorption with both ICAM-1-targeting 
antibodies (anti-ICAM) and enzyme (either αGal or GAA; 50:50 antibody to enzyme mass 
ratio). Placing anti-ICAM and enzyme on the surface allows binding of anti-ICAM to ICAM-
1 and interaction of the lysosomal enzyme with its lysosomal substrate once internalized by 
cells, modeling a “pro-drug” formulation. Polystyrene nanocarriers were used as model 
nanocarriers (not intended for clinical use) since this polymer is non-degradable and particles 
can be traced while avoiding confounding results of degradation. In cell culture and 
laboratory animals, these ICAM-1-targeted polystyrene particles display similar targeting and 
intracellular transport mechanisms than biocompatible poly(lactic-co-glycolic acid) 
nanocarriers [41, 42], a material  approved by the Food and Drug Administration for use in 




To validate presence of enzyme coat onto model anti-ICAM NCs, enzymes were 
labeled with 125I (anti-ICAM/125I-αGal NCs or anti-ICAM/125I-GAA NCs). As shown in 
Table 1, at a 50:50 anti-ICAM to enzyme coating ratio, anti-ICAM/αGal NC had a size of 
223.2±2.6 nm in diameter, with a PDI of 0.128±0.008, carrying ~138 anti-ICAM 
molecules/NC and ~530 αGal molecules/NC. Similarly, anti-ICAM/GAA NCs were 
180.1±0.9 nm in diameter, with a PDI of 0.232±0.000, carrying ~123 anti-ICAM 
molecules/NC and ~278 GAA molecules/NC. The number of total αGal molecules coated 
onto a NC is almost 2-folds greater than that of GAA (Table 1). This is most likely due to the 
size difference between the two enzymes (MW of αGal is ~32.3 kDa versus GAA is ~68.5 
kDa). Interestingly, both nanocarrier preparations showed similar coating of anti-ICAM 
molecules per NCs (~130 molecules/NC), which is in agreement with that reported for anti-
ICAM/ASM NCs prepared with the same method (~135 anti-ICAM molecules/NC) [41, 42, 
47]. This is approximately half the amount of anti-ICAM molecules coated on NCs which 
contained only anti-ICAM (~220 molecules/NC; Table 1) [41, 42, 47]. This suggests that all 
three enzymes, regardless of size, presented similar steric hindrances that reduced the coating 
of the targeting moiety onto the nanocarrier comparably. This is in agreement with the fact 
that all three formulations were prepared with similar anti-ICAM to enzyme mass ratio. 
Hence, it is expected that NCs bearing these three different enzymes would bind similarly to 








Table 1. Characterization of ICAM-1-targeted nanocarriers coated with lysosomal 
enzymes. (Table adapted from [47]) 
 Non-loaded ASM αGal GAA 
Enzyme coating efficiency (%) N/A 80 77 94 
Enzyme molecule per NC (50:50 mass) N/A 230 530 278 
Anti-ICAM molecule per NC (50:50 mass) 222* 135 138 123 
Size (nm in diameter) 283*  223 180 
Polydispersity index (PDI) 0.18*  0.13 0.23 
Binding (NCs per cell) 165 160 70 80 
% Internalization (1 hour) 80 70 67 80 
% Lysosomal transport (3 hours) 75 70 70 65 
% Lysosomal storage degradation (5 hours) N/A 98 70 75 
Enhanced degradation  
(anti-ICAM/enzyme NCs : free enzyme) N/A 2 2.5 3 
N/A = not applicable.  * Non-loaded anti-ICAM NCs was coated 100% with anti-
ICAM only. Data are mean values from [41, 42, 47, 48].  
 
4.1.3. Enzyme release from ICAM-1-targeted nanocarriers  
Since the model formulations carry both the targeting moiety and the enzyme cargo on the 
surface of nanocarriers, the stability of enzyme coating the formulation was first tested, which 
was assessed in various in vitro conditions. First, the enzyme coat was found to be stable 
under various physical stresses, including centrifugation, resuspension by pipetting, and 
sonication (≤11.6±0.3% enzyme release). Then, to mimic storage conditions, anti-ICAM/125I-
αGal NCs were incubated in storage buffer (1% BSA-PBS) up to several days, periodically 
collecting samples to measure 125I content to calculate enzyme release from the nanocarrier. 
125I-αGal was stably retained on anti-ICAM NCs for up to 3 days when stored in this solution 
at 4°C (2.4±4.8% enzyme release at day 3; Figure 4a). In addition, storage at 37°C did not 






Figure 4. Release of αGal from anti-ICAM/αGal nanocarriers. 125I-αGal released from anti-
ICAM/125I-αGal NCs was separated from the particle-bound fraction by centrifugation after 
incubation for varying periods of time in (a) 1% BSA in PBS buffer at 4°C or 37°C; (b) 1% 
BSA in PBS, HUVEC medium, or FBS at 37°C and pH 7.4; (c) HUVEC medium at 37°C and 
either pH 7.4 or pH 4.5; and (d) HUVEC medium at 37°C and pH 4.5 in the absence or 
presence of NBD-Gb3. Data are mean±SEM, n≥3. *p≤0.05, compares each time point to time 
0 within the same condition. #p≤0.05, compares (for each time point): (a) 4°C to 37°C, (b) 
HUVEC medium and FBS to BSA, (c) pH 4.5 to pH 7.4, and (d) Gb3 to non-Gb3; by 
Student's t-test. Statistical significance for time 0-8 hours is shown only in the left panel and 




Next, to evaluate enzyme release under physiological conditions, anti-ICAM/125I-
αGal NCs were incubated at physiological temperature (37°C) with either complete cell 
medium, serum, acidic cell medium (mimicking lysosomal pH), or acid cell medium with 
substrate (mimicking lysosomal storage condition in LSD) for 3 days. Incubation of anti-
ICAM/125I-αGal NCs in complete cell medium or serum (which mimic physiological fluids) 
still showed a marked retention of 125I-αGal on nanocarriers, with only 6.7±3.4% and 
5.6±0.5% 125I-αGal release at 1 hour, and 8.0±3.8% and 11.3±1.9% release at 5 hour (Figure 
4b). Enzyme release was significant after 3 days of incubation in cell medium (14.8±2.0%) 
and a comparable release was seen after 8 hours incubation in serum (19.5±1.6%). This 
suggests that although coating is relatively stable, αGal can be released from nanocarriers 
after delivery in cell culture or animal models. Supporting this, release at 37°C of 125I-αGal 
from anti-ICAM NCs in cell medium was accelerated at pH 4.5, which mimics lysosomal pH 
(Figure 4c). At acidic pH, enzyme release was significant after only 5 hours incubation 
(2.5±0.5%) versus 3 days incubation at neutral pH (Figure 4c). The presence of substrate 
Gb3, which mimics the lysosomal environment in this disease, further enhanced 125I-αGal 
release (Figure 4d). Under this condition, release at 5 hours tripled that in the absence of 
substrate (7.2±0.7%) and reached a plateau (27.8±1.6%) by day 1 (Figure 4d). 
In addition, anti-ICAM/125I-GAA NCs showed similar characteristics (Figure 5). The 
enzyme coat was stable during storage at 4°C in saline buffer (0.0±0.1% to 6.1±0.5% enzyme 
release within 3 days; Figure 5a). Incubation of anti-ICAM/125I-GAA NCs at 37°C and 
neutral pH in complete cell medium also showed marked enzyme retention: 3.8 ± 0.2% 
release at 3 hours and 11.9 ± 0.3% release at 72 hours (Figure 5a). Enzyme release was 
notably enhanced under conditions mimicking the lysosomal storage environment, pH 4.5 
and presence of the enzyme substrate, glycogen: 3.1-, 7.9-, and 11.5-fold increased compared 




Figure 5. Release of GAA from anti-ICAM/GAA nanocarriers. (a) Anti-ICAM/125I-GAA 
NCs were incubated in either storage buffer (1% BSA-PBS, pH 7.4) at 4°C or in a 
physiological-like fluid (cell medium supplemented with serum, pH 7.4) at 37°C. Samples 
were collected at the indicated time points to determine the release of 125I-GAA from carrier 
particles after separation from 125I-GAA stably bound to the nanocarrier coat by 
centrifugation. (b) Release of 125I-GAA from anti-ICAM/125I-GAA NCs at 37°C in a 
lysosomal-like environment (e.g., serum-supplemented cell medium, pH 4.5, presence of 
glycogen) was compared to that of similar counterparts incubated at neutral pH and in the 
absence of the enzyme substrate (fold increase is represented). Data are mean±SEM, n=6. 
*p≤0.01, by Student’s t-test (GAA release in lysosomal-like environment compared to GAA 
release in saline). (Figure reproduced from [47]) 
 
All in all, these results suggest that lysosomal enzymes can remain stably coated on 
nanocarrier particles under storage and exposure to physiological conditions. Additionally, 
the enzymes were conditionally released from the nanocarrier surface when in a lysosomal-
like environment with the presence of their substrates (Figures 4 and 5).  
 
4.1.4. Binding of anti-ICAM/enzyme nanocarriers to cells 
Intravenously (i.v.) injected material will first encounter endothelial cells (ECs) of the 
vasculature as the first layer of cells that must be targeted in order to penetrate through and 




ECs in the vaculature is a main goal of lysosomal ERT. Hence, in the following experiments, 
ECs were used to test the efficacy of anti-ICAM/enzyme NCs.  
First, the binding efficiency of anti-ICAM NCs was tested using HUVECs pre-
exposed to TNFα, to mimic ICAM-1 expression in pathological-like conditions, or to control 
cells.  After 30 minute incubation of anti-ICAM NCs with cells, fluorescence microscopy 
showed a 3.3-fold increase in binding of anti-ICAM NCs to ICAM-1 on TNFα treated cells 
(Figure 6a). This is in agreement with enhanced ICAM-1 expression induced by TNFα  
 
Figure 6. Binding of ICAM-1-targeting systems to endothelial cell models. (a) To confirm 
ICAM-1 expression on endothelial cell model, HUVECs were treated with or without TNFα 
and incubated with green fluorescent anti-ICAM NCs for 30 minutes at 4°C to test binding. 
Scale bar = 10 µm. (b) To study the effects of loading an enzyme onto anti-ICAM NCs on 
binding, TNFα-treated macrovascular (HUVECs) and microvascular (HBMECs) models 
were incubated with either green fluorescent anti-ICAM NCs or anti-ICAM/αGal NCs for 1 
hour. (c) PD-model HUVECs and excised skeletal muscle from mice (see Section 3.4.) were 
incubated with green fluorescent anti-ICAM/GAA NCs. Arrowheads indicate NCs aligned 
along cytoskeletal fiber (pseudocolored red). Scale bar = 10 µm for PD-model HUVEC; scale 
bar = ~2 µm for skeletal muscle cell. (d) Binding kinetics of green fluorescent anti-
ICAM/GAA NCs to PD-model HUVECs at 37°C. Data are mean±SEM. *p<0.05 comparing 
anti-ICAM/enzyme NCs to anti-ICAM NCs; #p<0.05 comparing HUVEC to HBMEC. 




activation, as expected. Then, in addition to evaluating ICAM-1 targeting on HUVECs, 
which models macrovacular ECs, HBMECs modeling microvascular ECs was assessed 
(Figure 6b), since both ECs are targets for FD. Similar to HUVECs, fluorescence microscopy 
showed that binding of anti-ICAM NCs increased 3.4-folds in TNFα stimulated HBMECs 
compared to control HBMECs, also indicative of enhanced ICAM-1 expression under this 
condition (data not shown). Even though statistical difference was detected, anti-ICAM NC 
binding profile to microvascular ECs was comparable to that of macrovascular ECs 
(96.5±5.1%; Figure 6b) [48]. Therefore, in subsequent experiments, we used HUVECs as a 
representative model for evaluating EC response to incubation with anti-ICAM NC systems. 
Historical work with anti-ICAM/ASM NCs was performed using HUVECs, allowing 
comparative analysis between previous and subsequent studies on anti-ICAM/enzyme NCs. 
As previously shown (Section 4.1.2.), the addition of these enzyme displaced the 
total number of anti-ICAM molecules on the surface of the NCs (Table 1), thereby potentially 
affecting the binding efficiency of anti-ICAM/enzyme NCs. This was confirmed 
experimentally: in both macrovacular and microvascular ECs, the addition of αGal to anti-
ICAM NCs did slightly alter binding efficiency, e.g. 63.3±9.1% and 62.5±7.4% of anti-
ICAM NCs (Figure 6b). Yet, historical work using anti-ICAM/ASM NCs had showed that 
binding was not decreased as a result of replacing 50% of the targeting moiety on the NC 
surface with ASM (160 anti-ICAM/ASM NCs bound per cell versus 165 anti-ICAM NCs 
bound per cell; Table 1). Perhaps, ASM has affinity towards the membrane of cells, assisting 
in targeting, while αGal did not. ASM hydrolyzes sphingomyelin, a sphingolipid present on 
the cell membrane, into phosphocholine head group and ceramide [170-173], which is found 
to be abundant at sites of ICAM-1-engagement on the cell membrane [174]. This could 
explain the lack of a decreased binding of anti-ICAM/ASM NCs to cells (Table 1). On the 




engagement sites, even though globotriaosylceramide (Gb3), the substrate that αGal 
hydrolyzes, is also found on the cell membrane [175]. Another reason for this difference 
could simply be due to different preparations and batches of antibody used, as well as 
different equipment used (microscope and camera). 
Nonetheless, significant amount of anti-ICAM/enzyme NCs did bind to stimulated 
ECs, and compared to non-loaded anti-ICAM NCs, which was enhanced in TNFα vs control 
ECs: 40.7±4.8 anti-ICAM/αGal NCs/cell in TNFα versus 19.2±3.2 anti-ICAM NCs/cell in 
control HBMEC, a 2.1-fold difference. Moreover, binding of anti-ICAM/αGal NCs to FD-
model HUVECs which exhibit excess Gb3 storage (see Methods, Section 3.11.) as compared 
to only TNFα stimulated HUVECs increased binding even more (76.7±7.5 NCs/cell versus 
42.7±6.1 NCs/cell, respectively), suggesting that ICAM-1 expression heightens on cells 
under conditions of lysosomal storage, and, thus, this targeting strategy is valuable for such 
an application.  
With regard to anti-ICAM/GAA NCs, these NCs bound to PD-model HUVECs 
which exhibit excess glycogen storage (see Methods, Section 3.11.) also with good efficacy: 
51.3±22.0 anti-ICAM/GAA NCs bound per cell after 30 minutes, comparable to anti-
ICAM/αGal NC binding within the same time frame (42.7±6.1 NCs/cell, Figure 6d). Binding 
of anti-ICAM/GAA NCs increased with time and quickly saturated (79.8±8.3 NCs/cell by 1 
hour and 66.5±6.4 NCs/cell by 3 hours), with a t1/2 of 9.7 minutes and a Bmax of ~77 NCs/cell 
(Figure 6d). Similarly, by 1 h, 76.7±7.5 anti-ICAM/αGal NCs bound per FD-model HUVEC 
(data not shown). Also, as a proof-of-model experiment, anti-ICAM/GAA NCs was capable 
of binding to excised muscle fibers extracted from mice grastrocnemius and quadriceps 
(Figure 6c).  This set of results suggests that anti-ICAM/enzyme NCs can carry different 




disease conditions, yet the binding efficiency may slightly differ depending on the precise 
anti-ICAM/enzyme NC formulation, which emphasizes the need to study each application 
separately. 
 
4.1.5. Endocytosis of anti-ICAM/enzyme nanocarriers by cells 
We next examined endocytosis of anti-ICAM NCs, which is a requirement for lysosomal 
transport of these enzymes. Using fluorescence microscopy, we studied the internalization 
efficiency of anti-ICAM/enzyme NCs into control, TNFα-stimulated, and LSD-disease 
model HUVECs (Figure 7). Cells were incubated with green fluorescent anti-ICAM/enzyme 
NCs for 30 minutes, 1, 3, or 5 hours, non-bound NCs were removed and cells were then 
fixed. To distinguish surface bound versus internalized NCs, surface bound NCs were 
counter-stained with TexasRed secondary IgG to bind to anti-ICAM on the NC coat (green + 
red = yellow). Since the cells were not permeabilized prior to staining, internalized NCs are 
only visualized in the green channel [40].  
Since FD particularly affects vascular ECs (among others), we first compared 
internalization efficiency in microvascular ECs (HBMECs) versus macrovascular ECs 
(HUVECs). Internalization of anti-ICAM NCs after 30 minutes was 76.4±2.8% into 
HBMECs versus 88.1±1.7% in HUVECs (Figure 7a), demonstrating a similar uptake 
efficiency in both cell types. Then, since addition of enzyme cargo to anti-ICAM NCs 
displaces 50% of the targeting moiety on NC surface, we evaluated whether internalization 
would be affected in anti-ICAM/enzyme NCs. Contrary to the decreased binding efficiency 
observed in Figure 6b, the addition of an enzyme (αGal) on the anti-ICAM NC did not affect 
the internalization efficiency into either macrovascular or microvascular ECs: e.g. 




efficiency does not affect internalization efficiency. Internalization of every individual carrier 
is an independent event, which has been previously observed for this system [40]. 
 
 Figure 7. Uptake of anti-ICAM/enzyme nanocarriers by cells. (a) Green fluorescent anti-
ICAM NCs or anti-ICAM/αGal NCs were incubated with TNFα-treated HUVECs or 
HBMECs for 1 hour at 37°C, to study whether internalization efficiency is affected by 
enzyme addition onto anti-ICAM NCs or whether this uptake differs in these 2 cell types. (b) 
Green fluorescent anti-ICAM/GAA NCs were incubated at 37°C with PD-model HUVECs 
for 30 min, 1 hour, or 3 hours to study the rate of internalization. Surface bound NCs were 
counterstained with Texas-Red secondary antibody (green + red = yellow). Arrowheads point 
to internalized NCs (green); arrows point to surface bound NCs (yellow). Percent 
internalization was calculated based on fluorescence microscopy results. Scale bar = 10 µm. 
Data are mean±SEM. (Figure adapted from [47, 48]) 
 
Furthermore, internalization of anti-ICAM/αGal NCs was comparable to that of anti-
ICAM/GAA NC (Figure 7). After 30 minutes, 74.6±3.4% of anti-ICAM/αGal NCs bound to 
TNFα-treated cells were endocytosed (not shown) compared to anti-ICAM/GAA NCs 
(78.6±1.7% internalization, Figure 7b). This is also comparable to the uptake previously 
observed for anti-ICAM/ASM NCs (~70%; Table 1), and implies that even with lysosomal 




without storage. Indeed, endocytosis of anti-ICAM/GAA NCs quickly plateaus by 1 hour: 
85.0.6±1.7% internalization (Table 1) compared to 89.4±0.4% internalization by 3 hours, 
with a rapid t1/2 of 5.1 minutes and an Imax of 92.0% internalization (Figure 7b).  
 
4.1.6. Mechanism of endocytosis of anti-ICAM/enzyme nanocarriers  
Clathrin-mediated and caveolae-mediated endocytosis are known as the classical pathways of 
endocytosis commonly used for vesicular endocytosis as a result of ligand-receptor binding in 
most cell types of the body [176, 177]. In fact, current ERT for LSDs, including FD and PD, 
capitalize on M6PR-bindng of lysosomal enzymes, which relies on clathrin-mediated uptake 
[82, 83]. However, as mentioned (see Background, Section 2.3.), clathrin-mediated 
endocytosis is often impaired in LSDs [27-29, 51]. Endocytosis of ICAM-1-targeted NCs has 
previously been elucidated to be mediated via the CAM-pathway, independent of the classical 
endocytic pathways that rely on clathrin- or caveolae-mediation [40]. However, the enzyme 
load may alter this because these lysosomal enzymes may co-induce the clathrin pathway. 
Hence, we studied the possible endocytic route elicited by anti-ICAM/αGal NC and anti-
ICAM/GAA NCs (Figure 8).  
To inhibit CAM-mediated endocytosis cells were treated with amiloride, while to 
inhibit clathrin-mediated endocytosis cells were treated with MDC (see Methods, Section 
3.7.). Only amiloride inhibited significantly endocytosis for both anti-ICAM/αGal NCs and 
anti-ICAM/GAA NCs (54.8±2.8% and 67.9±1.9% internalization compared to control, 
respectively; Figure 8). MDC did not inhibit internalization (95.5±3.2% and 101.1±1.2% of 
control, respectively), suggesting that endocytosis of anti-ICAM/enzyme NCs occurred via 




strategy may prove to be beneficial in assisting enzyme delivery via this non-classical route. 
This is especially important since clathrin-mediated endocytosis is impaired in several LSDs 
[27-29, 51].  
Figure 8. CAM-mediated endocytosis of anti-ICAM/enzyme nanocarriers. Green fluorescent 
anti-ICAM/αGal NCs or anti-ICAM/GAA NCs were incubated with TNFα-stimulated 
HUVECs, treated or not with inhibitors of CAM-mediated endocytosis (Amiloride) or 
clathrin-mediated endocytosis (MDC) for 1 hour at 37°C. Surface bound NCs were 
counterstained with Texas-Red secondary antibody (green + red = yellow). (a) Arrowheads 
point to internalized NCs (green); arrows point to surface bound NCs (yellow). Scale bar = 10 
µm. (b) Percent internalization was calculated based on fluorescence microscopy results. 
Data are mean±SEM. *p<0.01, comparing % internalization in inhibitor treated cells to 
control cells, by Student’s t-test. (Figure adapted from [47, 48]) 
 
As expected, all three formulations tested thus far (anti-ICAM/ASM NCs, anti-
ICAM/αGal NCs, anti-ICAM/GAA NCs) capitalize on CAM-mediation as the dominant 
endocytic route [42, 47, 48]. Interestingly, anti-ICAM/ASM NCs was shown to be inhibited 
by amiloride (~55% internalization compared to control) but enhanced by MDC (~20% 
increased internalization relative to control) [42]. This could indicate that anti-ICAM/ASM 
NCs may bind to both ICAM-1 and M6PR, but with M6PR being inefficient this may 
compete against CAM-uptake. By inhibiting clathrin, anti-ICAM/ASM NCs possibly were 




ICAM/ASM NCs did not suffer a reduction in binding versus anti-ICAM NCs (Table 1). Yet, 
this phenomenon was not exhibited in the other two ICAM-1-targeting systems. Since the lab 
has found that ASM plays a role in CAM-mediated endocytosis, this may explain this 
difference [161, 174]. To our knowledge, neither αGal nor GAA have a role in CAM-
mediated endocytosis. This different result suggests that different enzymes affect anti-ICAM 
NC properties differently. 
 
4.1.7. Lysosomal trafficking of anti-ICAM/enzyme nanocarriers  
Lysosomal delivery is the main goal for LSD treatment, e.g. ERT currently available aims to 
target recombinant enzymes to lysosomes by using M6PR-mediated transport [82, 83]. 
Previous work has shown that CAM-mediated endocytosis results in anti-ICAM NCs being 
transported to this location as well [40]. In fact, anti-ICAM/ASM NCs were shown to traffic 
to lysosomes within 3 hours, with similar efficiency as non-loaded anti-ICAM NCs [42]. 
Because different enzymes could elicit or add different properties that may affect lysosomal 
trafficking of anti-ICAM NC system, here, we study whether anti-ICAM/αGal NCs and anti-
ICAM/GAA NCs trafficked similarly to lysosomes. We assessed this by labeling lysosomes 
with TexasRed dextran, as previously described [40], and following the anti-ICAM/enzyme 
NCs over time via fluorescence microscopy (Figure 9).  
Results show that by 3 hours, majority of endocytosed anti-ICAM/αGal NCs were 
trafficked to the lysosome in TNFα-stimulated HUVECs (27.4±3.4%, 73.5±2.1%, and 




Figure 9. Intracellular trafficking of anti-ICAM/enzyme nanocarriers in diseased HUVECs. 
(a) TNFα-stimulated HUVECs or (b, c) LSD-model HUVECs were pre-treated with (a, b) 
Texas-Red dextran to label lysosomes (red) or (c) NBD-Gb3 (pseudo-colored here as red), to 
visualize Gb3 substrate accumulation. Cells were then incubated with green fluorescent anti-
ICAM/enzyme NCs for 1 hour, washed to remove non-bound NCs, and then examined (1 
hour) or incubated with media for an additional 2 or 4 hours (for a total time of 3 or 5 hours). 
Fluorescence microsopy determined percent of NCs which trafficked to (a, b) lysosomes or 
(c) regions of concentrated Gb3, shown in micrographs as yellow (red + green). Scale = 10 
µm. Data are mean±SEM. (Figure adapted from [47, 48]) 
 
similar intracellular trafficking profile was exhibited by anti-ICAM/GAA NCs in PD-model 
HUVECs: 32.8±2.5%, 63.6±2.2%, and 77.3±2.8% of NCs localized within lysosomes at 1, 3, 
and 5 hours, respectively (Figure 9b). Both trafficking profiles yielded a t1/2 of ~2.5 hours, 
indicating no difference in the lysosomal transport potential regardless of the enzyme loaded 
or of the disease model. Previous work with anti-ICAM/ASM NCs showed this consistent 
trend as well: ~70% localization with lysosomes by 3 hours in TNFα-stimulated HUVECs 
(Table 1). Non-loaded anti-ICAM NCs localized to lysosomes at a slightly higher efficiency: 




a slight 5 to 10% difference observed could be due to the additional enzyme cargo on anti-
ICAM NCs, potentially affecting lysosomal trafficking efficiency of the nanocarrier systems. 
In LSD treatment, delivery of enzyme to lysosomes directly positions the enzyme at 
the site at which to degrade the accumulated substrate. As shown above, anti-ICAM/enzyme 
NCs are capable of trafficking to lysosomes. Additionally, we found that, endocytosed anti-
ICAM/αGal NCs trafficked to areas of Gb3 substrate accumulation in FD-model HUVECs, 
as required in order to degrade Gb3 (Figure 9c). Specifically, 29.3±3.4%, 31.8±3.8%, and 
46.4±5.0% of anti-ICAM/αGal NCs localized to Gb3 positive compartments at 1, 3, and 5 
hours, respectively, with a t1/2 of ~47 minutes. This set of results suggests that lysosomal 
delivery is possible, positioning the enzyme precisely at the location where it is needed. 
 
4.1.8. Alleviation of excess lysosomal storage by anti-ICAM/enzyme nanocarriers 
Delivery of active enzymes to lysosomes is the ultimate goal for LSD treatment. To assess 
functionality of the enzymes delivered via anti-ICAM NC, we examined the ability of these 
enzymes to degrade the accumulated substrate (Figure 10). For this purpose, in addition to 
TNFα-stimulation, disease EC models exhibiting respective substrate accumulation (Gb3 or 
glycogen) traceable via fluorescence analysis or PAS assay, respectively, were developed to 
mimic FD and PD pathology (see Methods, Section 3.11.). Since the exogenous enzymes we 
used here are active under neutral environments (versus the endogenous lysosomal enzymes, 
which are active under acidic environments) cells were also treated with chloroquine. This 
compound neutralizes the pH of lysosomal compartments, allowing the delivered enzyme to 
degrade the induced lysosomal substrate while inhibiting degradation by the endogenous 





Figure 10. Degradation of lysosomal substrate by anti-ICAM/enzyme nanocarriers. TNFα-
stimulated HUVECs were treated with either (a) DGJ and Gb3 to develop a traceable FD 
model or (b) turanose to develop a PD model. Cells were then incubated with non-
fluorescence anti-ICAM/enzyme NCs for 5 hours in the presence of chloroquine. Through (a) 
fluorescence microscopy or (b) PAS assay, percent degradation of substrate was analyzed and 
calculated by comparing either cells treated with enzyme or anti-ICAM/enzyme NCs to 
untreated disease-model cells and control “healthy” cells (see Methods, Section 3.12.). Data 
are mean±SEM. *p<0.01, comparing anti-ICAM/enzyme NCs to non-targeted enzyme, by 
Student’s t-test. Scale = 10 µm. (Figure adapted from [47, 48]) 
 
As shown in Figure 10, by 5 hours, excess Gb3 in FD-model HUVECs was reduced 
by 68.9±5.0% when incubated with anti-ICAM/αGal NCs, which represents a 2.1-folds 
enhancement in efficiency versus non-targeted αGal (Table 1, Figure 10a). Similarly, anti-
ICAM/GAA NCs reduced excess glycogen in PD-model HUVECs by 73.9±2.3%, 2.8-folds 
more efficient than non-targeted GAA (Table 1, Figure 10b). These results suggest that anti-




delivered by anti-ICAM NCs remained similarly active as well [42, 158]. In fact, anti-
ICAM/ASM NCs reduced accumulated sphingomyelin in ASM-deficient cells (fibroblast 
cells from NPD patients) by 98%, a 2-fold enhancement over the free enzyme (Table 1) [42]. 
Whereas 70–75% substrate reduction was observed for α-Gal and GAA, ASM delivered by 
anti-ICAM NCs reduced substrate levels to control values, which may be a result of 
experimental differences: an acidic enzyme (ASM) was tested in genetic models [42, 158] 
versus neutral αGal and GAA tested in pharmacological models. In any instance, the enzymes 
delivered by anti-ICAM NCs improved substrate reduction by 2- to 3-folds compared to non-
targeted counterparts (Table 1). These differences may be more acute in vivo, where binding 
of non-targeted enzymes may be further hindered as a result of blood flow. 
 
4.1.9. Conclusion 
Current ERT for LSDs fail to deliver enzyme therapeutic to lysosomes in cells due to poor 
binding and endocytosis. Targeting ICAM-1 can potentially amend this. Since FD affects all 
vascular ECs, we first confirmed that the binding and internalization pattern of anti-ICAM 
NCs in microvascular ECs (HBMECs) was similarly efficient in macrovascular (HUVECs), 
the model in which comparative historic work was performed. We then validated our cell 
culture model by confirming that binding is in fact enhanced on stimulated diseased cells. 
Interestingly, binding efficiency of anti-ICAM NCs to our LSD-model HUVECs exhibiting 
lysosomal storage conditions was in fact enhanced compared to stimulated HUVECs.  
Previous work with anti-ICAM/ASM NCs showed promise in delivering ASM to 
diseased cells to attenuate accumulated lysosomal storage in cell culture models and to NPD 
target organs in mice [41, 157]. To study whether this anti-ICAM NC platform can be 




and PD, respectively. Interestingly, we noted that the addition of αGal or GAA to the 
nanocarrier surface, which resulted in a 50% reduction in anti-ICAM coating density, did 
slightly decrease binding efficiency, contrary to previous work with ASM that showed that 
binding efficiency was conserved [42]. Nonetheless, binding was still very significant and the 
internalization efficiency was not affected. In fact, anti-ICAM/αGal NCs, anti-ICAM/GAA 
NCs, and anti-ICAM/ASM NCs all were efficiently internalized by cells via CAM-mediated 
endocytosis. This is important since ICAM-1-targeting provides a means to bypass clathrin-
mediated endocytosis, a route that is currently utilized in ERT and reported to be impaired in 
some LSDs, affecting ERT treatment [27-29]. By targeting ICAM-1, anti-ICAM/enzyme NCs 
were also capable of efficiently delivering the enzyme cargo to lysosomes, the intended 
destination of these enzyme treatments. In all three formulations (anti-ICAM/ASM NCs, anti-
ICAM/αGal NCs, and anti-ICAM/GAA NCs) the delivered enzyme was capable of 
degrading ≥70% of aberrant storage, 2- to 3-folds more efficiently than non-targeted enzyme 
counterparts, suggesting that anti-ICAM NCs can enhance delivery of active lysosomal 
enzymes for treatment of NPD, FD, and PD. Hence, these similarities suggest that previous 
results seen with anti-ICAM/ASM NCs were not unique to NPD treatment model. In fact, it 
seems that ICAM-1-targeting platform can be used to similarly enhance binding, uptake, 
lysosomal trafficking, and substrate degradation of lysosomal enzymes, as evaluated here 





Figure 11. Cross section schematic of the 
blood-brain barrier and the surrounding 
brain tissue (glial cells and neurons). 
4.2. Targeting of cells of the blood-brain barrier and the brain by ICAM-1-targeted 
nanocarriers 
4.2.1. Introduction 
To treat neuropathy and/or neurodegeneration associated to many LSDs, recombinant 
lysosomal enzymes must be delivered to glial and neurons inflicted by disease of the central 
nervous system (CNS) [16]. Yet brain delivery remains notoriously difficult because of the 
blood-brain barrier (BBB), an almost impermeable cell lining that distinctly separates 
circulating blood and brain tissue, and regulates transport and brain homeostasis to protect the 
CNS [17, 18]. Structurally, the BBB is made up of endothelial cells (ECs) that lack 
fenestrations [178] and form a tight cell layer directly in contact with the microcirculation, 
and by an adjacent subendothelial layer consisting of periendothelial cells that are in direct 
contact with neuronal tissue (Figure 11) [17, 
18]. The most abundant periendothelial cells are 
pericytes (PCs) and astrocytes (ACs) [179]. 
Together, brain microvascular ECs, immune 
and structural regulative ACs [180], and 
contractile PCs that help regulate blood flow 
[181] contribute to the nature of the BBB, 
which is nearly impermeable to passive 
transport of substances [17, 18].  
Delivery of therapeutics to the brain circumventing the BBB has been attempted, 
such as direct injection into this tissue (e.g. intraparenchymal, intracerebral) or the 
cerebrospinal fluid (e.g. intrathecal, intracerebroventricular) [10]. Although somewhat 




methods are invasive and fail to provide the systemic relief necessary for LSDs. Systemic 
delivery is preferred and, hence, there is a need for strategies to traverse the BBB from the 
circulation. 
Transport across the BBB rarely takes place via paracellular transport that opens cell-
cell junctions, which can render leakage and disrupt homeostasis [186]. Rather, transport 
occurs more commonly via the transcellular route, requiring either transporter proteins for 
small molecules or vesicular transcytosis assisting transport of larger molecules [132]. Drug 
delivery strategies have attempted to capitalize on this natural phenomenon by targeting 
endothelial receptors to induce such vesicular transport, including insulin, low density 
lipoprotein, and transferrin receptors [187]. However, routing via these receptors requires 
mediation by clathrin-coated pits, which is impaired in some LSDs [27-29]. Therefore, an 
alternative transcytosis route is coveted to treat LSDs. Previous work in the Muro lab has 
shown that ICAM-1 can be targeted to assist transcytosis of nanocarriers across epithelial 
models [43]. However, whether this is possible for the BBB was unknown. 
To explore if delivery of recombinant lysosomal enzymes to the brain could be 
achieved, bypassing clathrin-mediated transport across the BBB, in this section we first 
examined the capacity of ICAM-1-targeted systems to target cells of the BBB and brain. In 
particular, we focused on human brain microvascular ECs, ACs, PCs, and neuron-like cells 
(NLCs).  
 
4.2.2. Expression of ICAM-1 on cells of the blood-brain barrier 
To evaluate basal and disease-induced ICAM-1 expression levels on cells of the BBB, ECs, 




or pathology-like stimulation (Figure 12), respectively. Previous works have reported ICAM-
1 expression on healthy and activated brain cells [188], so this represents a confirmation for 
our experimental set-up. 
Figure 12. ICAM-1 expression on cells of the blood-brain barrier.  Cells were cultured with 
or without TNFα, then fixed and stained for ICAM-1 using immunofluorescence. ICAM-1 
expression was then measured by fluorescence microscopy. (a) ICAM-1 expression for 
control astrocytes (ACs) and pericytes (PCs) was normalized to control human brain 
microvascular endothelial cells (ECs). (b) Fold increase of ICAM-1 expression (∆) on 
pathological-stimulated (TNFα treated) ACs, PCs, and ECs versus healthy control cells. Scale 
bar = 10 µm. Data are mean±SEM. Statistical difference observed by ANOVA. #p<0.05, 
comparing ACs or PCs to ECs for each respective condition; *p<0.05, comparing TNFα to 
control for each cell type, by Student’s t-test. (Figure reproduced from [49]) 
 
Using immunofluorescence, we observed that although all three cell types had fairly 
low detectable level of expression under control conditions (3- to 5-fold over background 
fluorescence), ECs had the highest ICAM-1 expression of the three cell types, with ACs and 
PCs expressing 88.3% and 75.8% of endothelial ICAM-1, respectively (Figure 12a). Once 
exposed to TNFα, ICAM-1 expression increased significantly for all three cell types: 
expression on ECs was enhanced the most with a 4.6-fold increase versus healthy conditions. 
ICAM-1 expression enhancement between diseased and healthy conditions for ACs and PCs 




(Figure 12b). We observed a higher ICAM-1 expression level and higher increase as a result 
of TNFα-stimulation in ECs (Figure 12), as expected, since these cells make up the 
endothelial layer of the BBB with an active role in adhesion and transportation of leukocytes 
[189]. Also, recent studies imply that ACs play an important role in leukocyte recruitment to 
the brain through production of chemoattractant and pro-inflammatory factors, thereby 
regulating both resident and recruited immune cells [180]. Therefore, as expected, ACs also 
express ICAM-1 (Figure 12), as previously shown [190]. As per PCs, previously it was 
deemed that these cells have a less prominent role in leukocyte recruitment and more of a role 
in BBB structural support [191], which correlates well with our results showing the least 
ICAM-1 expression (Figure 12). This may be influenced also by the fact that similar to ACs 
placed in the subendothelial lining of the BBB structure, PCs are not subjected to blood flow, 
and therefore express less ICAM-1. This experiment demonstrates that ICAM-1 is expressed 
on all cells of the BBB, particularly under pathological stimulation, with higher expression on 
ECs, necessary for targeting from the blood stream, as intended.  
 
4.2.3. Binding of ICAM-1-targeted nanocarriers to cells of the blood-brain barrier 
We then tested the potential specificity and efficiency of ICAM-1-targeting nanocarriers to 
bind cells of the BBB (Figure 13). Green fluorescent NCs were coated with anti-ICAM to 
prepare anti-ICAM NCs as described in the Methods section (Section 3.3.). This yielded a 
coat of 222±8 antibodies/NC, and a resultant size of 283±4 nm diameter, with a PDI of 
0.18±0.01 and a ζ-potential of -33±3 mV. Similarly, as a control, non-specific IgG NCs were 
prepared by coating green fluorescent NCs with non-specific IgG, which yielded a coat of 
170±8 antibodies/NC, and a resultant size of 288±8 nm in diameter, with a PDI 0.18±0.02 




Figure 13. Binding of anti-ICAM nanocarriers to cells of the blood-brain barrier. (a) Anti-
ICAM NCs were incubated with control or TNFα-activated BBB cells for 1hour at 37°C. 
Scale bar = 10 µm. (b) Stimulated cells were continuously incubated with anti-ICAM NCs for 
1, 3, or 5 hours. Data were fitted to non-linear regression curves, all with r2>0.92. Data are 
mean±SEM. Statistical difference observed by ANOVA. #p<0.05, comparing ACs or PCs to 
ECs of each respective condition; *p<0.05, comparing TNFα to control cells for each cell 
type, by Student’s t-test. (Figure reproduced from [49]) 
 
In agreement with its positive expression on ECs, ACs, and PCs, binding of anti-
ICAM NCs to these three cell types was significant as compared to control non-specific IgG 
NCs (1 hour, 37°C): ~40 to 57 anti-ICAM NCs/cell (Figure 13a) versus ~3 IgG NCs/cell (not 
shown) in control conditions. This demonstrates specificity of binding of anti-ICAM NCs to 
ICAM-1.  
Also in agreement with ICAM-1 overexpression in pathologically conditions [38], 
binding of anti-ICAM NCs was enhanced in all three cell types upon TNFα-stimulation, with 
the greatest increase observed for ECs (3.9-fold enhancement), followed by ACs (2.0-fold) 
and PCs (1.7-fold). Hence, the absolute binding was considerably greater for ECs 
(199.9±11.6 NCs/cell), followed by PCs (95.4±8.4 NCs/cell; 48% of ECs) and ACs (79.0±8.0 
NCs/cell; 39% of ECs). In general, this result correlates with the pattern of ICAM-1 presence 




of overexpression of ICAM-1 by TNFα was similar to the enhancement in anti-ICAM NC 
targeting (4.6-fold and 3.9-fold, respectively). However, for subendothelial cells the increase 
in nanocarrier targeting in disease over control cells was lower than the change in ICAM-1 
expression observed for these conditions (2- to 4-fold difference in binding versus 3- to 5-
fold difference in expression; Figures 12 and 13). Hence, it seems that not all surface ICAM-
1 overexpressed during pathology is available for targeting on subendothelial cells. 
Nanocarrier binding is likely to depend on the receptor location, interaction with other 
molecular partners, etc. (apart from other factors) [24, 160], explaining this result. This could 
be due to the multi-valent binding of anti-ICAM NCs, as oppose to individual antibody 
targeting that was used to detect expression. For instance, while PCs expressed the lowest 
ICAM-1 levels under control conditions, they afforded levels of anti-ICAM NC targeting 
greater than ACs and to the same extent as ECs. These examples illustrate that the 
relationship between target presence and its functional “targetability” is not always 
straightforward and may also vary from one cell type to another. This is often 
underappreciated and makes success of targeting strategies somewhat unpredictable. 
However, with time, saturation of binding of anti-ICAM NCs correlated to the 
ICAM-1 expression initially observed. For instance, ECs accumulated the most anti-ICAM 
NCs of the three BBB cells types tested with 199.9±11.6 NCs/cell in diseased cells and 
50.9±6.2 NCs/cell in control cells (Figure 13b), as predicted since it yielded the most ICAM-
1 expression. Additionally, binding of anti-ICAM NCs to ECs increased with time and even 
by 5 hours (with 381.4±26.9 anti-ICAM NCs/cell) the calculated binding saturation had not 
yet been reached (t1/2 of ~85.6 minutes, Bmax of 503.6±35.9 anti-ICAM NCs/cell; Figure 13c). 
 Interestingly, while both ICAM-1 expression and its increase due to disease was 




NCs under healthy conditions compared to ECs or ACs: 56.9±4.4 NCs/cell in control cells. 
However, under disease conditions, PCs only accumulated half of NCs as compared to ECs: 
95.4±8.4 NCs/cell 1 hour. By 5 hours of incubation, binding to diseased PCs had not 
increased much more: 116.7±9.9 NCs/cell (Figure 13c).  
ACs accumulated the least amount of NCs initially with 39.9±4.5 NCs/cell in control 
cells and 79.0±8.0 NCs/cell in diseased cells by 1 hour. However, this amount doubled by 5 
hours: 138.5±15.7 NCs/cell, surpassing PCs (Figure 13b, c). Kinetic studies showed a t1/2 of 
~70.5 minutes to ACs versus ~8.3 minutes for PCs, yielding binding saturation indicative of 
the relationship between ICAM-1 expression and anti-ICAM NC binding: Bmax of 163.8±17.4 
anti-ICAM NCs/cell for ACs versus 104.4±19.4 anti-ICAM NCs/cell for PCs. Therefore, 
binding of anti-ICAM NCs increased with enhanced ICAM-1 expression and offers 
preferential selectivity toward diseased versus control cells.  
 
4.2.4. Internalization of ICAM-1-targeted nanocarriers by cells of the blood-brain barrier 
In addition to binding, endocytosis is important as it represents a key step towards transport 
across the BBB. Also, its efficiency could be impacted by the observed binding rate. Using 
immunofluorescence, the total number of anti-ICAM NCs endocytosed by these cells was 
determined (Figure 14a). In agreement with the fact that more anti-ICAM NCs bound to 
diseased ECs as compared to ACs and PCs, more were endocytosed into these cell over time: 
109.5±4.2, 202.1±6.2, and 221.8±7.9 anti-ICAM NCs/cell by 1, 3, and 5 hours (Figure 14b). 
Similar to their binding pattern, the saturation point for uptake by ECs was not achieved by 5 
hours: t1/2 of ~99.9 minutes, Bmax of 302.1±19.8 anti-ICAM NCs/cell. For ACs, anti-ICAM 




NCs/cell by 1, 3, and 5 hours, resulting in a t1/2 of ~87.4 minutes and a Bmax of 96.6±14.2 anti-
ICAM NCs/cell. Interestingly, even though the binding rate was rapid for PCs (t1/2 of ~8.3 
minutes), the internalization rate in these cells was much slower and similar to that of ACs, 
with only a slightly faster rate and lower saturation limit: 43.1±1.7, 49.5±1.2, and 76.9±2.7 
anti-ICAM NCs/cell by 1, 3, and 5 hours; t1/2 of ~76.9 minutes, Bmax of 87.2±0.9 anti-ICAM 
NCs/cell. 
Figure 14. Internalization of anti-ICAM nanocarriers into cells of the blood-brain barrier. 
Control or TNFα-stimulated cells were incubated with green fluorescent anti-ICAM NCs for 
1, 3, or 5 hours at 37°C. Non-bound NCs were then washed, surface bound anti-ICAM NCs 
were stained with Texas Red secondary antibody (red), and the nucleus was labeled with 
DAPI (blue). Fluorescent images were captured and analyzed by microscopy. (a) Kinetics of 
anti-ICAM NC uptake by TNFα-stimulated cells over a 5 hour period. Data were fitted to 
non-linear regression curves, all with r2>0.92. (b) Percent of anti-ICAM NCs internalized by 
cells from the total cell-associated amount and (c) absolute number of anti-ICAM NCs 
internalized per cell under control or TNFα-stimulated conditions (1 hour). Micrographs 
depict TNFα-stimulated cells at 1 hour. Green (arrows) depicts internalized anti-ICAM NCs, 
yellow (arrowheads) points to anti-ICAM NCs on the surface of the cell (red + green = 
yellow). Scale bar = 10µm. Data are mean±SEM. Statistical difference observed by ANOVA. 
#p<0.05, comparing ACs or PCs to ECs under each condition; *p<0.05, comparing TNFα to 




To determine the efficiency of endocytosis, the percentage of anti-ICAM NCs 
internalized by the cell from the total cell-association fraction was calculated. Interestingly, 
this was similar between diseased and healthy cells: 46.2±1.8% in healthy versus 53.4±1.3% 
in diseased ACs, 53.2±2.7% in healthy versus 54.8±2.1% in diseased ECs, and 45.5±2.0% in 
healthy versus 45.2±1.8% in diseased PCs (1 hour; Figure 14b). Only ACs exhibit significant 
difference between healthy and disease condition, which could be a reflection of their role in 
recruiting immune cell to the brain [180]. Yet, the absolute increase of the number of anti-
ICAM NCs endocytosed per cell showed significant differences between diseased and 
healthy cells, 2.2-fold in ACs, 4.1-fold in ECs, 1.7-fold in PCs (Figure 14c). Again, this 
verifies selectivity of anti-ICAM NCs to bind and internalize into diseased cells. 
Interestingly, this suggests that induction of endocytosis via the ICAM-1 pathway does not 
depend on the diseased state of the cell nor the number of nanocarriers able to target the cell 
surface, and rather endocytosis of each bound carrier is an independent event, as observed by 
ECs in the previous chapter. This is in agreement with previous observations on this pathway 
obtained in other cell types [162], which may warrant transport without the need to surpass a 
certain targeting threshold. Because of this phenomenon, the absolute level of internalization 
of anti-ICAM NCs was ruled by the absolute level of binding on cells. As a consequence, 
subendothelial cells internalized lower absolute levels of anti-ICAM NCs as compared to 
ECs, which was particularly evident under disease conditions (about half the EC level). 
 
4.2.5. Mechanism of endocytosis of ICAM-1-targeted nanocarriers into cells of the blood-
brain barrier 
ICAM-1-targeting nanocarriers showed mechanism of endocytosis to be independent of 




mentioned in the previous section, this mechanism was conserved with anti-ICAM NCs 
bearing different lysosomal enzymes (Section 4.1.6.) [47, 48]. Since cells of the BBB are 
more restrictive in terms of transport, we tested whether the mechanism operates in human 
brain microvascular ECs, ACs, and PCs (Figure 15).  
Figure 15. Endocytosis mechanism of anti-ICAM nanocarrier uptake into cells of the blood-
brain barrier. TNFα-activated cells were incubated with anti-ICAM NCs for 3 hours at 37°C 
in absence (control) or in presence of either amiloride (CAM-mediated endocytosis inhibitor), 
filipin (caveolae-mediated endocytosis inhibor), or MDC (clathrin-mediated endocytosis 
inhibitor). Cells were washed to remove non-bound NCs and stained with Texas Red 
secondary antibody. The nucleus was stained with DAPI. (a) Arrows point to internalized 
anti-ICAM NCs (green). Arrowheads point to surface bound anti-ICAM NCs (red + green = 
yellow). Scale bar = 10µm. (b) Percent of internalization relative to control cells. Data are 
mean±SEM. *p<0.05, comparing ACs or PCs to HBMECs of respective conditions, by 
Student’s t-test. (Figure reproduced from [49]) 
 
When cells were incubated with amiloride, the pharmacological agent known to 
inhibit CAM-mediated endocytosis, internalization of anti-ICAM NCs was significantly 
reduced by 35.1±4.7% in ACs, 40.0±3.7% in ECs, and 27.3±2.7% in PCs. Endocytosis in 
cells treated with filipin, which inhibits caveolae-mediated endocytosis, was not significantly 
reduced, as expected. Interestingly, while endocytosis in cells treated with MDC, which 
inhibits clathrin-mediated endocytosis, was not affected in PCs (102.4±2.8% of control), this 




reduction; Figure 15). Interestingly, CAM-mediated transport of anti-ICAM NCs by BBB 
cells seemed influenced by the clathrin pathway, where inhibition of this pathway enhanced 
transport of anti- ICAM NCs by ECs while it decreased it in ACs. This may be related to the 
function of the cellular components of the BBB. For instance, while ECs from most other 
origins display a diversity of pathways (clathrin-, caveolae-, phagocytosis-like, etc. [177, 
192]), yet endocytic transport in brain microvascular ECs seems restricted to the clathrin 
route [132, 187, 193]. Because of this, it is possible that common endocytic machinery (e.g., 
dynamin, cytoskeletal elements, motor proteins, SNARES, etc.) is “sequestered” by the 
clathrin pathway and not fully available for other endocytic routing. Inhibition of clathrin-
mediated transport may “free” such common elements, allowing enhancement of the CAM 
pathway in brain ECs. In contrast, ACs regularly display additional endocytic routes 
(caveolae-mediated, phagocytic, etc. [194, 195]) and such an effect would not be expected. 
Since ACs actively mobilize several toll-like and scavenger-like receptors associated to the 
clathrin route [194, 195], it is possible that a small fraction of anti-ICAM NCs are not being 
specifically internalized by the CAM pathway but their antibody component may interact 
with these other clathrin-associated receptors. Although ECs may also express these other 
receptors [177], it is possible that this route is avoided since activated ECs express higher 
levels of ICAM-1 compared to activated ACs. Indeed, anti-ICAM NCs bound at a much 
greater extent on activated ECs versus ACs. 
In summary, this set of results shows that binding and internalization rate of anti-
ICAM NCs into all three BBB cell types vary depending on the cell phenotype. The 
endothelial layer of the BBB binds and internalizes anti-ICAM NCs faster and to a great 
absolute extent than ACs or PCs, which represents the subendothelial layer of the BBB. ECs 
are directly in contact with blood and therefore more capable of accessing anti-ICAM NCs 




anti-ICAM NCs more readily, as these cells regulate vesicular transport across the BBB via 
transcytosis. Hence, high traffic of anti-ICAM NCs into ECs could potentially equate to more 
transport across the BBB. Indeed, the subsequent subendothelial layer does not internalize 
anti-ICAM NCs as efficiently as brain ECs. With less “entrapment” of anti-ICAM NCs in 
these cells, there is more potential for anti-ICAM NCs to penetrate further into the brain 
parenchyma. 
 
4.2.6. Lysosomal trafficking of ICAM-1-targeted nanocarriers in cells of the blood-brain 
barrier 
To treat brain tissue plagued by LSD, delivery of lysosomal enzyme across the BBB is 
required. However, since all cells are affected by LSD pathology, delivery of lysosomal 
enzyme to lysosomes of all cells is desirable, even cells that make up cell barriers. Hence, 
through fluorescence microscopy, we evaluated whether cells of the BBB could effeciently 
traffic endocytosed anti-ICAM NCs to their respective lysosomes (Figure 16). Lysosomes 
were labeled with Texas-Red dextran (a 10 kDa polysaccharide that cannot be enzymatically 
degraded in mammalian cells) and anti-ICAM NCs with green fluorescence were used to 
allow for fluorescence tracing. After 1 hour incubation of anti-ICAM NCs with cells, cells 
were washed to remove non-bound excess anti-ICAM NCs and continued to be incubated for 
a total of 1, 3, or 5 hours at 37°C to study trafficking of internalized NCs.  
Similar to macrovascular ECs shown in the previous chapter, a considerable amount 
of NCs trafficked to lysosomes: by 1 hour, 18.3±2.3%, 24.5±2.4%, and 16.9±1.8% of bound 
anti-ICAM NCs trafficked to the lysosome of ACs, human brain microvascular ECs, and 
PCs, respectively (Figure 16). By 5 hours, ACs accumulated the least percentage of anti-




at 1 hour. PCs accumulated 49.4±2.4% of cell-associated NCs in lysosomes by 5 hours, ~3-
fold increase over the percentage at 1 hour. ECs’ lysosomes accumulated a greater portion of 
carriers, 71.2±1.9% of cell-associated anti-ICAM NCs by 5 hours, also ~3-folds the amount 
versus 1 hour. All three types of BBB cells tested showed similar trafficking rates (t1/2 of ~3.7 
to ~4 hours) but differed in absolute lysosomal trafficking, which was greater for ECs. 
 
Figure 16. Intracellular trafficking of anti-ICAM nanocarriers to the lysosome of cells of the 
blood-brain barrier. TNFα-activated cells were pre-incubated Texas Red dextran to stain 
lysosomes, then incubated with green fluorescent anti-ICAM NCs for 1 hour at 37°C. To 
synchronize internalization trafficking of anti-ICAM NCs, cells were then washed to remove 
non-bound NCs and were then examined or continued to be incubated for a total of 3 or 5 
hours at 37°C. Nuclei were stained blue with DAPI. (a) Micrographs of cells incubated for 5 
hours. Arrows point to anti-ICAM NCs that do not co-localize with lysosomes (green). 
Arrowheads point to anti-ICAM NCs that co-localized with lysosomes (red + green = 
yellow). Scale bar = 10µm. (b) Kinetics of lysosomal trafficking over 5 hours. Data were 
fitted to non-linear regression curves, all with r2>0.90. Data are mean±SEM. #p<0.05, 
comparing ACs or PCs to ECs for each respective time point; *p<0.05, comparing 1 hour to 3 





Since the intended subcellular destination for LSD treatment is the lysosome, 
lysosomal delivery of anti-ICAM NCs will be optimal for treatment of affected cells, 
including BBB cells. As seen here, all BBB cell types were able to traffic anti-ICAM NCs to 
lysosomes to some extent, similar to observations in the previous chapter. This shows ICAM-
1-targeting potential to enhance delivery for LSDs. Yet, different cell types yielded various 
absolute degrees of lysosome transport, and this difference may be due to their different roles. 
As previously mentioned, brain ECs are heavily involved in endocytotic transport between 
the blood stream and the brain as compared to ACs or PCs. Hence, it may be expected that 
ECs could also traffic more material to lysosomes in absolute levels. Yet, due to its role in 
transcytosis across the BBB, brain ECs are expected to retain less endocytic cargo within 
intracellular compartments, which may explain the slower trafficking rate to lysosomes: t½ of 
~4 hours compared to ~1-2.5 hours for peripheral ECs (HUVECs) (see Section 4.1.5.). 
Nonetheless, significant lysosomal delivery achieved in brain ECs is beneficial for many 
LSDs. 
 
4.2.7. Binding and transport of ICAM-1-targeted nanocarriers across blood-brain barrier 
endothelial monolayers 
In order to treat tissue beyond the vasculature, i.v. administered anti-ICAM NCs must 
traverse cell barriers to reach the tissue parenchyma. Such is the challenge in crossing the 
BBB where NCs must traffic across the endothelial and subendothelial linings. The previous 
experiments involved cells seeded on glass coverslips (Figure 17a). This model is limited in 
that it does not offer a basolateral compartment underneath the cells and does not allow us to 
study transport across cells. Therefore, our next step was to study transport of anti-ICAM 




transcellular transport of anti-ICAM NCs across an endothelial monolayer representative of 
the BBB endothelium. For this purpose, ECs were grown to confluence on porous membrane 
transwell inserts (Figure 17b). Binding and transport of ICAM-1-targeted delivery systems 
was evaluated by tagging anti-ICAM with a radioisotope, 125I-anti-ICAM. 
 
Figure 17. Experimental cell culture models. (a) Cells were seeded onto coated coverslips to 
analyze binding, internalization, and intracellular trafficking. (b) A BBB monoculture 
(endothelial) model was developed by culturing human brain microvascular ECs to 
confluence on 1.0-µm pore transwell inserts for transport assays. (c) Endothelial and 
subendothelial co-culture models of the BBB were developed by culturing ECs to confluence 
on apical side of 1.0-µm transwell inserts and either ACs or PCs on the basolateral side of the 
insert, to study transport across bi-layered cell barrier. 
   
One hour after adding the carriers to the apical chambers above the cells, as many as 
1.3x106 anti-ICAM NCs per mm2 surface associated to control healthy cells, a 5.4-fold 
difference versus non-specific IgG NCs (Figure 18a). In TNFα-stimulated cells, a total of 
6.2x106 NCs/mm2 of anti-ICAM NCs associated to cells, a 4.7-fold increase over control 
healthy cells (Figure 18a). The difference between anti-ICAM NCs and IgG NCs associated 
to cells increased to 18.7-fold difference in TNFα-stimulated cells, confirming the specificity 
of anti-ICAM NCs and selectivity toward diseased areas (Figure 18a). Additionally, by 5 
hours, there was a 42% reduction in the amount of anti-ICAM NCs associated to cells 
compared to that at 1 hour. This decrease could be due to active transport across cells and 




Figure 18. Specific binding and transport of anti-ICAM nanocarriers across brain endothelial 
monolayers. Control or TNFα-activated HBMECs were cultured to confluence on porous 
transwell inserts and incubated with 125I-anti-ICAM NCs or non-specific 125I-IgG NCs added 
to the apical chamber for 30 minutes at 37°C. Non-bound carriers were washed and cells 
were incubated for a total time of 1 or 5 hours at 37°C. The radioisotope content of the cell 
fraction (filter inserts) and transported to the basolateral chamber was quantified as absolute 
number of NCs per mm2 insert surface area. (a) Specific binding of anti-ICAM NCs 
compared to IgG NCs of cells. (b) Amount of NCs transported per surface area of cells. Data 
are mean±SEM. *p<0.05, comparing TNFα to control; #p<0.05, comparing anti-ICAM NCs 
to IgG NCs; !p<0.05, comparing 1 hour to 5 hours for each condition, by Student’s t-test. 
(Figure reproduced from [49]) 
 
Indeed, by 1 hour, 2.8x105 NCs/mm2 of anti-ICAM NCs had accumulated in the 
basolateral chamber, which suggests transport. Although basolateral recovery of control IgG 
NCs was 3-fold less than anti-ICAM NCs, it was still detectable (8.4x105 NCs/mm2), 
suggesting that the model may allow some non-specific leakage between the compartments. 
Nonetheless, subtracting this non-specific transport still yielded 1.4x106 NCs/mm2 of anti-
ICAM NCs being specifically transported to the basolateral chamber by 5 hours (Figure 18). 
This is in line with previous work using transwell models of gastrointestinal epithelial cells 
(Caco-2 cells [43]), which showed significant ICAM-1-mediated transport across a 
monolayer of cells. However, less anti-ICAM NCs were transported across epithelial cells 
compared to that of ECs (~250 NCs/cell by 3 hours across Caco-2 monolayers versus ~2000 
NCs/cell by 5 hours across EC monolayers), possibly because a higher tightness of the Caco-




to contribution by other transport pathways that was apparent in our results for brain ECs, but 
was not observed in Caco-2 cells [43]. Hence, the mechanism of transport needs to be studied 
further. 
 
4.2.8. Mechanism of transport of ICAM-1-targeted nanocarriers across blood-brain barrier 
endothelial monolayers 
Since previous studies have shown CAM-mediated endocytosis to be the primary mechanism 
of uptake by ECs and also in the case of transcytosis in epithelium (Caco-2 cells [43]), we 
focused here on testing whether this is conserved for transcytosis by brain ECs (Figure 19).  
Figure 19. Transport mechanism of anti-ICAM nanocarriers across brain endothelial 
monolayers. Binding and transport of 125I-anti-ICAM NCs incubated with human brain 
microvascular EC monolayers in the absence or presence of anti-ICAM molecules 
(competitive binding of ICAM-1) for 1 hour or amiloride derivative (EIPA, inhibitor of 
CAM-mediated endocytosis) for 5 hours. (a) Total anti-ICAM NCs remaining in the cell 
fraction normalized to control. (b) Total anti-ICAM NCs transported into the basolateral 
chamber normalized to control. Data are mean±SEM. *p<0.05, comparing each inhibition 
condition to respective control, by Student’s t-test. (Figure reproduced from [49]) 
 
First, to ensure the mechanism of transport was mediated selectively by ICAM-1 
binding, we performed a competitive inhibition assay by incubating brain EC monolayers 
with anti-ICAM NCs in the presence of additional “naked” anti-ICAM molecules. Binding 




40.6±7.5% of control (Figure 19), verifying ICAM-1-dependence for this process. In 
addition, incubation of cells in the presence of EIPA, an amiloride-derivative that inhibits 
CAM-mediated endocytosis [43], also markedly reduced basolateral transport (45.6±17.4% 
of control), indicating that this occurs mainly reliant on the CAM-mediated pathway. As 
expected, EIPA did not reduce binding of anti-ICAM NCs to cells (93.7±12.7% of control) 
since this molecule only affect endocytic mobilization and not ICAM-1-expression. 
Altogether, this set of results shows that ICAM-1-targeted NCs are capable of 
specifically targeting and traversing through the endothelial layer of the BBB, which is 
mediated by the CAM-pathway.  
 
4.2.9. Transport of ICAM-1-targeted nanocarriers across blood-brain barrier endothelial-
subendothelial bi-layers 
Then, to test for transport across both endothelial and subendothelial aspects of the BBB, bi-
layer co-culture BBB models were constructed where human brain microvascular ECs were 
cultured on the apical side of the insert and either ACs or PCs were placed on the opposing 
basolateral side of the membrane insert (EC-AC or EC-PC co-cultures; Figure 17c). TNFα-
stimulated cells were continuously incubated with green fluorescent anti-ICAM NCs. To 
visually confirm the presence of anti-ICAM NCs associated to cells, transwell membrane 
inserts were excised and mounted onto microscopy slides, and images were captured with 
confocal microscopy (Figure 20a). To validate this and avoid potential visual interference of 
fluorescent carriers which may accumulate in the membrane between the cells, we used 125I-
anti-ICAM NCs and separately quantified carriers associated with either the endothelial or 




Confocal images show that by 24 hours, substantial anti-ICAM NC accumulation in 
both endothelial and subendothelial layers (Figure 20a). Slightly more anti-ICAM NCs 
associated to ECs of the bi-layer models versus the subendothelial layer (8.5-fold 
enhancement over ACs and 20.0-fold over PCs; Figure 20b). Despite the difference and 
significant accumulation of anti-ICAM NCs in cells, transport of anti-ICAM NCs across both 
layers and into the basolateral chamber was detectable even by 1 hour (2.6x105 NCs/mm2 for 
ECs-ACs and 2.1x105 NCs/mm2 ECs-PCs) and increased over time (13.1- and 5.8-fold 
increase by 5 hours, 41.5- and 45.5-fold increase by 24 hours; Figure 20c).  
Figure 20. Binding and transport of anti-ICAM nanocarriers across endothelial-
subendothelial cell layers. Apical side of porous transwell inserts was seeded with human 
brain microvascular ECs and grown to confluence and the basolateral side of the same 
transwell was seeded with either ACs or PCs, also grown to confluence. TNFα-activated cells 
were incubated with anti-ICAM NCs added to the apical chamber for 1, 5, or 24 hours at 
37°C. (a) Confocal images of the endothelial and subendothelial cell linings showing green 
fluorescent anti-ICAM NCs associated to cells after 24 hours at 37°C. The nuclei of cells 
were stained blue with DAPI. (b) Total 125I-anti-ICAM NCs associated per mm2 surface area 
of endothelial or subendothelial cell layers after 5 hours of incubation at 37°C. (c) Total 125I-
anti-ICAM NCs transported per mm2 surface area across both endothelial-subendothelial cell 
layers and into the basolateral chamber over 24 hours period. Data are mean±SEM. *p<0.05, 
comparing endothelial layer (ECs) to subendothelial layer (ACs or PCs); #p<0.05, comparing 




These results are considerately relevant since successful transport across the BBB 
and into the brain parenchyma requires that drug delivery systems traverse all layers of both 
the endothelial and the subendothelial layers of the BBB. Our previous assays had confirmed 
ICAM-1 expression of ACs and PCs, as well as binding and endocytosis of anti-ICAM NCs 
via CAM-mediated uptake (Sections 4.2.2. to 4.2.4.). We have also shown transport across 
brain endothelial monolayers was possible by targeting ICAM-1 (Section 4.2.5.). Here we 
have complemeted this information by showing that binding and further transport across both 
endothelial and subendothelial layers of the BBB is possible. We noted that association of 
anti-ICAM NCs to the endothelial layer of the BBB is in fact more relevant than of the 
subendothelial layer, paralleling our findings performed with individual cell cultures, where 
also ECs bound and internalized anti-ICAM NCs more significantly than ACs and PCs. This 
difference could be due to more involved role of the ECs on the BBB compared to supporting 
roles of subendothelial cells. Association of anti-ICAM NCs in subendothelial cells confirms 
transport across the endothelial layer and also implies that transported anti-ICAM NCs can 
still interact with subendothelial cells. Additionally, transport yielded across two layers of 
cells is indicative that anti-ICAM NCs can traverse across the entire BBB structure, therefore, 
amenable for brain delivery. 
 
4.2.10. ICAM-1 expression on neuroblastoma derived neuron-like cells 
Delivery to cells of the brain must be tested to evaluate the potential of ICAM-1-targeted 
drug delivery to the brain. To evaluate if cells in the brain parenchyma (e.g. neurons) could 
bind and internalize anti-ICAM NCs, as a proof of concept, we used human neuroblastomas 
differentiated into neuron-like cells (NLCs). ICAM-1 expression on NLCs was first evaluated 




As shown in Figure 21, ICAM-1 was expressing on healthy control NLCs (3.0-fold 
over background fluorescence). Pathological-mimicking conditions (TNFα-stimulation) 
heightened the overall ICAM-1 expression (7.7-fold over background; Figure 21a). This 
correlates well with historic work portraying abundant ICAM-1 expression on neurons [196], 
especially of those affected by disease [197, 198]. Although, the role of ICAM-1 on neurons 
has not been clearly elucidated, but speculated to be similar to that of other cell types [196], 
its involvement in inflammation and immune cell recruitment [139]. Curiously, we noted that 
ICAM-1 expression was not uniform between the NLC body and cellular processes. In fact, 
in control healthy cells, 1.9-fold more ICAM-1 expressed at the cell body versus processes. 
This difference diminished to 1.3-fold under pathological-like conditions. Normalization of  
Figure 21. ICAM-1 expression on healthy versus disease-like human neuron-like cells. 
Differentiated SH-SY5Y cells (NLCs) were cultured with or without TNFα then fixed and 
stained for ICAM-1 expression using immunofluorescence. ICAM-1 expression levels were 
imaged and analyzed through fluorescence microscopy. (a) Phase-contrast images and 
corresponding fluorescence images portraying ICAM-1 expression on control and TNFα-
activated cells. Arrows point to cell bodies and arrowheads point to processes. Scale bar = 10 
µm. (b) The sum intensity of fluorescence or (c) the mean intensity corresponding to ICAM-1 
expression per surface area of a whole cell, the cell body, or cell processes was calculated as 
fold-difference over background fluorescence. Data are mean±SEM.*p<0.05, comparing 





expresssion to the cell surface area in each of these compartments showed that ICAM-1 
expression was more concentrated on the cell body versus processes (2.4-fold difference in 
control cells, 2.0-fold in diseased cells; Figure 21b). Yet, the overall fold-enhancement of 
ICAM-1 expression as a result of TNFα-stimulation was higher in the processes: 2.3-fold 
increase on the cell body versus 3.4-fold increase on cellular processes compared to healthy 
controls (Figure 21a). It was interesting to observe regional differences in ICAM-1 
expression. This also suggests the possibility of controlling avidity of ICAM-1-targeting drug 
delivery systems to differentiate regional targeting on neurons altogether.  
  
4.2.11. Binding of ICAM-1-targeted nanocarriers to neuron-like cells 
Previous works suggest that the level and pattern of ICAM-1 expression on cells does not 
necessarily predict the cell’s potential to bind anti-ICAM NCs. Hence, binding specificity, 
efficiency, and disease selectivity was studied on NLCs. Indeed, ICAM-1 expression did not 
correlate to binding efficiency. For instance, even though the overall expression difference 
between healthy versus TNFα-activated NLCs was 2.7-fold (Figure 21b), the binding 
difference was 4-folds by 1 hour, with anti-ICAM NCs binding more efficiently to TNFα-
activated cells (107.5±9.8 NCs/cell) than healthy cells (27.1±1.8 NCs/cell; Figure 22a, b). 
Interestingly, this fold difference between healthy and diseased cells was consistent amongst 
different cellular regions: 3.9-fold increase in cell body and 4.0-fold increase in cell process 
(Figure 22a, b). A closer look revealed that processes bound ~2.1-fold more anti-ICAM NCs 
than cell body in both healthy and diseased conditions (Figure 22b), opposite to the fact that 
less ICAM-1 was expressed on processes versus the cell body (1.3- to 1.9-fold less than cell 
body; Figure 21b). Normalizing binding to area to assess density of bound anti-ICAM NCs 




diseased cells. Binding density on NLC processes proved to be 2.1-fold more dense compared 
to the cell body in control conditions and 1.6-fold more dense in diseased conditions 
(11.0±0.5 NCs/mm2 and 39.7±1.7 NCs/mm2; Figure 22c).  
Figure 22. Binding of anti-ICAM nanocarriers to neuron-like cells. Green fluroescent anti-
ICAM NCs were incubated with control or TNFα-activated NLCs for 1 hour at 37°C, then 
washed and fixed for immunofluorescence analysis. (a) Phase-contrast images and 
corresponding fluorescence images portraying anti-ICAM NCs bound on control versus 
TNFα-activated cells. Scale bar = 10 µm. (b) Comparison of total anti-ICAM NCs bound per 
control or TNFα-activated whole cell, cell body, or cell processes. (c) Comparison of total 
anti-ICAM NCs bound per µm2 area of control or TNFα-activated cells quantified per whole 
cell, cell body, or cell processes of a cell. Data are mean±SEM.*p<0.05, comparing TNFα to 
control within each group; #p<0.05, comparing cell body to processes, by Student’s t-test.  
 
By 5 hours, binding of anti-ICAM NCs to NLCs had minimally increased (127.3±7.8 
NCs/cell; Figure 23a). Regionally, binding of anti-ICAM NCs did not change over this time 
in processes (73.4±3.1 NCs/cell at 1 hour, 65.6±5.2 NCs/cell by 5 hours). However, binding 
of anti-ICAM NCs did increase with time on the cell body (34.1±3.1 NCs/cell at 1 hour, 
61.8±5.2 NCs/cell by 5 hours), accounting for the minimal increase in the whole cell. Hence, 




than the cell body (t ½ of 83.9 minutes), reaching a similar binding saturation: Bmax of ~63.2 
NCs/cell for the cell process versus Bmax of ~70.2  NCs/cell for the cell body. Interestingly, 
when analyzing change in binding over time as binding density per surface area, similar 
binding rates were observed. However, saturation of binding density of the cell body was 1.5-
fold more than processes: Bmax of ~51.2 NCs/µm2 of the cell body versus Bmax of ~34.2 
NCs/µm2 of processes (Figure 23b), suggesting that more anti-ICAM NCs could potentially 
bind to the cell body versus the cell process. 
 
Figure 23. Kinetics of anti-ICAM NCs binding to neuron-like cells and cell regions. Green 
fluorescent anti-ICAM NCs were incubated with TNFα-activated NLCs for 1, 3, or 5 hours at 
37°C, then washed and fixed for immunofluorescence analysis. (a) Total anti-ICAM NCs 
bound per whole cell, cell body, or cell processes over time. (b) Total anti-ICAM NCs bound 
per µm2 area of a whole cell, cell body, or cell processes over time. Data were fitted to non-
linear regression curves, all with r2>0.90. Data are mean±SEM. *p<0.05, comparing TNFα to 
control within each group; #p<0.05, comparing cell body to processes, by Student’s t-test.  
 
Once again, the level of ICAM-1 expression did not dictate accessibility and 
availability for binding. Total anti-ICAM NCs bound to cell processes (absolute or 
normalized by surface area) was greater than that bound to the cell body, even though more 
ICAM-1 was expressed on cell body over processes. This might be due to accessibility of 
ICAM-1 protein on the neuron surface, e.g. either dispersed versus concentrated in clusters, 




cause steric hindrance affecting binding of NCs differently from binding of antibodies used 
for assessing expression. Or, maybe simply binding saturation as a result of accessibility and 
availability of ICAM-1 varies depending on the rate of binding. As seen, a slower binding 
rate to the NLC body could potentially result in greater binding of anti-ICAM NCs compared 
to the rapid binding to NLC processes, suggesting that total amount of anti-ICAM NCs 
capable of binding is not necessarily dependant on the rate of binding. Nonetheless, anti-
ICAM NCs can bind to both regions, albeit at different densities and at different rates. This is 
promising for drug delivery purposes as processes in many mature neurons are myelinated 
creating another barrier to delivery and, therefore, anti-ICAM NCs may be able to circumvent 
this issue and bind directly to the cell body. Depending on the purpose of the delivery, anti-
ICAM NCs can possibly be controlled by adjusting NC formulation to control avidity. In 
these studies, it is possible that binding saturation may also be dependent of subsequent 
cellular trafficking of NCs, such as endocytosis, which has the potential for recycling ICAM-
1 back to the surface for sustained binding of NCs or the potential for limiting binding due to 
endocytosis with concomitant uptake of surface ICAM-1, as observed in macrovascular 
endothelial cells (HUVECs) [157]. 
 
4.2.12. Endocytosis of ICAM-1-targeted nanocarriers into neuron-like cells 
Next, using fluorescence microscopy, we examined whether bound anti-ICAM NCs were 
endocytosed by NLCs. Within 1 hour of incubation, anti-ICAM NCs was in fact endocytosed 
into NLCs (9.7±0.3 NCs/cell; Figure 24b). Similar to selectivity in binding, uptake of anti-
ICAM NCs was significantly higher in cells stimulated with TNFα versus healthy cells  
(35.9±1.4 NCs/cell; 3.7-fold increase over control cells; Figure 24a, b). Interestingly, upon 





Figure 24. Internalization of anti-ICAM nanocarriers into neuron-like cells. Green fluorescent 
anti-ICAM NCs were incubated with control or TNFα-activated NLCs for 1 hour at 37°C, 
then washed and fixed. Surface bound NCs were stained with Texas Red secondary antibody 
and nuclei were stained blue with DAPI for fluorescence microscopy analysis. (a) 
Fluorescence images of anti-ICAM NCs internalized into TNFα-activated NLCs after 1 hour. 
Arrows point to internalized anti-ICAM NCs (green) and arrowheads point to surface bound 
anti-ICAM NCs (red + green = yellow). Scale bar = 10 µm or 2 µm. (b) Total internalized 
anti-ICAM NCs per control or TNFα-activated whole cell, cell body, or cell processes.  (c) 
Percentage of bound anti-ICAM NCs internalized into control or TNFα-activated whole cell, 
cell body, or processes of a cell. Data are mean±SEM. *p<0.05, comparing TNFα to control 
within each group; #p<0.05, comparing cell body to processes, by Student’s t-test.  
 
in anti-ICAM NC binding was conserved regarding the endocytosis pattern. Cell processes 
endocytosed 1.5- to 2-folds more NCs than cell bodies in both control and diseased cells 
(Figure 24b). Interestingly, endocytosis efficiency, described as percent uptake relative to 
total anti-ICAM NCs associates to cells, remained consistent between healthy and diseased 
cells (~35%; Figure 24c), suggesting that uptake efficiency is not dependent nor affected by 
pathological state of cell. This is also true when examining the cell body (~38% 
internalization). However, this is not the case for cell processes, in fact, internalization 
efficiency decreases with TNFα-stimulation (34.6±1.8% in control cells versus 27.9±1.5% in 
diseased cells), contrasting ICAM-1-expression and anti-ICAM NC binding pattern which 
increased in the cell processes of diseased cells (Figures 21 and 22). Perhaps binding of anti- 
ICAM NCs to cell processes is rapid (as with a rapid t1/2 of <0.1 minute; Figure 23) and hence 
quickly saturates, but the mobilization of vesicular uptake is slow. Nonetheless, even though 




processes versus 13.6±0.7 NCs/cell in the cell body; Figure 24b), it seems that the cell body 
is more efficient in internalizing associated anti-ICAM NCs (39.7±2.2% in cell body versus 
27.9±1.5% in cell processes; Figure 24c). 
With regard to the kinetics of endocytosis, similar to binding patterns, absolute 
number of anti-ICAM NCs endocytosed into whole NLCs minimally increases over time, 
35.9±1.4 NCs/cell at 1 hour to 40.3±2.6 NCs/cell by 5 hours (Figure 25a, b). This may be due 
to a rapid internalization rate (t1/2 of 1.2 minutes), yielding an Imax of ~35.7 NCs/cell. The 
rapid internalization rate is largely contributed by rapid uptake into NLC processes (t1/2 
of<0.1 minute) similar to the observed binding rate. A modest maximum internalization (Imax) 
calculated to be ~17.3 NCs/cell, and interestingly, total number of NCs internalized into 
processes decreases over time (Figure 25b). This may suggest that uptake is rapid in 
processes perhaps followed by retrograde transport to the cell body. In agreement with this, 
 
Figure 25. Kinetics of anti-ICAM nanocarriers uptake by neuron-like cells. Green fluorescent 
anti-ICAM NCs were incubated with TNFα-activated NLCs for 1, 3, or 5 hours at 37°C, then 
washed and fixed.  Surface bound NCs were stained with Texas Red secondary antibody and 
nuclei were stained blue with DAPI for fluorescence microscopy analysis. (a) Fluorescence 
images of anti-ICAM NCs internalized into TNFα-activated NLCs after 1, 3, or 5 hours. 
Arrows point to internalized anti-ICAM NCs (green) and arrowheads point to surface bound 
anti-ICAM NCs (red + green = yellow). Scale bar = 10 µm. (b) Total anti-ICAM NCs 
internalized per whole cell, cell body, or cell processes over time. (c) Total anti-ICAM NCs 
internalized per µm2 area of a whole cell, cell body, or cell processes over time. Data were 
fitted to non-linear regression curves, all with r2≥0.89. Data are mean±SEM. #p<0.05, 




uptake rate in the NLC body was observed to be extremely slow (t1/2 of 3.5 hours) and total 
anti-ICAM NC accumulation increases 2.1-fold by 5 hours compared to 1 hour, with the 
potential to reach an Imax of ~44.4 anti-ICAM NCs/cell (Imax of ~32.4 anti-ICAM NCs/µm2 in 
cell body versus ~ 10.2 anti-ICAM NCs/µm2 for cell processes and whole cell; Figure 25c). 
As compared to our previous data, this study revealed that the endocytosis efficiency 
is not affected by pathological state of the cell, a similar phenomenon to that seen in other 
cell types (e.g. HBMECs, PCs). However, relative uptake in NLCs remained modest (~35%) 
in comparison to BBB cells, which had an average uptake efficiency of ~50% (Figure 14). 
Nonetheless, this could be due to the innate role of these cell types. BBB cells regulate 
transport of small and large material and protect the brain parenchyma from foreign 
invasions, and therefore may endure higher frequency of endocytosis. Indeed, rate of 
endocytosis into these cell types is not as rapid as NLC processes but not as slow as NLC 
body (t1/2 of ~3.5 hours in NLC body versus an average t1/2 of 88 minutes in BBB cells; Figure 
25 and 14, respectively), but the achievable internalization maximum is much higher, ~90 to 
~300 NCs/cell in BBB cells versus ~30 NCs/cell in NLC body. In any instance, this may still 
be relevant from the perspective of delivery into NLCs via ICAM-1-mediated mechanisms.  
 
4.2.13. Mechanism of endocytosis of ICAM-1-targeted nanocarriers in neuron-like cells 
Uptake of molecules into neurons appears largely been dependent on clathrin endocytosis 
(e.g. neurotransmitters [199, 200]), yet ICAM-1-targeted carriers do not capitalize this 
pathway but on CAM-mediation for endocytosis. In agreement with this, amiloride did inhibit 
internalization of anti-ICAM NCs in NLCs more so than any other inhibitor (15.9±3.4% 
reduction; Figure 26). However, interestingly, the effect of amiloride was significant only for 




reduction in processes (Figure 26b). Moreover, MDC treatment to inhibit clathrin-mediated 
endocytosis resulted in a modest increase of internalization into the cell processes, although 
without statistical significance (7.9±9.5% increase), but slightly decreased internalization in 
the cell body (11.7±4.5% reduction; Figure 26b). Additionally, filipin treatment, inhibitor of 
caveolae-mediated endocytosis, did not affect internalization efficiency in either cell regions 
(~95% of control for both cell body and cellular processes). 
 
Figure 26. Mechanism of uptake into neuron-like cells and cell regions. TNFα-activated 
NLCs were incubated with FITC-analog labeled anti-ICAM NCs for 3 hours at 37°C in 
absence (control) or presence of either amiloride (CAM-mediated endocytosis inhibitor), 
filipin (caveolae-mediated endocytosis inhibor), or MDC (clathrin-mediated endocytosis 
inhibitor. Cells were washed to remove non-bound NCs and stained with Texas Red 
secondary antibody, nucleus was stained with DAPI. (a) Arrows point to internalized anti-
ICAM NCs (green). Arrowheads point to surface bound anti-ICAM NCs (red + green = 
yellow). Scale bar = 10µm. (b) Percent of internalization relative to control cells. Data are 
mean±SEM. *p<0.05, comparing inhibitors to control within each group; #p<0.05, comparing 
cell body to processes, by Student’s t-test.  
 
Therefore, similar to other cell types previously tested, the main mechanism of 
endocytosis into NLCs is via CAM-mediation, although, whole NLC internalization was only 
modestly reduced compared to BBB cells (e.g. reduction of 40.0±3.7% in ECs (Figure 15). 
This was similar to the effect seen on the NLC body. Perhaps this is because neuron 




BBB cells, have a more uniform cell surface and more dynamic plasmalemmas. 
Internalization into NLC processes, on the other hand, was not affected by amiloride. 
Neuronal processes are known to heavily utilize clathrin-mediated endocytosis for uptake 
[199, 200]. Therefore, it is possible that anti-ICAM NCs bound to ICAM-1 can be passively 
incorporated into the abundant clathrin-pits that continuously form in NLC processes in the 
case of CAM-inhibition so that no effect is observed. As previously emphasized, some 
classical endocytic mechanisms, such as clathrin-mediated endocytosis, are impaired in some 
LSDs [27-29]. Hence, anti-ICAM NCs may overcome this impediment not only by CAM-
mediation, but also by relying on multiple options of endocytosis (Figures 16, 26).  
 
4.2.14. Lysosomal trafficking of ICAM-1-targeted nanocarriers in neuron-like cells 
Lysosomal delivery of anti-ICAM NCs into model neurons was analyzed by fluorescently 
labeling the lysosome with Texas Red dextran and tracing green fluorescent anti-ICAM NCs 
for co-localization with lysosomes (red + green = yellow) (Figure 27a). Immunofluorescence 
showed a low level of anti-ICAM NCs colocalization with intracellular lysosomes by 1 hour 
(25.4±2.4% of all cell-associated anti-ICAM NCs; Figure 27b), but this was increased with 
time: up to 42.8±2.4% of all cell-associated carriers localizing within this compartment by 3 
hours in activated human NLCs (arrows pointing to yellow particles; Figure 27a). This 
seemed to be a saturating level of lysosomal transport, as it did not further increased by 5 
hours (45.9±2.3% colocalization, with a t1/2 of ~74.5 minutes and a calculated co-localization 
maximum of 58.4%), which is in agreement with a total level of ~35% of carrier being 
internalized by this time (compare with Figure 25). Therefore, focusing only on those carriers 
internalized by cells, the level of lysosomal transport would be ∼100%. A closer examination 




trafficking than cell processes (t1/2 of ~22.2 minutes in cell body versus t1/2 of ~75.9 minutes 
in processes; Figure 27b). In fact, by 5 hours a greater percentage of anti-ICAM NCs 
trafficked to the lysosome of the cell body (54.6±2.5%) versus that of NLC processes 
(36.7±5.5% in lysosomes). 
 
Figure 27. Lysosomal trafficking of anti-ICAM NCs in neuron-like cells. TNFα-activated 
NLCs were pre-incubated Texas Red dextran to stain lysosomes, then incubated with green 
fluorescent anti-ICAM NCs for 1 hour at 37°C. To synchronize internalization trafficking of 
anti-ICAM NCs, cells were then washed to remove non-bound NCs and were then examined 
or continued to be incubated for a total of 3 or 5 hours at 37°C. Nuclei were stained blue with 
DAPI. (a) Fluorescence images of cells incubated for 1, 3, or 5 hours (top). Boxed regions are 
magnified 2-folds (bottom). Arrows point to anti-ICAM NCs in lysosomes (red + green = 
yellow). Arrowheads point to anti-ICAM NCs which do not co-localize with lysosomes 
(green). Scale bar = 10µm. (b) Kinetics of lysosomal trafficking over 5 hours. Data are 
mean±SEM. *p<0.05, comparing cell body to processes, by Student’s t-test.  
  
Lysosomes is the intended destination for LSDs, hence these results show the 
potential of targeting ICAM-1 for lysosomal delivery in neurons. Interestingly, neurons 
trafficked anti-ICAM NCs to the lysosome faster than BBB cells (t1/2 of ~4 hours, see Section 
4.2.6.; Figure 16). The overall percentage of anti-ICAM NCs trafficked to the lysosomes of 
NLCs was actually similarly efficient compared to ACs and PCs (45.9±2.3% in lysosomes of 
NLCs versus 39.6±2.6% in ACs and 49.4±2.4% in PCs; Figure 27 and 16, respectively), but 
less efficient than brain ECs (1.6-fold less). It is especially interesting that a greater 




processes and total amount of NCs associated with processes decreased with time. In fact, the 
cell body traffics anti-ICAM NCs faster to the lysosome than NLC processes, yet the opposite 
is seen for rate of endocytosis. This may indicate that lysosomes in the NLCs are 
predominately located in the cell body and anti-ICAM NCs follow a processes-to-body 
transport. Since neuron processes actively and frequently retrograde endocytosed material to 
the cell body, such as other delivery vectors [201], this phenomenon could indirectly increase 
the lysosomal co-localization detected in cell body and diminish the absolute values in the 
NLC processes. Nonetheless, anti-ICAM NCs ultimately target lysosomes, showing that 
ICAM-1-targeted drug delivery systems can systemically deliver NCs to lysosomes of 
various cell types, including difficult to reach tissue.  
 
4.2.15. Conclusion 
Targeting to the brain is highly coveted for several neuropathy and/or neurodegenerative 
treatments. However, the highly regulating BBB have often been the main impediment. Here 
we show that targeting ICAM-1, a cell surface molecule inherently involved in leukocyte 
extravasation, assisted the binding, uptake, and transport of NCs to and across cell barriers 
[49]. Specifically, anti-ICAM NCs were capable of binding and internalizing into cells of the 
BBB (ECs, ACs, and PCs), traverse this lining, and target cells of the brain, such as NLCs. 
Uptake of anti-ICAM NCs into cells was shown to be achieved mainly via CAM-mediated 
endocytosis, although other routes may assist and compensate endocytosis. This shows that 
uptake of anti-ICAM NCs into these cells can bypass clathrin-mediated endocytosis if that 
route is impaired, as speculated in several LSDs [27-29]. Moreover, a fraction of anti-ICAM 




ICAM NCs by 5 hours). This is important for LSD treatment since all cells are affected by 
LSDs, hence the need for systemic delivery.  
Interestingly, due to cell morphology and phenotype, subendothelial cells and NLCs 
portrayed different binding and uptake profiles than ECs. Since ECs directly interact with the 
circulating blood, ECs could have a tendency to bind and internalize more anti-ICAM NCs 
faster than other BBB cell, as seen in our results. Additionally, ACs and PCs uptake less anti-
ICAM NCs. This suggests that anti-ICAM NCs traversing across the BBB would not be 
“entrapped” in the subendothelial layer, and can further bind to cells of the brain. Indeed, 
anti-ICAM NCs can target cells of the brain. Another interesting phenomenon is that different 
regions of the NLC behave differently in response to anti-ICAM NCs. In fact, faster and more 
anti-ICAM NCs bound to cell processes, yet more anti-ICAM NCs internalized and trafficked 
to lysosomes, and faster, in the cell body. This may be in line with historic observations 
showing reliance on cellular neurites to uptake material versus the cell body, and for 
endocytosed materials to retrograde towards the cell body [201]. This may explain how we 
observed less anti-ICAM NCs binding to cell body, but more internalized in this region.  
All in all, in addition to vascular endothelial cell targeting, anti-ICAM NCs seem to 
traverse the BBB and target lysosomes in cells of the BBB and the brain, showing promise in 
utilizing ICAM-1-targeting platform to enhance delivery of therapeutic to treat diseases that 





4.3. Enhanced delivery of lysosomal enzyme to organs in mice by ICAM-1-targeting 
4.3.1. Introduction 
As mentioned, currently available ERTs target M6PR for lysosomal delivery. However, this 
method renders poor cellular uptake and leads to suboptimal distribution of ERT to target 
organs while accumulating into clearance organs (e.g. kidneys, liver, spleen) [35, 84, 85], 
pairing well with liver and spleen having high M6PR expression [80, 90-92]. Moreover, the 
major tissues that are severely affected by FD (kidney, vasculature) [45], PD (heart, liver, 
skeletal muscles) [46], and NPD (brain, liver, lungs) [202] are challenging to reach by a 
therapeutic that does not preferentially target to diseased organs, especially intractable tissue 
that requires transport across cell barriers (e.g. brain) [34]. Hence, an alternative targeting 
strategy to help deliver the enzyme therapeutic to all tissues affected by the disease may 
improve ERT efficacy. 
Previous work with anti-ICAM/ASM NCs has shown promise [41]. ICAM-1-
targeting of ASM, for NPD treatment, was able to enhance enzyme delivery to major tissues 
(heart, kidneys, liver, lungs, spleen) versus non-targeted enzyme, while avoiding majority of 
delivered enzyme from being cleared to clearance organs [41]. However, it is unknown 
whether this is unique to anti-ICAM/ASM NCs or if other cargoes could contribute a steric 
hindrance or somehow disrupt binding pattern of anti-ICAM NCs. Hence, we assess here 
whether ICAM-1-targeted αGal and GAA share the same fate. Furthermore, the brain is a 
major target organ for neuropathic LSDs. Enzyme delivery to this organ via anti-ICAM NCs 





4.3.2. Circulation of anti-ICAM/enzyme nanocarriers versus non-targeted enzyme in mice 
We first studied enzyme enzyme circulation after i.v. injection, for which αGal and GAA 
were radioactively labeled with 125I to enable tracing in vivo. As a proof-of-concept model, 
100 nm diameter polystyrene nanoparticles were coated with ICAM-1-targeting antibodies 
and 125I-enzyme molecules (95:5 antibody to enzyme mass ratio; minimal amounts of enzyme 
were needed to trace its distribution). As previously discussed, polystyrene nanoparticles 
enable tracing without the effects of biodegradation. As an anti-ICAM NC model, 
polystyrene NCs have been previously characterized and determined to behave similarly to 
biodegradable PLGA NCs [41, 203]. Anti-ICAM/125I-αGal NCs, anti-ICAM/125I-GAA NCs, 
and respective dose matched non-targeted enzyme were i.v. injected into mice. To evaluate 
rate of retention or removal of 125I-αGal and 125I-GAA in circulation, mouse blood was 
collected 1, 15, and 30 minutes post-injection and analyzed by determining the presence of 
125I using a gamma counter.  
Within 1 minute of injection, minimal amount of anti-ICAM NC-associated enzymes 
were traceable in blood (Figure 28): only 5.85±0.67% and 2.60±0.47% of injected dose 
(%ID) of anti-ICAM/αGal NC and anti-ICAM/GAA NC, respectively, remained in 
circulation, and continued to remain low throughout the duration of the experiment (Figure 
28a, b). The rapid removal of anti-ICAM/enzyme NCs from circulation correlates well with 
historical data on anti-ICAM/ASM NCs, of which only 3.32±0.46%ID remained in 
circulation 30 minutes post-injection [41]. This was opposite for non-targeted enzyme 
equivalents, where the majority of the injected dose was detected in circulation by 1 minute: 
64.72±3.96%ID and 51.76±1.62%ID of non-targeted αGal and GAA, respectively, which 
only minimally decreased by 30 minutes (42.07±2.22%ID and 38.40±2.11%ID; Figure 28a, 




of non-targeted ASM remained in circulation by 1 minute post-injection, and similarly, 
decreased only to 31.6±2.9%ID by 30 minutes.  
Figure 28. Circulation of anti-CAM/enzyme nanocarriers. 125I-labeled enzyme was used to 
trace enzyme in the body. Mice were injected with either anti-ICAM/125I-enzyme NCs or 
non-targeted 125I-enzyme and blood was collected at 1, 15, or 30 minutes post-injection. 
Percent of injected dose (%ID) describes the total amount of enzyme traced in blood samples 
from mice injected with (a) anti-ICAM/125I-αGal NCs versus 125I-αGal or (b) anti-ICAM/125I-
GAA NCs versus 125I-GAA. Data are mean±SEM. *p<0.01, comparing anti-ICAM/enzyme 
NCs to non-targeted enzyme, by Student’s t-test. (Figure adapted from [47, 48]) 
 
A priori, short half-life in blood of anti-ICAM/enzyme NCs may seem detrimental to 
efficient therapy. Indeed, this is the case for delivery strategies that rely on diffusion of 
relatively small drug molecules from the circulation into tissues, or for drug carriers designed 
for delivery of cancer therapeutics [204]. These strategies require passive transport into the 
tumor parenchyma across the leaky vasculature of tumor blood vessels, via the enhanced 
permeability and retention effect [204]. However, in the case of ERT for LSDs, the non-
targeted enzyme counterparts studied here that remained in circulation for longer most likely 
due to the lack of active targeting, which is needed to achieve receptor-mediated endocytosis 
through the body. Such extended circulation time could prolong therapeutic effects by 
allowing slow accumulation to tissue, but it can also give rise to immune recognition and 




Hence, rapid removal from the blood may be beneficial in this case to avoid premature 
degradation and/or recognition by the immune system [95, 205]. This is particularly relevant 
in the case of therapeutic biologics, as long as fast clearance from blood does not impair 
targeting of the intended tissues. Rapid clearance may be indicative of fast targeting to 
ICAM-1-rich tissue. Presentation of multiple copies of the enzyme on the nanocarrier surface 
may also pose immunological concerns, which remain to be investigated. Yet, this model 
represents a proof-of-concept for ICAM-1-targeting and enzymes can be encapsulated to 
avoid such outcome. 
 
4.3.3. Blood versus tissue distribution of anti-ICAM/enzyme nanocarriers in mice 
Bulk biodistribution of anti-ICAM/enzyme NCs was studied in vivo to evaluate the potential 
of this s trategy for targeting compared to non-targeted enzymes. Previous work with anti-
ICAM/ASM NCs had shown promise in distributing ASM through tissues, while the naked 
enzyme had rapidly cleared from circulation [41]. To evaluate the bulk distribution of 
enzyme in tissues or retention in circulation, mice were injected with anti-ICAM/125I-enzyme 
NCs or non-targeted 125I-enzyme. Blood from mice was collected at time of enuthanization 
(30 minutes) and peripheral organs (heart, kidneys, liver, lungs, spleen) were harvested. 
Samples were measured with a gamma counter to detect the presence of 125I-enzyme. 
Again, while minimal NCs remaining in circulation by 30 minutes post-injection 
(~4.5%ID; Figure 29), majority of injected anti-ICAM/αGal NCs or anti-ICAM/GAA NCs 
were found in collected organs: 60.1±4.5%ID and 71.8±1.9%ID, respectively (Figure 29). 
The opposite was seen for non-targeted enzymes, with a large percentage of injected dose 
remaining in the circulation after 30 minutes after injection (~40.3%ID; Figure 29) and only 




contained in organs. All in all, a marked ~4-fold difference in tissue was observed in the 
enzyme detected in all tissues, which indicates the contrast between targeted versus non-
targeted enzyme. 
Figure 29. Enzyme distribution in tissue 
versus circulation in mice. 125I-labeled 
enzyme was used to trace enzyme 
distribution. Mice were injected with 
either anti-ICAM/125I-enzyme NCs or 
non-targeted 125I-enzyme and blood and 
organs (heart, kidneys, liver, lungs, 
spleen) were collected 30 minutes post-
injection. Enzyme presence was 
expressed as the percent of injected 
dose (%ID) remaining in blood or %ID 
collected from mouse organs. *p<0.01, 
comparing anti-ICAM/enzyme NCs to 
non-targeted enzyme, by Student’s t-
test. Data are mean±SEM. (Figure 
adapted from [47, 48]) 
 
4.3.4. Visualization of anti-ICAM nanocarriers in mice 
We then imaged the pattern of biodistribution of anti-ICAM NCs injected i.v. in mice. For 
this purpose, nanocarriers consisted of green fluorescent nanoparticles coated with anti-
ICAM and tracer amounts of NIR-labeled IgG, to allow co-visualization of both nanoparticle 
and coat components, respectively. Optical (fluorescence) imaging of the nanoparticle 
component showed clear and predominant accumulation of anti-ICAM NCs in lungs 30 
minutes after i.v. injection, with lower accumulation in clearance organs such as the liver and 
spleen, whereas the opposite outcome was observed in the case of control IgG NCs (Figure 
30a, b). Pulmonary accumulation (11.6-fold greater for anti-ICAM NCs over IgG NCs, 
Figure 30c) suggests specificity of targeting, since this organ contains a significant fraction 
(1/5–1/4) of the total vascular endothelium in the body, has relatively high ICAM-1 




our previous studies showing pulmonary accumulation of anti-ICAM NCs ~14.2-fold over 
control IgG NCs in wild-type mice [203], but not in ICAM-1 knockout mice discussed below 
(11.4-fold below wild-type mice; Section 4.4.4.).  
 
Figure 30. Visualization of specific targeting of anti-ICAM nanocarriers in mice. Optical 
imaging of (a) mice or (b) isolated organs 30 min after i.v. injection with green fluorescent 
nanocarriers (4x1013 NCs/kg) coated with control IgG or anti-ICAM labeled with FITC-
analog (green fluorescent) and coated with either control IgG or anti-ICAM. (c) Semi-
quantitative measurement of nanocarrier distribution, from optical imaging results shown in 
(b). (d) Visualization of anti-ICAM NCs consisting of green fluorescent nanoparticles coated 
with anti-ICAM and Alexa Fluor 750-labeled IgG as a near-infrared (NIR) tracer, revealing 
co-localization of both nanocarrier and coat counterparts in the lungs. (Figure adapted and 
reproduced from [50]) 
 
Hence, these results confirm specific and dose-dependent targeting by anti-ICAM 
NCs, in accord with previous studies showing a similar outcome when the targeting-antibody 




localization of the green fluorescent (FITC-analog) and NIR signals, which correspond to the 
nanocarrier particle and the antibody coat, respectively (Figure 30d). This confirms in vivo 
stability of the coat on the nanocarrier surface, validating previous works that show a similar 
result in models in vitro in Section 4.1.2. [48]. 
 
4.3.5. Biodistribution pattern and specificity of anti-ICAM/enzyme nanocarriers in mice 
To confirm and quantify in vivo targeting by anti-ICAM/enzyme NCs, a closer examination 
of the presence of enzyme in each major organ was then conducted to evaluate the 
biodistribution pattern. This was achieved by using anti-ICAM/125I-enzyme NCs. 
Specifically, peripheral organs, including the heart, kidneys, liver, lungs, and spleen, were 
examined. Due to its dense vasculature [206-208], high ICAM-1 expression [41], and the fact 
that they receive the whole cardiac output as a first pass, the lungs are a main target of 
ICAM-1-targeting strategies (e.g. 26.35 ± 3.22%ID of anti-ICAM NCs [41, 47, 157]). Anti-
ICAM/αGal NCs and anti-ICAM/GAA NCs follow that similar pattern (Table 2). The lungs 
accumulated 36.24±3.47%ID and 48.75±3.25%ID of anti-ICAM/αGal NC and anti-
ICAM/GAA NC, respectively. This is significantly higher than the second most accumulating 
organ, the liver, which is also very densely vascularized and expresses ICAM-1 while also 
serving as a clearance organ [41]. Nevertheless, the liver is a main target for many LSDs, e.g. 
PD [46]. This organ accumulated 18.41±1.22%ID and 17.32±2.05%ID of anti-ICAM/αGal 
NCs and anti-ICAM/GAA NCs accumulated in the liver. Instead, since non-targeted enzymes 
lack ICAM-1-specificity, neither non-targeted αGal nor GAA accumulated in the lungs: 
0.7±0.1%ID and 1.0±0.1%ID, respectively (Table 2). As for the liver, since this is an RES 
organ, non-targeted αGal and GAA accumulated moderately here: (6.7±0.6%ID and 




Table 2. Biodistribution of anti-ICAM/enzyme nanocarriers and non-targeted lysosomal enzyme in mice. (Adapted from [47]) 
 
 Blood   Heart  Kidney  Liver  Lung  Spleen 
 %ID   %ID LR  %ID LR  %ID LR  %ID LR  %ID LR 
Non-targeted Enzyme:                   
ASM  31.56 ± 2.91   0.33 ± 0.02 0.18 ± 0.02  2.13 ± 0.15 0.41 ± 0.04  22.87 ± 2.55 1.19 ± 0.09  0.95 ± 0.09 0.33 ± 0.03  0.80 ± 0.06 0.46 ± 0.04 
αGal  42.07 ± 2.22   0.49 ± 0.06 0.16 ± 0.01  10.12 ± 0.77 1.21 ± 0.06  6.68 ± 0.56 0.22 ± 0.01  0.74 ± 0.07 0.19 ± 0.02  0.40 ± 0.03 0.18 ± 0.01 
GAA  38.40 ± 2.11   0.50 ± 0.05 0.17 ± 0.01  2.96 ± 0.07 0.40 ± 0.01  9.70 ± 0.77 0.37 ± 0.02  0.96 ± 0.13 0.27 ± 0.03  0.54 ± 0.03 0.30 ± 0.03 
Anti-ICAM/enzyme NCs:                 
Anti-ICAM NC  4.71 ± 0.94   0.34 ± 0.04 1.31 ± 0.27  1.34 ± 0.07 2.05 ± 0.34  31.90 ± 3.58 13.33 ± 3.16  26.35 ± 3.22 81.54 ± 21.54  4.08 ± 0.48 19.50 ± 4.21 
Anti-ICAM/ASM NC  6.94 ± 2.96   0.35 ± 0.02 1.64 ± 0.24  1.37 ± 0.05 2.07 ± 0.19  39.60 ± 2.81 17.31 ± 2.43  21.51 ± 2.73 63.61 ± 11.43  4.08 ± 0.37 23.24 ± 3.83 
Anti-ICAM/αGal NC  5.59 ± 0.33   0.33 ± 0.04 0.80 ± 0.13  1.89 ± 0.14 1.69 ± 0.09  18.41 ± 1.22 4.66 ± 0.40  36.24 ± 3.47 66.95 ± 9.51  3.11 ± 0.43 9.57 ± 1.14 
Anti-ICAM/GAA NC  3.32 ± 0.46   0.41 ± 0.03 1.91 ± 0.39  2.08 ± 0.18 3.49 ± 0.63  17.32 ± 2.05 8.42 ± 2.19  48.75 ± 3.25 159.74 ± 37.79  2.91 ± 0.27 20.00 ± 4.12 
N/A = not applicable, no enzyme was loaded. %ID = percentage of injected dose. LR = localization ratio of %ID/g of tissue to %ID/g of blood. Data are 





To account for density of accumulation in an organ, which allows us to compare 
organs of difference sizes, we normalized %ID per weight of the organ. The liver 
accumulated 12.36±0.71%ID/g of anti-ICAM/αGal NCs and 12.80±1.65%ID/g of anti-
ICAM/GAA NCs, which represented is the third most densely accumulating organ, exceeded 
by the spleen (25.69±2.78%ID/g and 30.88±3.38%ID/g) and the lungs (175.3±21.4%ID/g 
and 246.8±20.4%ID/g). Interestingly, even though the liver and the spleen are RES organs, 
the accumulation could be due to a combination of targeting and clearance, since both non-
targeted αGal and GAA did accumulate in the liver and spleen but still to a lower level than 
anti-ICAM/enzyme NCs: 4.5±0.4%ID/g and 7.0±0.4%ID/g, respectively, in liver and 
3.7±0.3%ID/g and 5.7±0.4%ID/g, respectively, in spleen.  
We then normalized organ accumulation (%ID/g) to the circulating amount of 
enzyme, since the circulation levels are very different for anti-ICAM/enzyme NCs versus 
non-targeted enzyme, where the enzyme detected in an organ can be contributed by the 
circulating fraction in the case of circulating free enzyme. This parameter is called 
localization ratio (LR, Table 2) and represents more accurately enzyme retention in the tissue 
versus in blood. As expected, LR of lungs for anti-ICAM/αGal NCs (67.0±9.5) and anti-
ICAM/GAA NCs (159.7±37.8) were significantly higher than their non-targeted counterparts 
(0.19±0.02 and 0.27±0.03, respectively). This shows a specific enzyme delivery improvement 
by ICAM-1-targeting of 351.4- and 584.1-fold (specificity index, SI; Figure 31a) compared to 
the non-targeted enzymes, which is similar to previous work on anti-ICAM/ASM NCs 
(195.2-fold, [41]). Resultant LR of liver for anti-ICAM/αGal NCs (4.76±0.51) and anti-
ICAM/GAA NCs (8.42±2.19) were also significantly higher than their non-targeted 
counterparts (0.22±0.01 and 0.37±0.02, respectively). This indicates a 21.67-fold specific 




targeted αGal, and similarly by anti-ICAM/GAA NCs over non-targeted GAA (23.1-fold). 
Indeed, this shows that in addition to RES clearance, targeting of ICAM-1 can lead to specific 
accumulation in the liver. This is largely beneficial for treatment of LSDs, since the disease 
plagues all tissues, inclusive of vascular ECs. It is particularly beneficial for treatment of FD, 
a vasculopathy, and for PD, where liver is a target organ.  
 
Figure 31. Specificity index of tissue targeting by anti-ICAM/enzyme nanocarriers versus 
non-targeted enzyme counterpart. Mice were injected with either anti-ICAM/125I-enzyme 
NCs or 125I-enzyme equivalent. Blood and organs were collected 30 minutes post-injection to 
measure 125I-enzyme in a gamma counter. The specificity index (SI) was calculated as a ratio 
comparing the localization ratio (LR, %ID/g in tissue versus %ID/g in blood) of anti-
ICAM/enzyme NCs to LR of non-targeted enzyme equivalent, depicting fold increase of 
enzyme presence in tissue as a result of ICAM-1-targeting compared to non-targeted enzyme. 
SI of (a) liver, lungs, and spleen and (b) heart, kidneys, gastrocnemius muscle, and 
quadriceps muscle.  
 
Other important FD target organs are the kidneys and the heart, which portrayed a 
bulk accumulation of 1.89±0.14%ID and 0.33±0.04%ID, respectively (Table 2), with a 
density 4.58±0.32%ID/g and 2.12±0.32%ID/g, respectively, for anti-ICAM/αGal NC 
treatment. Even though the kidneys and heart were less densely targeted by anti-ICAM/αGal 
NCs than most other organs and apparently accumulated less anti-ICAM/αGal NCs than non-




reached these tissues as a result of ICAM-1-targeting versus non-targeted αGal since a good 
fraction of non-targeted αGal detected was actually in the blood and not the tissue (SI of 1.41 
and 5.06, respectively; Figure 31b). Additionally, the heart and skeletal muscles are key 
target organs for PD treatment. The heart accumulated anti-ICAM/GAA NCs at a density of 
2.88±0.19%ID/g, compared to 3.30±0.23%ID/g of non-targeted GAA. Yet, due to high 
retention of non-targeted GAA in the blood, resultant LR showed that anti-ICAM/GAA NCs 
accumulated better to this tissue versus non-targeted GAA (LR: 1.91±0.39 versus 0.17±0.01; 
Table 2). Indeed, GAA delivery to the heart was enhanced as a result of anti-ICAM NC, by 
an 11-fold increase. Additionally, enzyme delivery to the left gastrocnemius and left 
quadriceps were evaluated as examples of skeletal muscle tissue, which is difficult to reach 
and another main PD target. Specific targeting by anti-ICAM NCs improved delivery of 
GAA to these skeletal muscles by 7.8- and 7.0-folds (SI, Figure 31b). These results show that 
enzyme delivery can be enhanced by anti-ICAM NC platform, even to difficult to reach 
tissue. 
All in all, enzyme delivery to all peripheral tissues tested was enhanced by ICAM-1-
targeting compared to non-targeted delivery, with a difference from 1.4- to 67.8 for αGal and 
5.6- to 584.2-folds for GAA depending on the organ. This is somewhat similar to 
enhancement of ASM delivery to tissue, which was within a range of 5.1- to 195.2-fold 
enhancement. Interestingly, for some formulations, adding an enzyme cargo on the 
nanocarrier surface at the expense of displacing some targeting molecules seems to have 
increased targeting to certain tissues, e.g. anti-ICAM/ASM NCs improved delivery to the 
liver and spleen versus anti-ICAM NCs, and anti-ICAM/GAA NCs improves delivery to 
heart, lungs, and kidneys versus anti-ICAM NCs (LR, Table 2). Yet, this was not the case for 
anti-ICAM/αGal NC. Also interestingly, amongst the three enzymes, anti-ICAM NCs 




provided greatest GAA delivery enhancement to the all tissue except the brain (this will be 
discussed in further detail in Section 4.3.6.). This correlates well with cell culture studies 
showing internalization efficiency of anti-ICAM/GAA NCs to be the greatest amongst the 
three preparations, even with the least number of targeting moieties on the surface (Table 1). 
All in all, these results show that each individual enzyme cargo may elicit similar 
biodistribution pattern but achieve varying degrees of delivery improvement compared to the 
non-targeted enzyme. Yet, since all tissues are affected in LSDs, delivery enhancement by 
ICAM-1-targeting show potential in improving enzyme delivery to all tissues, especially 
target organs.   
 
4.3.6. Brain targeting of anti-ICAM/enzyme nanocarriers in mice 
Many LSDs manifest neuropathy and/or neurodegenerative symptoms [16], hence, treatment 
must also be delivered to the brain, which requires targeting and traversing across the BBB. 
Cell culture work showed promise in delivering anti-ICAM NCs across cell barriers [43], 
including the BBB as shown in the previous chapter [49]. Hence, we studied the potential of 
anti-ICAM NCs to deliver lysosomal enzymes to the brain in mice.  
Previous work showed that 0.27±0.05%ID of anti-ICAM/ASM NCs reached th brain 
(Muro, unpublished results). In this work we also found that 0.13±0.01%ID of anti-
ICAM/αGal NCs and 0.15±0.01%ID of anti-ICAM/GAA NCs also reached this organ 
(Figure 32a). Density of brain accumulation was 0.65±0.13%ID/g for anti-ICAM/ASM NCs, 
0.28±0.02%ID/g for anti-ICAM/αGal NCs, and 0.32±0.03%ID/g for anti-ICAM/GAA NCs 





Figure 32. In vivo brain accumulation and specificity of anti-ICAM/enzyme nanocarriers. 
Mice were injected (a, b, c) with anti-ICAM NCs carrying 125I-radioisotope labeled ASM, 
αGal, or GAA or (c) with non-targeted 125I-enzyme counterparts. Blood samples and the brain 
were collected 30 minutes post-injection and analyzed for 125I content. (a) Percent of injected 
anti-ICAM/enzyme NC dose (%ID) found in brain tissue. (b) %ID normalized to the weight 
of the organ (%ID/g) showing the density of accumulation in the brain tissue. (c) Brain 
localization ratio (LR) was calculated by comparing %ID/g of brain tissue to %ID/g of blood. 
Data are mean±SEM. *p<0.05, comparing enzyme delivered ICAM-1-targeted NCs to non-
targeted enzyme, by Student’s t-test.  
 
To account for free enzyme in circulation, the LR was calculated as in the previous 
section (ratio of %ID/g in tissue versus %ID/g in blood) which was 0.27±0.03, 0.11±0.02, 
and 0.21±0.05 for anti-ICAM/ASM NCs, anti-ICAM/αGal NCs, and anti-ICAM/GAA NCs, 
respectively (Figure 32c). By comparing the LR of anti-ICAM/enzyme NCs versus non-
targeted enzyme, the specificity index (SI) can be determined, defining the specific 
enhancement provided by ICAM-1-targeting. Targeting ICAM-1 specifically enhanced 
delivery of ASM, αGal, and GAA to the brain by 7.2-, 3.9-, and 5.6-fold, respectively, after a 
single injection. This is in line with other difficult to reach tissues previously discussed (see 
Section 4.3.5.). 
Therefore, all three formulations of anti-ICAM/enzyme NCs accumulated efficiently 
to the brain, althoughat different levels. Interestingly, amongst the three types of anti-
ICAM/enzyme NCs, delivery of ASM to the brain seemed the most efficient, ~2-folds greater 




This is particularly favorable for NPD, as the neuropathy is most severe in this disease 
compared FD or PD. Although, in comparison to other organs, the total amount of anti-
ICAM/enzyme NCs to reach the brain may seem trivial (Figure 32 versus Table 2), this 
strategy seems to be more efficient compared to other targeting methods, such as targeting 
transferrin receptors (TfR) [162], a favorable and well studied method of brain delivery. In 
fact, ICAM-1-targeting enhanced ASM delivery to the brain 2.5-fold greater than the 
enhancement provided by ASM targeted to transferrin receptors [162]. 
 
4.3.7. Visualization of anti-ICAM/enzyme nanocarriers in the brain of mice 
Both cell culture studies on BBB transport and in vivo brain accumulation showed the ability 
of anti-ICAM NCs to target the brain. To examine in detail the distribution of green 
fluorescent anti-ICAM/125I-enzyme NCs in regions of the brain, this organ was collected 30 
minutes after i.v. injection and was then divided into eight sections and measured for 125I-
enzyme content, and green fluorescent NCs were visualized by optical fluorescence imaging. 
NCs and enzyme were observed throughout the brain, with a greater accumulation toward the 
caudal region, especially the cerebellum (Figure 33).   
Even though the whole brain is highly vascularized, the cerebellum seems to be more 
dense with capillaries than any other region of the brain [209, 210]. Hence, circulating anti-
ICAM NCs have the opportunity to target and traverse the vast surface area provided by the 
vascular endothelial cells. In case of treating NPD, the cerebellum is known to be particularly 
vulnerable, hence delivery to purkinje cells of the cerebellum would be optimal [211]. 
Additionally, since PD also severely affects muscles, delivery of enzyme to smooth muscles 
in the brain vasculature may relieve symptoms seen in these tissue, e.g. rupturing of 





Figure 33. Distribution of anti-ICAM/enzyme nanocarriers in brain of mice. Green 
fluorescent NCs were coated with anti-ICAM/125I-αGal (50:50 antibody to enzyme mass 
ratio) to formulate anti-ICAM/enzyme NCs. Mice were injected with anti-ICAM/125I-αGal 
NCs (2.4x1013 NCs/kg) and euthanized 30 minutes post-injection. Brains were collected and 
sliced into 8 coronal sections. Sections were imaged, analyzed for 125I content, and weighed. 
(a) Fluorescence image of nanocarriers in sectioned brain samples. (b) Percent of αGal in 
each section relative to the total αGal targeted to the brain tissue. Data are mean±SEM. 
 
has been reported in neurons of the cerebellum of PD patients which exhibit motor control 
issues [213, 214]. Hence, since motor control is affected in PD and is likely due to excess 
glycogen storage in the cerebellum, the region of the brain that coordinates and fine-tune 
movement, treatment to this region would be beneficial. All in all, targeting ICAM-1 to 
deliver ERT for neuropathic LSDs could prove to be optimistic, especially in treating the 
cerebellar region of the brain.  
 
4.3.8. Tissue retention of anti-ICAM/enzyme nanocarriers in mice tissue 
The results discussed above indicate enhanced targeting of lysosomal enzymes to both 




tissues with transport into tissues we performed similar injections followed by intravascular 
perfusion, which would eliminate the circulating fraction and that loosely bound to the 
vascular endothelium. As shown in Figure 34, intravascular perfusion did not result in release 
of nanoparticles accumulated in organs (Figure 34a); in fact, an average of 98.2±11.9%ID 
relative to %ID of non-perfused tissue was retained. The heart retained the least amount and 
yet this was 81% of non-perfused heart, while the kidneys increased in αGal targeting (136% 
of non-perfused tissue; Figure 34a), perhaps through forced perfusion lingering anti-
ICAM/αGal NCs passed through the kidneys allowing for increased binding. This increase 
shows the potential for kidneys to accumulate more anti-ICAM/αGal NCs that the allotted 
amount retained by 30 minutes. 
At 24 hours post-injection, anti-ICAM/αGal NCs were still present in tissue, 
although the particular amount had shifted slightly (Figure 34b). For instance, about 60% of 
the lung fraction of anti-ICAM/αGal NCs was removed from the organ by 24 hours after 
injection, in part which appearted in the liver and spleen, as traced by fluorescence (Figure 
34b). Similarly, by 24 hours 60% of residual αGal in lungs was also re-distributed in part to 
the liver and spleen (increase of 10-22%; Figure 34c), as traced by 125I-αGal. This is in 
contrast to previous results showing lung retention of 75% anti-ICAM NCs [215] and may be 
due to either lower affinity binding of anti-ICAM/αGal NCs carrying lower anti-ICAM 
surface density and/or rapid metabolism of nanoparticles bearing a lysosomal enzyme by 
pulmonary endothelial cells. In any case, the fraction of anti-ICAM/αGal NCs retained in the 
lung still represented a 150-fold enhancement in the amount of enzyme delivered to this 





Figure 34. Anti-ICAM/αGal nanocarriers target and remain in tissue. (a) Mice injected with 
anti-ICAM/125I-αGal NCs were perfused at 30 minutes. Data shows relative quantity of anti-
ICAM/αGal NCs remaining in perfused organs as a percent of non-perfused organs. *p<0.05, 
comparing perfused tissue to non-perfused tissue, by Student t-test. (b) Green fluorescent 
anti-ICAM/αGal NCs were injected into mice, which were then perfused at 30 minutes or 24 
hours after injection. The amount of anti-ICAM/αGal NCs remaining in perfused tissue after 
24 hours was assessed via fluorescence microscopy and compared to that of perfused organs 
harvested at 30 minutes. (c) Mice were perfused at 30 minutes or 24 h post-injection of anti-
ICAM/125I-αGal NCs. Relative 125I-αGal remaining per organ by 24 hours was calculated as 




In the previous two sections we discussed the potential of improving enzyme delivery for 
treatment of LSDs by using anti-ICAM NCs to enhance binding, internalization, and 
intracellular delivery of lysosomal enzymes to lysosomes of disease-model cells to alleviate 
substrate accumulation. We also discussed the potential of anti-ICAM NCs to improve 
transport across the BBB to target cells of the brain. Pairing well with cell culture results, in 
vivo work showed mice treated with anti-ICAM/enzyme NCs rapidly cleared enzyme from 
circulation and majority of enzyme was found to target tissue within 30 minutes, while non-
targeted enzyme lingered in circulation with little bound to tissue. This was indicative of fast 
targeting of enzyme to tissue by ICAM-1-targeted nanocarriers. Indeed, previous work has 
shown that anti-ICAM/ASM NCs can enhance delivery of enzyme to tissue in vivo as a 




ASM and translatable to two other lysosomal enzymes, αGal and GAA for treatment of FD 
and PD. As a result, delivery of all three enzymes to all tissues of mice was enhanced by 
ICAM-1-targeting systems compared to non-targeted enzyme treatment counterparts, 
although with unique ranges of improvement. Delivery of GAA was most effectively 
enhanced to all organs by anti-ICAM NCs, compared to other anti-ICAM/enzyme NC 
systems. We note that perhaps this effect is seen in the tissue due to a synergistic effect 
between the ICAM-1-targeting antibody and the enzyme, unique to the combination that is 
not present or distinguishable in cell culture. Regardless of variance, successful enhancement 
of enzyme delivery demonstrates the potential of using ICAM-1-targeted delivery systems for 
LSD treatment by ERT delivery.  
In agreement with peripheral organs, in vivo works showed promise in enhancing 
enzyme delivery to the brain as well. Anti-ICAM/enzyme NCs were ~4- to 7-folds more 
effective in delivering lysosomal enzyme to the brain than non-targeted enzyme counterparts 
within 30 minutes of administration. Moreover, a closer examination illustrated by delivery 
of αGal that the enzyme accumulated preferentially to the cerebellum, the region notably 
affected by NPD and other LSDs. This rapid accumulation to the brain shows the potential 






4.4. Enhancement of enzyme delivery by modulation of ICAM-1-targeted 
nanocarriers 
4.4.1. Introduction 
Previous sections have focused on the applicability of anti-ICAM/enzyme NCs to be 
extended to other lysosomal enzymes aside from the previously examined ASM enzyme. 
Additionally, we also examined if anti-ICAM NCs could be used to improve delivery to the 
brain. Given positive results indicative of the potential for anti-ICAM NCs to improve ERT 
delivery for treatment of LSDs, we then examined how modulation of nanocarrer parameters 
can enhance enzyme delivery further. In particular, we evaluated the influence of two 
parameters: variation of the coat and the bulk nanocarrier concentration. 
Previous work has examined the effects of these variables in the biodistribution of 
anti-ICAM NCs [44]. Specifically, results showed that increasing the density of anti-ICAM 
on the surface of nanocarriers or increasing the concentration of anti-ICAM NCs injected 
increases shifts the biodistribution from high accumulation in liver and spleen to high 
accumulation to lungs, and low accumulation in the liver and spleen [44]. However, it was 
unknown whether the presence of a cargo on the nanocarrier surface may further impact 
biodistribution, particularly in the case of lysosomal enzymes because they typically have 
residues targeting the M6PR [216]. Since both the targeting moiety and the cargo is coated on 
the nanocarrier surface, we evaluate whether shifting the targeting avidity to increase cargo 
load could affect targeting efficacy and biodistribution of anti-ICAM/enzyme NCs. 
Additionally, it is well known that binding interactions depend on the ligand-receptor 
concentration and, thus, by increasing the bulk-concentration of anti-ICAM/enzyme NCs 




4.4.2. Visualization of dose-dependent targeting of anti-ICAM nanocarriers in mice 
As shown in Section 4.3.4. above, we first visualized the biodistribution of anti-ICAM NCs 
injected i.v. at different doses, using optical imaging. Figure 35 shows that accumulation of 
anti-ICAM NCs over the level of control IgG NCs in lungs and kidneys was dose-dependent: 
e.g., 11.6-fold and 26.4-fold enhancement when using 4x1013 versus 8x1013 NCs/kg, 
respectively, in the case of lungs. The observed linear dependence in targeting of both organs 
suggests that binding saturation has not been reached at the doses tested. In contrast, liver 
accumulation of anti-ICAM NCs was consistently lower (0.6-fold) compared to IgG NCs. 
 
Figure 35. Visualization of dose-dependent targeting of anti-ICAM nanocarriers in mice. 
Optical imaging of isolated organs of mice 30 minutes after i.v. injection with model 
nanocarriers (4x1013 or 8x1013 NCs/kg) labeled with green fluorescent and coated with either 
control IgG or anti-ICAM. (b) Semi-quantitative measurement of nanocarrier distribution, 
from optical imaging results shown in (a). (Figure reproduced from [50]) 
 
4.4.3. Comparative tissue versus blood re-distribution of anti-ICAM/enzyme nanocarriers 
We next focused on examining in more detail the effect of varying bulk nanocarrier dose and 
also the coated antibody surface density on the biodistribution of anti-ICAM/enzyme NCs. 
We prepared three different anti-ICAM/αGal NC formulations by varying (1) targeting 




of these variations on the in vivo biodistribution of the lysosomal enzyme (Figure 36). For 
two formulations, the surface-density of anti-ICAM-to-αGal was varied from ~95:5 to 50:50 
mass ratio, which rendered an enzyme load of ~50 versus 500 αGal molecules/NC. These 
formulations were injected at a concentration of 1.6x1013 NCs/kg, which represents final 
enzyme doses of ~45 (low) versus 449 (intermediate) αGal µg/kg. In the “high dose”, the 
coating was maintained at a 50:50 anti-ICAM-to-αGal mass ratio (as is in the “intermediate 
dose”), yet the concentration of the injected dose was varied to 2.4x1013 NCs/kg (1.5-folds 
greater than low and intermediate dose), which represents a final enzyme dose of ~550 (high)  
Figure 36. Anti-ICAM/αGal nanocarriers formulations. Model 100-nm diameter, polystyrene 
nanoparticles were coated with anti-ICAM as a targeting moiety and αGal as an enzyme 
cargo. Three formulations were prepared by varying the antibody-to-enzyme ratio on the 
nanoparticle surface or the final concentration of nanoparticles in solution, as indicated. 
These variations rendered three different enzyme doses: low, intermediate, or high. The size, 
polydispersity, zeta potential, surface coating, and nanoparticle bulk-concentration of these 





αGal µg/kg (Figure 36). For all formulations, the size, polydispersity, and zeta-potential of 
the resulting nanoparticles was similar, ranging between 223 to 240 nm in diameter, 0.126 to 
0.129 polydispersity, and from -9.12 to -12.0 mV (Figure 36).  
 
All three anti-ICAM/125I-αGal NC formulations or equivalent doses of non-targeted 
125I-αGal were administered separately into mice to examine their overall biodistribution after 
i.v. injection. In all three cases, anti-ICAM/αGal NCs rapidly disappeared from the 
circulation, while free αGal remained in blood to a much greater extent (Figure 37a, b), 
consistent to previously discussed enzyme delivery enhancement patterns. For instance 
(Figure 37c), 30 min after injection, the level of αGal in circulation associated with anti-
ICAM NCs ranged from ~2 to 6%ID, contrasting with ~40 to 60%ID of free αGal, a ~10-fold 
decrease in circulation of anti-ICAM/αGal NCs compared to the naked enzyme. 
Additionally, anti-ICAM/αGal NCs accumulated in tissues at a greater extent than naked 
αGal (Figure 37d). Considering collectively the major organs of the body (brain, heart, 
kidneys, liver, lungs, and spleen), ICAM-1 targeting resulted in tissue accumulation ranging 
from ~60 to 70%ID, compared with only ~20%ID in the case of the free enzyme. This 
represents ~3.5-fold increase of global tissue distribution as a result of ICAM-1 targeting. 
This level of enhancement still underestimates the targeting potential of anti-ICAM NCs, 
because the circulating enzyme level is significantly higher for naked αGal (Figure 37c), and 
this circulating fraction also contributes to the level of enzyme detected in each organ. This 
result is comparable and pairs well with previously discussed work (Figure 29, Section 4.3.3.) 
where anti-ICAM/ASM NCs for NPD and anti-ICAM/GAA NCs for PD were prepared 





Figure 37. Presence of non-targeted αGal versus anti-ICAM/αGal nanocarriers in circulation 
and tissue. Non-targeted 125I-αGal or anti-ICAM/125I-αGal NCs were injected i.v. in mice. 
Blood samples collected at 1, 15, and 30 minutes post-injection and major organs (brain, 
heart, kidney, liver, lungs, and spleen) collected at 30 minutes post-injection were measured 
for 125I-αGal content to determine percent of total injected dose (%ID) remaining in 
circulation or tissues. (a, b) %ID remaining in circulation over time of mice injected with (a)  
non-targeted 125I-αGal or (b) anti-ICAM/125I-αGal NCs. (c,d) %ID in (c) circulation or (d) all 
collected tissue by the 30 minute endpoint. Intm = Intermediate dose. Data are mean±SEM. 
Comparison by Student’s t-test of each anti-ICAM/αGal NC formulation to its naked αGal 
counterpart rendered p<0.001. (Figure reproduced from [50]) 
 
With regard to comparing the global targeting efficacy (cumulative %ID in all 
organs) of the different anti-ICAM/αGal NC formulations, the amount of targeting anti-
ICAM on the nanoparticle surface was reduced by half (from 181 to 83 molecules per 
particle; Figure 36) when increasing the enzyme load by 10-fold (low and intermediate αGal 
doses). This is in line with the size difference between these molecules, e.g., ~150 kDa for 
anti-ICAM versus ~32.25 kDa for the αGal form used. However, despite this variation of 
surface-density of the targeting coat, as well as the change concerning nanoparticle-bulk 
concentration (from 1.6x1013 to 2.4x1013 NCs/kg), no statistically significant differences were 




4.4.4. Effects of varying targeting surface-density or nanocarrier bulk-concentration on 
enzyme distribution in vivo    
We next evaluated whether modification of these design parameters led to changes in the 
biodistribution pattern of anti-ICAM/αGal NCs. Very few changes were found concerning 
different antibody surface-densities (low versus intermediate αGal doses; 45 versus 449 µg 
αGal/kg), which occurred in the liver (figure 38). For instance, a 2-fold reduction of the 
antibody surface-density on the nanocarrier coat resulted in an increased liver accumulation 
of αGal from ~12 to 24%ID/g (Figure 38b). This seems to reflect reduced targeting, which is 
only noticeable (yet not statistically significant) in the brain, possibly due to the low 
magnitude of targeting to this organ compared to others. Instead, the cumulative effect of 
small reductions in targeting through the body was noticed in the liver, likely due to non-
specific clearance. In accord, coating of αGal alone on the surface of nanocarriers lead to an 
even more enhanced liver accumulation (53.4±2.6%ID; data not shown), which is a 
characteristic clearance pattern for particulate objects of this size range [158]. 
However, varying anti-ICAM surface density did not cause significant changes in the 
levels of enzyme accumulation in other organs, which represent FD targets. For example, the 
lungs accumulated the highest dose of anti-ICAM/αGal NCs for all formulations (~35%ID; 
Figure 38a). This was also the case after normalization by organ weight, with ~180%ID/g 
(Figure 38b). This suggests endothelial specificity, validated by the fact that control IgG NCs 
or αGal NCs did not accumulate in the lungs (1.6±0.3%ID and 0.9±0.1%ID, respectively; 
data not shown) and this was also the case for anti-ICAM NCs injected in ICAM-1 knockout 
mice (2.0±0.3%ID; data not shown). Kidneys and heart accumulated ~2%ID and ~0.3%ID 
αGal, equivalent to ~5%ID/g and ~2%ID/g of the enzyme, respectively, regardless of the 





Figure 38. Similar αGal biodistribution with varying the design parameters of anti-ICAM 
nanocarriers. Mice were injected i.v. with 1.6x1013 NCs/kg of anti-ICAM/125I-αGal NCs 
prepared to contain 95:5 or 50:50 antibody-to-enzyme surface-density ratios (52 versus. 524 
αGal molecules/NC), which rendered low (45 µg/kg) or intermediate (Intm; 449 µg/kg) αGal 
doses. In addition, anti-ICAM/125I-αGal NCs displaying 50:50 antibody-to-enzyme surface-
density ratios was injected at 2.4x1013 NCs/kg (high αGal dose; 555 µg/kg). Organs were 
harvested 30 minutes after injection, weighed, and measured for 125I content to determine (a) 
percent of total injected αGal dose (%ID) in each organ and (b) relative tissue-to-blood 
targeting efficiency as %ID αGal per gram of tissue (%ID/g) to compare among organs of 
different size. Data are mean±SEM. *p<0.05, comparing to low αGal doses, by Student’s t-
test. Comparing intermediate and high αGal doses rendered p>0.1, by Student’s t-test. (Figure 
reproduced from [50]) 
 
These findings are consistent with previous results demonstrating no significant 
changes in the pulmonary biodistribution of cargo-free anti-ICAM NCs, along with an 
enhanced accumulation in the liver, when antibody surface-densities varied between 55 and 
165 molecules/NC [44] (surface-densities in this study are 83 versus 181 antibodies/NC). 




avidity threshold that allows them to effectively bind to the target in vivo, and this makes it 
possible for the enzyme cargo to occupy the nanocarrier coat without impairing binding. 
Minimal retention in circulation described above (Figure 37) indeed suggests rapid targeting.  
In addition, no changes where observed by varying the carrier-bulk concentration 
within the range tested, corresponding to intermediate versus high αGal doses; 449 versus 
550 µg αGal/kg (note that the statistical significance associated with high dose in Figure 38 is 
compared to low dose, which also encompasses different targeting surface density). The lack 
of biodistribution changes observed here regarding variation of the nanocarrier bulk-
concentration is opposite to the outcome reported for cargo-free anti-ICAM NCs [44]. 
However, these differences may be due to the different nanocarrier concentrations used in 
these two studies: 1.6x1013 and 4.8x1013 NC/kg (a 3-fold change) employed in a previous 
work versus 1.6x1013 and 2.4x1013 NC/kg in this report, where the 1.5-fold concentration 
change may have been insufficient to cause targeting differences. This outcome may have 
been also affected by the allegedly lower avidity of nanocarriers used in this comparison, 
which displayed ∼85 anti-ICAM molecules/NC versus 209 anti-ICAM molecules/NC 
reported previously [44]. 
Interestingly, the relative extent of targeting versus clearance, exemplified by 
accumulation of anti-ICAM NCs in the lungs versus liver, is significantly different between 
cargo-free [44] and αGal-containing counterparts shown here. For instance, in a previous 
work, pulmonary accumulation of cargo-free anti-ICAM NCs displaying 55 versus 165 
antibody molecules/NC was 56%ID/g versus 63%ID/g, respectively, compared to 48%ID/g 
versus 46%ID/g for the liver [44]. In contrast, in this study using anti-ICAM/αGal NCs 
displaying 83 versus 181 antibodies/NC, pulmonary accumulation was 192%ID/g versus 




thus appears that targeting of αGal-loaded anti-ICAM NCs is enhanced. This could be due to 
relative differences between the anti-ICAM batch used and/or the presence of the enzyme on 
the nanocarrier coat, which could have conferred enhanced avidity. This is possible because 
most lysosomal enzymes display mannose or M6P residues that can interact with their 
receptors and also αGal can interact with glycosphingolipid ligands on the cell surface [216, 
217]. In particular, pulmonary accumulation of αGal NCs was negligible (0.9±0.1%ID; data 
not shown) and similar to that of control IgG NCs (1.6±0.3%ID; data not shown), indicating a 
synergistic rather that additive effect. It is likely that avidity of multivalent αGal is still 
relatively low as to confer relevant targeting by itself, yet after initial binding to the 
endothelium via ICAM-1, additional αGal interactions may occur. Similar effects have been 
observed for strategies where one nanocarrier particle is targeted to multiple receptors [44, 
218]; yet in this study the cargo, not a second targeting moiety, would provide this ability. 
 
4.4.5. Specificity and absolute enzyme delivery by anti-ICAM nanocarriers 
All anti-ICAM NC formulations resulted in similar overall shift αGal from the blood to 
tissues (Figure 37), with a similar relative biodistribution in organs (Figure 38). Since dose 
may also affect the biodistribution of naked αGal, we next examined the specificity offered 
by ICAM-1-targeting. This was achieved by determining the effect of varying antibody 
surface-density on the nanocarrier particle or the nanocarrier bulk-concentration (described 
above) on the specificity index (SI) of anti-ICAM/αGal NCs over non-targeted αGal, which 
corrects for the different circulating fractions in these formulations (see Methods). 
For all three formulations, SI was greater than 1 in all organs tested, reflecting a 




variations of the injected enzyme dose from ~45 to 555 µg/kg (Figure 39a). Counter-
intuitively, the formulation displaying a greater targeting specificity in each organ was the 
one with reduced antibody surface-density and nanocarrier bulk-concentration (intermediate 
αGal dose of 449 µg/kg). For this formulation, anti-ICAM NCs enhanced specific targeting 
of αGal from 4-fold (in kidneys) up to 981-fold (in lungs) over the equivalent naked 
counterpart. This could be explained if the range of anti-ICAM surface-density used in this 
study already surpassed the threshold for effective targeting in vivo, and αGal presented on 
the nanocarrier surface could provide a synergistic targeting effect, as discussed above. 
A reduced enhancement in tissue targeting specificity was seen when varying 
nanocarrier bulk-concentration between 1.6x1013 and 2.4x1013 NCs/kg. Judging by the similar 
biodistribution (Figure 38) but not specificity (Figure 39) patterns observed for these two 
formulations, it appears a change in the nanocarrier concentration within this range does not 
impact binding in the case of high-avidity multivalent anti-ICAM/αGal NCs. Instead, it is 
plausible that such a change in concentration enhances binding of allegedly low-avidity, 
monovalent naked αGal. If this was the case, the outcome would be a decreased SI for anti-
ICAM/αGal NCs, as observed. Nonetheless, even in this situation ICAM-1 targeting offered 
a marked and significant enhancement in the specific tissue accumulation of αGal, with SI 
values ranging from 3.5 to 496 for high dose, observed in the kidneys and lungs, respectively. 
Importantly, modulation of either antibody surface density or nanocarrier bulk-
concentration both resulted in an increase in the absolute amount of αGal accumulated in 
each organ (Figure 39b). Since variation of these nanocarrier design parameters did not 
negatively or significantly impact the potential for ICAM-1 targeting through the body, the 





Figure 39. Enhanced specificity and absolute αGal targeting by varying nanocarrier design 
parameters. Mice were injected i.v. with anti-ICAM/125I-αGal NCs displaying varying 
antibodyto-enzyme surface-density ratios, at varying nanocarrier bulkconcentrations, 
rendering low (45 µg/kg), intermediate (Intm; 449 µg/kg), or high (555 µg/kg) αGal doses, or 
with equivalent doses of naked, non-targeted 125I-αGal. Blood samples and organs were 
collected, weighed, and measured for 125I content 30 min after injection. (a) Specificity index, 
SI, was determined by comparing %ID/g per gram of organ over %ID per gram of blood 
(tissue-to-blood localization ratio) of anti-ICAM/125I-αGal NCs to the equivalent parameter 
for naked, non-targeted αGal. This parameter describes the fold enhancement of αGal 
targeted to tissue via anti-ICAM NCs. (b) Total dose (ng) of 125I-αGal accumulated in each 
organ. Data are mean±SEM. *p<0.05, comparing intermediate versus high αGal doses by 
Student’s t-test. Comparing intermediate or high to low αGal doses rendered p <0.001. 
(Figure reproduced from [50]) 
 
increase in the enzyme delivered. Anti-ICAM/αGal NCs displaying ~500 αGal molecules/NC 
(449 µg αGal/kg; intermediate dose) enhanced αGal accumulation in organs (cumulatively) 
over 10-fold versus counterparts displaying ~50 αGal molecules/NC (45 µg αGal/kg; low 
dose). Anti-ICAM/αGal NCs displaying ~500 αGal molecules/NC and administered at 




versus administration of the same nanocarriers at 1.6x1013 NCs/kg (449 µg αGal/kg; 
intermediate dose). Total αGal delivered to the lungs 30 minutes after i.v. injection increased 
from ~270 ng to ~5800 ng for these three formulations. Significant enhancement was also 
found even for organs that are difficult to target, such as the brain, where µGal delivery 
increased ~20-fold when comparing high to low dose (max. brain accumulation was 17.8 ng). 
This was also the case for the heart and kidneys, key FD organs, with maximum 
accumulation of ~48 ng and ~435 ng, respectively. 
Notably, total amount of αGal delivered to tissues increased from 0.45 µg (low dose) 
to 7.7 µg (intermediate dose) to 10.8 µg (high dose), which is very significant compared to 
the initial administered dose of ~0.73 µg, ~11.7 µg, and ~15.8 µg of αGal, respectively. This 
represents a consistent pattern of 65% of the injected dose accumulating in the six harvested 
organs. Although these data was obtained 30 minutes after injection, as mentioned above, 
previously published results indicated that a significant amount of αGal transported by anti-
ICAM NCs remain in the targeted organs 24 hours after administration (Figure 34c): e.g., 
150-fold pulmonary accumulation over free αGal at this time [48, 215]. This result suggests 
that these variations of the nanocarrier formulation have a linear effect on the enzyme 
delivery, rendering a relatively controllable system for delivering such a cargo. From a 
translational perspective, current ERT for FD in the clinic typically consists of i.v. infusions 
of 1 mg/kg every two weeks, associated with high probability for development of resistance 
due to generation of anti-αGal blocking antibodies [95]. The lowest dose of 45 µg of αGal/kg 
tested in this study is ~20-fold lower than current clinical doses, yet ICAM-1 targeting 






As a stable pro-drug coat of targeting moiety and drug model with conditional enzyme drug 
release (Figure 5, Section 4.1.2.), eliciting similar binding, uptake, lysosomal trafficking, and 
substrate degradation by 3 lysosomal enzyme cargos targeted to ICAM-1 (Section 4.1.), and 
similar biodistribution pattern with varying enzyme delivery enhancement levels to tissue 
(Section 4.3.), we further questioned whether anti-ICAM/enzyme NCs can be modulated to 
optimize enzyme delivery. Indeed, both the surface density of the targeting moiety on ICAM-
1-targeted NCs and NC bulk concentration injected in circulation can be varied to regulate 
the total amount of a surface-loaded cargo (such as the case of therapeutic lysosomal enzyme 
pro-drugs) that can reach target organs in the body, without negatively impacting targeting 
specificity and biodistribution. The presence on the nanoparticle surface of a cargo that has 
affinity toward cell-surface markers seems to somehow compensate for the potential decay in 
avidity associated with the reduced surface-density of the (antibody) targeting moiety. Hence, 
this strategy can be used to enhance tissue delivery of lower lysosomal enzyme doses, which, 
along with fast removal from the circulation, may help improve the efficacy of lysosomal 





Section 5. Overall conclusions 
5.1. Summary 
Treatment availability for LSDs in the past couple of decades has greatly improved the life 
expectancy and quality of life of patients. Currently, available treatments options include 
ERT, bone marrow transplant and substrate reduction therapy, and chaperone therapy [4, 10]. 
Research into gene therapy shows promise and is under clinical trial [4]. However, of 
available therapies, ERT is one of the most promising judging by demonstrated effects. At the 
moment, six LSDs are treatable by ERT, including FD and PD [4]. Yet, outcomes of ERT are 
still suboptimal: accumulation to clearance tissues with limited to no delivery to many 
diseased tissues, poor transport across the BBB, inadequate uptake due to impaired cellular 
internalization pathways, etc. [95-99, 101]. With concurrent advances in nanotechnology and 
drug delivery, improvements to ERT could be tangible, such as use of fusion proteins or 
targeted drug delivery vehicles [11, 41, 42, 62, 128, 129]. Yet, majority of these alternative 
approaches still rely on clathrin-mediated uptake, which seems to be disrupted in several 
LSDs [27-29]. This dissertation focuses on expanding an alternative model previously 
proposed by our laboratory, which rapidly delivers enzyme therapeutic to tissue, selectively 
bind to diseased cells, and allows for internalization and trafficking to lysosomes of cells via 
ICAM-1-targeting. 
Previous work with ICAM-1-targeting nanocarriers delivering ASM has shown 
favorable results with enhanced enzyme targeting to tissue in vivo, as well as binding, 
internalization, and lysosomal trafficking where the delivered enzyme can degrade 
accumulated substrate in cell culture [41, 42]. While this was observed for the delivery of 




observations for other lysosomal enzymes, (2) demonstrated ability of ICAM-1-targeting 
system to traverse across BBB models, (3) shown enhancement of enzyme accumulation in 
the brain in vivo, and (4) expanded means to manipulate the dose of enzyme delivered. 
We first examined the stability of these formulations and determined that both anti-
ICAM/αGal NCs and anti-ICAM/GAA NCs were indeed stable with minimal enzyme release 
from nanocarriers in storage and physiologically neutral pH conditions, but conditional 
release of enzyme was observed when anti-ICAM/enzyme NCs were exposed to lysosomal 
acidic conditions or lysosomal storage conditions (Section 4.1.2.). Since the two anti-
ICAM/enzyme NCs showed similar formulation stability and enzyme release characteristics, 
we then focused on expanding this application to two other LSDs, specifically delivering 
αGal and GAA to FD- or PD-models, respectively. As discussed in section 4.1., more 
enzyme was targeted diseased cells compared to healthy cells, and efficiently internalized and 
trafficked to lysosomes via CAM-mediated endocytosis, independent of classical pathways 
known to be impaired in most LSDs. Moreover, delivered enzymes into lysosomes 
effectively degrade excessively accumulated lysosomal substrate. Even though different 
patterns of efficiencies did arise amongst historical and tested anti-ICAM/enzyme NCs, such 
as specific binding, percent uptake, endocytic pathways involved, percent trafficked to 
lysosomes, alleviation of accumulated lysosomal substrate, etc., the collected results were 
positive to suggest that ICAM-1-targeting systems can be used to enhance lysosomal 
enzymes to treat LSDs in general. Yet, as indicated, each application must be thoroughly 
assessed. 
To address neurological effects that manifests in several LSDs, application of anti-
ICAM NCs to target cells of the BBB, which regulates transport between the circulation and 
the brain parenchyma, and cells of the brain were specifically examined in Section 4.2. Cells 




especially notable between diseased versus healthy cells for all three cell types, with diseased 
ECs expressing the most total and most dense ICAM-1 amongst the three cell types. Yet anti-
ICAM NCs target, internalize, and trafficked to lysosomes via mainly CAM-mediation 
pathway in all three cell types, although more anti-ICAM NCs tended to bind, internalize, and 
traffic to lysosomes in ECs than compared to subendothelial cells. Additionally, transport of 
anti-ICAM NCs across EC monolayer was selective to diseased cells and ICAM-1-targeting, 
occurring also mainly via CAM-mediation. In fact, transcytosis across ECs resulted in 
significant accumulation to the subendothelial layer in a bi-layer co-cultured BBB model. 
However, despite the noted lysosomal trafficking observed in cultures of individual cells, in a 
bi-layer co-cultured BBB model, a portion of bound anti-ICAM NCs continued to transport 
across the subendothelial layer as well, achieving transport across bi-layered BBB models. 
With anti-ICAM NCs confirmed to be able to traverse the BBB, we then examined the 
capability of targeting neurons. Indeed, anti-ICAM NCs can bind, internalize, and traffic to 
lysosomes of NLCs mainly via CAM-mediation, interestingly, in both cell body and cell 
processes regions. 
In Section 4.3., we discussed that the biodistribution of ICAM-1-targeted enzyme in 
vivo showed enhanced delivery over non-targeted enzyme to all major organs investigated 
(heart, kidneys, liver, lungs, spleen), which represents targets for intervention in these 
diseases, e.g. heart and kidneys for FD, and the heart and skeletal muscles for PD, apart from 
RES organs also involved. Additionally, for the first time, we examined brain targeting in 
vivo. In accord with other organs, anti-ICAM NCs enhanced enzyme delivery to the brain 
over non-targeted enzyme, preferentially accumulating in the cerebellum, a site responsible 
for motor control and balance, and known to be affected in NPD and several other LSDs. 
The above work emphasized the implementation of ICAM-1-targeting drug delivery 




model is in fact a pro-drug model with both the targeting moiety (anti-ICAM) and cargo 
(enzyme) coated onto the surface a polystyrene latex nanoparticle. Since this pro-drug model 
is deemed stable, in Section 4.4. we discussed efforts to optimize the formulation to increase 
bulk enzyme delivery to the six major organs studied. Total enzyme delivery to an individual 
organ could be enhanced by 12 to 29-folds by increasing the surface density of the enzyme on 
the NC by 10 folds, displacing 50% of the targeting moiety, and by increasing the bulk-
nanoparticle concentration administered by 1.5-folds, without adversely affecting targeting 
specificity and biodistribution pattern. 
All in all, targeting ICAM-1 does enhance enzyme delivery to tissue, and targets 
diseased cells, triggering uptake and lysosomal trafficking mainly via CAM-mediated 
pathway in both endothelial and non-endothelial cells, and lastly, delivered enzyme can 
alleviate lysosomal storage. Hence, through results from this dissertation, ICAM-1-targeting 
strategy can potentially be applied to improve ERT for LSDs.  
 
5.2. Future directions 
Through this dissertation, advances toward improving ERT for LSDs using ICAM-1-
targeting drug delivery system were achieved. However, the work presented here is a proof-
of-concept model and significantly more work still needs to be done to answer relevant 
questions and to expand this project. Firstly, future studies could focus on translatability of 
this work. One example would be to use PLGA particles as oppose to the model polystyrene 
latex particles. We note that the anti-ICAM/enzyme NC formulations tested in this thesis are 
of a “pro-drug” prototype with both the anti-ICAM targeting moiety and lysosomal enzyme 
cargo coated onto the surface of latex nanocarriers, previously confirmed to have similar 




biodegradable material that is already in several FDA-approved devices [108]. Future work 
will include confirming brain delivery achieved by anti-ICAM NCs presented in this thesis 
with PLGA particles. Additionally, we are currently working towards encapsulating the 
enzyme cargo into PLGA particles for added protection and controlled release upon 
degradation in the lysosome. Another way to expand this work into a translatable project is to 
improve the pro-drug formulation, specifically altering the targeting moiety without 
negatively impairing its binding efficiency. The work described utilizes whole antibodies 
from another species as the targeting moiety molecule, which can potentially lead to adverse 
immune recognition. Truncating the targeting antibody to only include the targeting aspect of 
the antibody, e.g. binding sequence of the antibody variable region, may minimize potential 
toxicity and immune recognition of antibody Fc regions humanized antibody. To address this, 
current work involving a 17-mer linear peptide (γ3) has been published [125]; future works 
will incorporate enzyme delivery, similar to previous studies.  
In addition to potential future work involving formulation optimization, we also 
suggest further cell culture work, particularly in studying transport across cell barriers, such 
as the case of the BBB. In this dissertation we show that anti-ICAM NCs can cross BBB 
models. The next step may be to incorporate enzyme cargo and see if transport across cell 
barriers may affect the integrity of the anti-ICAM/enzyme NC and enzyme activity. We also 
note from our work that anti-ICAM NCs transported across the BBB are actually transcytosed 
through cells of the endothelial BBB layer. It is possible that some NCs are transported 
paracellularly, especially between cells of the subendothelial BBB layer that are not as tightly 
bound. Since the method of transport through the extracellular matrix has not been elucidated 
(although is currently being studied), perhaps studies involving transport pathway can give 
insight into how anti-ICAM NCs can be better formulated to traffic to the brain parenchyma 




to the cargo the NC bears. Tissue damage can be elucidated by examining the BBB model 
integrity, specifically endothelial and subendothelial layer morphology, through histology or 
TEM. Leakage across the BBB model can be studied with radioisotope tracing of molecules, 
such as BSA, co-incubated along-side anti-ICAM NCs with cells. Presence of the molecule in 
the basalolateral chamber with transported nanocarriers can then be assessed. Additionally, 
future studies could evaluate the post-transport binding capacity of anti-ICAM NCs by 
incubating anti-ICAM NCs with BBB transwell model that also include neurons cultured in 
the basolateral chamber. As a result, using radio-isotope labeled NCs and/or 
immunohistochemistry, a detailed study differentiating percentage of targeting can analyzed, 
which could help with optimizing the design of the anti-ICAM/enzyme NC formulation. This 
work can be paired with in vivo studies with detailed histological stains of tissue and/or TEM 
to visualize delivered anti-ICAM NCs, which has begun to be addressed. Lastly, anti-ICAM 
NC binding and internalization into diseased NLCs varied between cell body and processes 
regions. Therefore, to better understand targeting, endocytosis, and lysosomal trafficking to 
study CNS treatment potential, LSD-model neurons could also be studied to confirm delivery 
and substrate attenuation by anti-ICAM/enzyme NCs. Immunohistochemistry similar to the 
described work with HUVEC models can be implemented. 
Additionally, in vivo work pertaining to this project could be extended. Since current 
ERT for LSD is a life-long treatment requiring bi-weekly doses, long term studies testing the 
efficacy of anti-ICAM/enzyme NCs to mice models bearing LSDs should be performed. We 
suggest future work to include focusing on improving ERT that are currently available, 
working with an existing LSD model mice, e.g. αGal A-deficient mice for FD [219] can be 
treated with anti-ICAM NCs bearing the recombinant enzyme currently used for ERT. Long-
term studies in the NPD model could examine animal behavior for phenotypic response (e.g. 




testings) and longevity, as well as compare cell morphological changes as a response to 
treatment by examining brain tissue morphology using histology and/or transmission electron 
microscopy (TEM). Since current ERT do not relieve symptoms and can trigger immune 
response, resulting in suboptimal treatment, by observing anti-ICAM/enzyme NC long-term 
effects on mice behavior and tissue, immune response and symptoms in intractable tissue can 
be monitored (through periodic blood samples and histology examination after euthanization) 
and compared to current ERT to evaluate whether this method can in fact improve delivery 
while minimizing immune response. Moreover, we note that targeting ICAM-1 to deliver 
enzyme was systemic, which is beneficial for LSDs since all tissue are affected. More 
comprehensive studies examining the depth of attenuation of lysosomal storage in tissue 
would be useful. This could be performed by examining tissue samples from mice studies 
(long-term or short-term) with histology and TEM to examine morphological changes and 
levels of lysosomal substrate present. 
In addition to in vivo work focused on treatment efficiency of enhanced enzyme 
delivery in LSD-model mice, in vivo work studying optimization of formulation could also 
be extended to adjust anti-ICAM/enzyme NC treatment efficacy. In Section 4.4. we discussed 
the potential of optimizing anti-ICAM/enzyme NC formulations by modulating the 
formulation itself to increase enzyme delivery. Interestingly, decreasing the targeting moiety 
density by half did not diminish specificity and distribution. Further studies with a smaller 
targeting moiety (such as γ3) may prove to also conserve targeting specificity and 
biodistribution pattern. Additional bulk-concentration studies (e.g. increasing administered 
dose to 4-folds) can also be performed to delineate the potential saturation point of binding or 
tissue delivery. Another method that was not examined here but was previously studied is 
administering multiple doses [157]. This can be performed by injecting mice with multiple 




ICAM NCs leave the circulation within ~1 minute of injection to rapidly target tissue, this 
first dose can be used to saturate certain binding sites, i.e. the highly targeted lungs and liver, 
such that subsequent dose(s) can reach to more intractable tissue, potentially resulting in a 
broader tissue biodistribution. This experiment could be performed using non-radioisotope 
labeled anti-ICAM/enzyme NCs for the first dose, while using radioisotope labeled anti-
ICAM/enzyme NCs for 2nd dose to trace and delineate broadened tissue targeting. 
All in all, this dissertation has shown the potential of using ICAM-1-targeted drug 
delivery to enhance enzyme delivery for possibly several LSD treatments, a method that can 
be optimized to potentially be expanded to other treatments as well. As mentioned, a likely 
synergistic and/or additive effect of having both the anti-ICAM and enzyme on the NC has 
shown to provide unique patterns of distribution. Hence, it is likely that other unique 
combinations could elicit unforeseeable delivery outcomes. In addition to capitalizing the 
unique combinations, there are several other methods that can be exploited to control the 
distribution pattern, the rate of delivery, and/or bulk of cargo delivery. By targeting a 
combination of receptors (within the same family or not) or epitotes (on the same receptor or 
not) [160], or modulating the size and shape of the NC [158], or route of administration 
[152], can yield a variety of targeting patterns, and therefore can be exploited depending on 
the purpose of the delivery. Therefore, much still needs to be answered to complete the 
project, but much more can be studied to find the unique combination to greatly enhance 
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